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 Abstract 
 
Rheumatoid arthritis (RA) is an autoimmune disease that primarily affects the 
joints and is characterized by bone and cartilage erosion. These patients have an 
increased risk of developing co-morbid cardiovascular disease (CVD). In this 
study the vascular adventitia from patients with coexisting RA and CVD was 
investigated to identify factors in the vascular environment that could affect the 
immune component of RA. This included the histological evaluation of aortic 
adventitial sections for known RA-associated autoantigens; B cells their survival 
factors and associated cytokines. In addition, these human studies were the 
impetus for the initiation of a study to investigate the effect of B cell depletion 
on atherosclerosis. 
 
Citrullinated proteins (CP), RA associated antigens, are an inflammation specific 
entity. These modified proteins are processed by (PADI), a calcium dependent 
enzyme expressed by inflammatory cells and some microbial species. The 
presence of RA specific autoantibodies (ACPA) suggests a role for citrullinated 
proteins in RA pathogenesis. The aim of the present study was to determine 
whether the inflammatory milieu in the vascular adventitia of RA patients had 
any association with CP. The expression of CP was confirmed in the vascular 
adventitia, and CVD patients with coexisting RA were found to have increased 
levels of CP compared to non-RA CVD patients. In addition, ACPA levels were 
detectable in serum samples of only RA patients. When ACPA positive RA 
patients were sub grouped (CP>5.5), a strong association was observed between 
ACPA levels and C-reactive protein (CRP) in this subgroup (CP>5.5). This is 
suggestive of a CP and ACPA link in vascular inflammation in patients with 
coexisting RA.  
 
The presence of B-lymphocytes has been shown in both murine and human 
vascular adventitia. In this study we demonstrated that the presence of B cell 
aggregates is tissue specific, since matched internal mammary artery (IMA) had 
no detectable B cells in the adventitia. Furthermore, BAFF and APRIL are present 
in the aortic adventitia and support the conclusion that a survival niche is 
present in the aortic adventitia; cytokine expression was demonstrated in 
 lymphocytes, adipocytes and vascular endothelial cells. Interestingly, smoking 
resulted in higher levels of BAFF expression in the aortic adventitia of CVD 
patients. Previous studies have shown that smoking induces vasoconstriction of 
small vessels (vasa vasorum), and hence hypoxia of the vascular endothelial 
cells. We hypothesised that hypoxia would induce the increased expression of 
BAFF and APRIL in vascular endothelial cells. Using murine vascular endothelial 
cells we investigated the effect of hypoxia on BAFF and APRIL mRNA transcript 
levels. However, hypoxia did not have any effect on transcript levels. In 
addition, significant correlations were observed in RA patients only, between B 
cells and APRIL, B cells and CP, APRIL and CP. This part of my thesis 
demonstrates that the aortic adventitia of RA patients with coronary heart 
disease is associated with an environment that is conducive to B cell survival and 
harbours a known RA-associated self-antigen. Importantly, these insights provide 
a rationale for the perpetuation of B cell auto-reactivity outside of both 
lymphoid tissue and the joint in RA. 
 
Previous studies have shown that atherosclerosis is a T cell mediated disease 
with an imbalance in Th1 and Th2 responses. Macrophages and interleukin 18 (IL-
18, proatherogenic) cytokine have been demonstrated in aortic adventitia of 
humans in previous studies. However, their expression in the vascular adventitia 
of RA patients has not been investigated. The present study confirmed 
macrophage IL-18 expression in vascular adventitia, which is similar among the 
Subgroups (RA vs. non RA) and (smokers vs. non smokers). 
Furthermore, a Th2 phenotype has been proposed as atheroprotective, mediated 
by anti oxLDL antibody producing B cells. Interestingly, recent studies have 
demonstrated interleukin 33 (IL-33) a Th2 cytokine to reduce the atherosclerotic 
lesion in an experimental model of atherosclerosis. However, it’s expression and 
significance in human vessels has not been extensively investigated. In this 
study, using immunohistochemistry, IL-33 was localised to vascular endothelial 
cells of vasa vasorum in aortic adventitia and lining layer of IMA. Importantly, IL-
33 was down regulated in smoker’s AA suggestive of failed protective mechanism 
of this Th2 cytokine. In contrast, IL-33 expression was not affected by smoking in 
the matched IMA tissue. 
 
 In the past B-lymphocytes have been shown as an atheroprotective pathway; 
whereas the use of B cells depletion therapy (Rituximab) suggests a 
proinflammatory role of these cells in RA. Could B cell depletion therefore 
mediate unexpected deficit on vascular lesions in RA? My thesis revealed 
expression of B cells and their survival factors in the aortic adventitia. Therefore 
to investigate the impact of B cell depletion therapy on atherosclerosis, a mouse 
model (huCD20/ApoE-/-) was generated. The preliminary data are suggestive of 
reduction in atherosclerotic plaques with B cells depletion. These studies will be 
extended in future to formally test the above hypothesis. 
 
In summary I have shown for the first time the cytokine and cellular niche that 
exists in human aorta in RA patients.  Such data will in due course inform the 
mechanism of accelerated vascular pathogenesis in RA. 
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1 Introduction 
1.1 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic progressive systemic autoimmune disease, 
which is characterized by joint destruction. It affects 1% of the adult population 
and women have a three times greater risk of developing disease compared to 
men. People of any age group can be affected but most frequently the onset of 
the disease is between the age of 40-50 year 1.  
In 1859 Garrod was the first to define Rheumatoid Arthritis (RA) as a disease and 
since then it has been recognised as a painful and disabling condition, which can 
lead to extensive compromise of function and mobility. The American 
Rheumatism Association set an initial criterion collection for clinically defining 
this disease, which have been a useful tool in the clinical diagnosis of disease 
and the selection of patients for the clinical trials 2. However, even with defined 
criteria for the diagnosis of RA in patients (Table 1)2 this is inadequate for the 
early diagnosis of patients, given that at least two of the seven criteria (nodules 
and erosions) are not present in the early stages of disease. One of the classical 
diagnostic criteria for RA is rheumatoid factor (RF), an autoantibody with 
specificity for the Fc region of immunoglobulin (IgG). However, the specificity of 
RF was argued and reported to be the result of secondary immune response 
during immune complex formation 3. Importantly, experimental studies have 
failed to attribute a pathogenic role to RF in rheumatoid arthritis. Even with its 
undefined role in RA pathogenesis, the diagnostic utility of RF, in conjunction 
with the other criteria, is indisputable.  Recently new criteria have been 
generated by a combined ACR / EULAR initiative.  Although not yet generally 
available for publication in this thesis they will allow early attribution of the 
diagnosis of RA and in the long term improved outcomes as clinical alogrithms 
evolve.  
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Table 1.1. ACR criteria for rheumatoid arthritis 
 
A patient is said to have rheumatoid arthritis if he or she meets at least four 
criteria. 
1. Morning stiffness lasting at least 1 hr, present for at least 6 weeks 
2. A least three joint areas simultaneously with soft-tissue swelling or fluid for     
at least 6 weeks 
3. At least one area swollen in a wrist, metacarpophalangeal or proximal 
interphalangeal joint, for at least 6 weeks 
4. Simultaneous involvement of the same joint areas on both sides of the body, 
for at least 6 weeks 
5. Subcutaneous nodules seen by a doctor 
6. Positive rheumatoid factor 
7. Radiographic changes on hand and wrist radiographs (erosions or unequivocal     
bony decalcification) 
 
1.1.1 Aetiology and Pathogenesis 
1.1.2 Joint inflammation 
The main feature of RA is joint damage, which is seen as a result of bone and 
cartilage erosion. The chronic progress in joint inflammation results in narrowing 
of joint spaces and severe deformity, which is associated with swelling, pain and 
loss of function.     
The precise mechanism of RA is not clear, however, during the past three 
decades many susceptibility genes have been identified. Including the major 
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histocompatibility complex class II (MHC II), which is strongly associated with RA 
4, 5. More specifically, the HLA DRB1 shared epitope alleles (SE) were identified 
as a major genetic risk factor for RA, and a rationale for MHC class II mediated 
activation of T cell was put forward 6. Around 80% of RA patients express DR4 
and DR1, which share an epitope mapping to amino acids 70-74 (QKRAA) of the 
DRβ chain 6.  Many other gene associations have also been identified including 
for example PTPN22, C-type lectin and interferon regulatory factor-5 (IRF-5) 7-9. 
Over the years epidemiological studies have highlighted a strong association 
between smoking and RA. Initially, smoking was not considered as an etiological 
factor in the pathogenesis of RA. However, a fascinating interaction was 
confirmed in RA patients between the shared epitope HLA-DRB1 and smoking 10, 
11. 
 
 Although we do not conclusively know the initiating events that lead to chronic 
disease, studies have demonstrated that joint damage is a result of chronic 
inflammation of the synovial membrane. The synovial membrane becomes 
hyperplastic with cellular infiltrates, which include macrophages, mast cells, 
CD4+ T cells, CD8+ T cells, B cells, plasma cells, natural killer (NK) cells and NKT 
cells. Synovitis is associated with extensive cellular infiltrates - pathogenesis of 
disease is thought to driven by antigen specific responses. This can be partly 
thought to be due to antigen presenting cells (APC) interacting with T cells 
through their MHC and T cell receptor (TCR) receptor respectively. This results 
not only in T cell activation, via co-stimulatory signals mediated through 
CD80/86 or CD28-B.7 receptor 12, but also in the activation of the APC. In 
response to activation, T cells and APC (macrophages or dendritic cells, or 
potentially B cells) produce pro-inflammatory cytokines, such as TNFα, 
interleukin 6 (IL-6), IL-12, IL-23 and interleukin 1 (IL-1) 13-15. This cytokine 
environment can promote the differentiation of naïve T cells to alternative 
phenotypes such as T helper 1 and Th 17, an IL-6 dependent T cell phenotype 
that produces amongst other things IL-17. Cytokines are implicated at every 
stage of RA pathogenesis from maintaining a chronic inflammatory synovitis to 
promoting articular destruction, through the subsequent activation of 
osteoclasts, chondrocytes and synovial fibroblasts 16. In addition, to the 
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initiating autoimmunity it has also been proposed that chronic inflammation and 
articular damage can lead to the generation of neo-epitopes that promote 
further autoimmune responses. Finally, it should also be appreciated that 
inflamed joints are associated with a hypoxic environment, which supports 
angiogenesis 17. 
Serological markers in RA 
Rheumatoid factor (RF) has been widely used as a serological marker for the 
diagnosis of rheumatoid arthritis and is currently the only serological marker 
included in the ACR criteria, however, its specificity is limited as it can also be 
found in other diseases. More recently, an important addition in the clinician’s 
diagnostic arsenal has emerged in the form of a new serological marker, anti-
citrullinated peptide antibodies (ACPA). These antibodies are specific for 
citrullinated proteins, which will be discussed in detail (Section 1.1.2.1). ACPA 
are now recognised as a more specific diagnostic tool for RA patients and will be 
included in new EULAR / ACR criteria 18. The sensitivity of ACPA is similar to RF 
ranging from 55% to 80%, however, ACPA are highly specific for RA (98%) 19. They 
are also detectable in the early stage of the disease. The presence of these 
highly specific ACPA in 55-80% of patients does suggest that there are two 
distinct subsets of RA, an ACPA positive and an ACPA negative subset. Genetic 
associations in RA patients further support this RA sub-setting. The PTPN22 gene 
has a strong association with the ACPA positive RA patients 8, while other genes 
such as C-type lectin 7 and Interferon regulatory factor 5 (IRF-5) are exclusively  
associated with ACPA negative RA patients 9.   
The presence of ACPA is strongly associated with the shared epitope gene 
HLADRB 1 within the major histocompatibility complex (MHC) in RA pathogenesis 
. This association between ACPA and HLADRB1 is true for 60% of RA patients; 
whereas, the remaining patients of the ACPA negative subset completely lack 
this genetic association 10 20-22. It is established that smoking is a risk factor for 
ACPA positive subset of RA and no link existed between smoking and ACPA 
negative subset. In humans, a comparison of citrullinated protein in broncho-
alveolar lavage (BLA) cells between smokers and non smokers revealed 
dominance of citrullinated protein among smokers 10.  
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 Immunity to citrullinated Protein in RA 
 In the early 1960’s it was demonstrated that RA serum contained an anti-
perinuclear factor; by the end of the 1970’s this reactivity was shown to be  
against keratin. This was further defined in the late 1990’s by Schellekens et al 
who demonstrated that the actual reactivity of these autoantibodies was 
directed against self-proteins with citrullinated epitopes. Since then a number of 
proteins have been proposed as potential targets of ACPA. RA synovium harbours 
citrullinated fibrin as a target of anti-filaggrin auto-antibodies  (AFA) 23 while, 
vimentin 24, collagen 25, Epstein-Barr virus nuclear antigen 1 26 and alpha enolase 
27 were also introduced as potential targets of the anti-citrulline antibodies.  
Citrulline a product of deimination 
Citrulline (cit) is an amino acid that can be formed as a result of a 
posttranslational modification, the deimination of the amino acid arginine (arg). 
This conversion of arginine to citrulline is performed by one of the five known 
enzymes in humans designated as peptidyl arginine deiminases (PADIs) 28, 29. The 
isoenzymes of PADI listed in (Table 1.2) are all calcium dependent and tissue 
specific. The physiological role of these isozymes is unclear and still needs to be 
addressed. Cytoskeletal proteins reported to undergo citrullination include 
cytokeratin (intermediate filament in keratinocytes), filaggrin, vimentin, glial 
fibrillary acidic protein (specific to astrocytes), myelin basic protein (produced 
by oligodendrocytes), and histones 30. Peptidyl arginine deiminase also catalyzes 
deimination of arginine under inflammatory conditions, as was demonstrated in 
the lining and sublining layer of RA synovium 31. Other tissues have been shown 
to contain citrullinated proteins including; Stratum corneum of human epidermis 
32, the deep cornified layer of human epidermis (citrullinated keratin, more 
specifically filaggirin) 33 and glial cells in the brain 34, 35. Although, citrullinated 
proteins are found in different tissues constitutively, their functional 
significance is unclear. Perhaps, posttranslational modification of 
peptidylarginine a positively charged form to a neutral peptidylcitrulline makes 
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proteins vulnerable to proteolytic degradation, due to changes in the primary, 
secondary and tertiary structure of proteins 30. Nevertheless, it cannot be 
assumed that citrullination is designated for physiological denaturation. 
Peptidylarginine deiminases:  
 PADI isozymes  Expressed in Tissues  
1 PADI1 Epidermis  
2 PADI2 Skeletal muscle, spleen, brain, secretory glands 
3 PADI3 Hair follicle 
4 PADI4 Neutrophils, Eosinophils, T cells, B-cells, FLS and 
endothelial cells.  
5 PADI6 Eggs ovaries and embryos 
Table 1.2. Human isozymes of Peptidyl arginine deiminases 
 
There are factors that regulate these deiminases. For instance, the epidermal 
isozyme has been shown to be highly calcium dependent with special preference 
to specific pH in vitro 36. The activation of these isozymes is optimal under high 
calcium concentrations. Interestingly, in physiological conditions calcium 
concentrations are low and these isozymes remain inactive. Takahara et al 
demonstrated that the PADI2 isoform is activated at Ca2+ concentration of 40-60 
µM. This enzyme is inactive at intracellular calcium concentrations. Either it is 
calcium ion influx or release of PADI from the cells that ultimately exposes it to 
high calcium levels that cause its activation 37. So this might support the 
argument that ‘intense’ conditions, like terminal differentiation occurring in the 
stratified layer of the skin, apoptosis and oxidative stress during inflammatory 
responses, triggers activation of these isozymes and ultimately citrullination of 
protein takes place.  
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The peptidylarginine deiminase isozymes 1-4 have been examined in the synovial 
tissue of RA patients; PADI2 and PADI4 were specifically found to be expressed in 
the RA synovium with a strong association with severity of inflammation 38. In 
addition, at a pathophysiological level the presence of ACPA in around 80% of RA 
patients and the genetic association of PADI 4 in (Koreans and Japanese) with 
inflamed synovium supports the notion that PADI might have a critical role in RA 
pathogenesis 39. As shown in table 2, PADI4 is expressed in neutrophils, 
eosinophils, natural killer (NK) cells, T cells and B cells. In addition, non-
haemopoietic lineage cells e.g. fibroblast like synoviocytes (FLS), endothelial 
cells and sublining areas of RA synovium can also express this isoform. 
Importantly, citrullinated proteins were co localized with PADI4 around the 
lining and sublining layer of RA patients 37.  
 A model of RA pathogenesis 
1 Klareskog et al presented an etiological model for disease pathogenesis in 
the ACPA positive subset of RA.  It was proposed that smoking as an 
environmental factor triggers the citrullination of proteins in the lungs, 
which results in the generation of an immune response and production of 
ACPA in genetically susceptible individuals (HLA DRB1 shared epitope). In 
these individuals, any type of trauma or infection that leads to a non-
specific inflammatory environment in joints could result in citrullination of 
proteins in the affected joints 40. Pre-existing circulating ACPAs enter the 
joint and form immune complexes with the newly generated citrullinated 
proteins. The formation of these CP immune complexes leads to the 
recruitment of inflammatory cells, secretion of pro-inflammatory cytokines, 
and antibody production that eventually results in the development of 
chronic RA (Figure 1.1,Taken from Annual Review immunology)6. 
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Figure 1.1 A possible Etiological model for ACPA positive subset of RA 
 
1.1.3 Disease progression and Treatment  
1.1.3.1 Treatment 
There is no known cure for RA but many treatments are in place to stop the 
progression of this chronic ailment. Early and aggressive treatment of RA 
patients with disease modifying anti-rheumatic drugs, such as sulfasalzine, 
hydroxychloroquine, methotrexate, leflunomide and glucocorticoids is the first 
line of care. These small molecules, so called conventional disease modifying 
anti-rheumatic drugs (DMARD), are effective at controlling inflammatory activity 
41. Recently, a new powerful emerging therapeutic arsenal for the 
rheumatologist has changed practice namely the advent of biological agents. The 
first of these biological therapies was the anti-TNFα monoclonal antibody, 
infliximab 42. Many different TNF blocking agents are now used in clinical 
practice; infliximab (chimeric anti TNF antibody), adalimumab (humanized anti 
TNF antibody) and etanercept (soluble TNF receptor).  Two new agents will 
shortly be available, namely certolizumab (a pegylated Fab anti-TNF) and 
golimumab (a monoclonal antibody with monthly administration). TNF blockade 
provides approximately 60% improvement at the ACR20 level in MTX inadequate 
responder patients. However only around 25% of patients achieve a DAS29 low 
disease state or ACR70 level of improvement. Moreover, remission is not well 
maintained even if achieved in a majority of patients. Therefore new biologic 
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agents have emerged. Most recent in the cytokine blockade field, an alternative 
to the TNFα blocking agents is the anti-IL-6 receptor antibody, Tocilizumab 43.  
This is now licenced and approved for use on a wide basis and delivers 
approximately similar responses to TNF blockade if used for first biologic in MTX-
IR population but lower rates of responses in TNF blockade resistant patients. 
This initial trend for targeting biological agents to specific cytokines and their 
receptors, however, does not always prove to be efficacious. This was the case 
for the recombinant interleukin 1 receptor antagonist, anakinra, which although 
reduced erosion in RA patients did not match the effectiveness of TNF blocking 
agents 44.  
Some of the most recent additions to the therapeutic armamentarium have been 
generated to specifically target T and B-lymphocytes 43. Abatacept is a fusion 
protein that blocks the co-stimulatory signals necessary for T cell activation; it is 
composed of an immunoglobulin Fc region fused to the extracellular domain of 
CTLA4. This mechanism of action for this fusion protein relies on its ability to 
interact with B7 on APC and therefore inhibit this APC – T cell co-receptor 
interaction 43. When it comes to refractory cases of rheumatoid arthritis, in 
particular those that are anti-TNFα non-responders, a further therapeutic option 
is B cell depletion therapy. This therapy utilises a monoclonal antibody 
(Rituximab) that binds to the CD20 receptor present on the surface of pre B and 
mature B cells resulting in the depletion of circulating B cells 45.  The 
therapeutic and pathogenetic clues offered by this approach formed an 
important part of my thinking in generating the data contained in my thesis.  
  
1.2 B lymphocytes in RA 
Thirty years ago research in RA was focused on B cells because of the importance 
of RF - with time trends changed and cytokines and T cells were seen as the 
more relevant aspect of RA immunopathology. More recently with the advent of 
B cell depleting agents it is now appreciated that the immunopathology is not 
restricted to one cell type or cytokine. In fact to understand the disease we 
have to have a thorough understanding of all the immune components. 
Researchers have also started to think outside of the box and investigate non-
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traditional functions of cells demonstrating for example that B cells have 
additional immune functions (Table 1.3 Adapted from Martinez-Gamboa et al 46) 
Table 1.3. Role of B cells in the regulation of immune responses 
 
• As precursors of (auto) antibody-secreting plasma cells  
• As antigen presenting cells  
• In the differentiation of follicular dendritic cells in secondary lymphoid 
organs 
• In lymphoid organogenesis  
• In the initiation and regulation of T and B cell responses  
• In the differentiation of effector T cells  
• In the polarization into cytokine producing effector B cells  
• In the expression of co-stimulatory molecules  
• In the immune regulation (IL-10 positive B cells) 
 
1.2.1 Murine B lymphocytes 
Murine B cells can be divided into various subsets, some of which reside in 
specific anatomical locations e.g. B-1 B cell, which is a population primarily seen 
in the pleural and peritoneal body cavities. Another is the B-2 population, which 
is found in spleen, lymph nodes and blood. They are further classified on the 
basis of function, micro anatomical location and expression of surface receptors. 
Newly formed B cells are generated in the bone marrow and once they 
differentiate to an ‘immature stage’ they migrate to the spleen and can be 
identified based on surface expression of markers, IgMhi IgDhi CD21- CD23- CD24hi 
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are termed transitional type-1 (T1). These cells further differentiate into 
transitional type-2 (T2) B cells IgMhi IgDhi CD21hi CD23hi CD24hi. From these 
transitional cells marginal zone and mature follicular (B2) B cells are generated. 
Marginal zone B cells, IgMhi IgDlo CD21hi CD23- CD24hi are a specialized population 
that reside in the marginal sinus of the spleen. Whilst B2 cells which reside in 
the main follicle (inside of the marginal sinus) and express IgMhi IgDlo CD21int 
CD23hi CD24int. Interestingly, humans do not have exactly the same functional 
equivalent subsets compared to the murine B cell populations 47. 
For a long time RA was regarded as a disease mediated by macrophages and T 
cells 48. However, a case report for a 53 year old suffering from non-Hodgkin 
lymphoma (NHL) with coexistent RA, showed that after a course of B cell 
depletion therapy to treat the NHL, which in this instance was unresponsive, 
resulted in an enormous improvement in the patient’s inflammatory synovitis.  
Importantly, this observation recognized a central role for B cells in RA 
pathogenesis 49. This was further supported by another case of RA in association 
with chronic lymphocytic leukaemia (CLL). This patient had a significant 
decrease in the RA symptoms after the selective depletion of B cells by 
Rituximab a monoclonal antibody to CD20 receptor specific to B cells 50. These 
findings were further confirmed by a randomized clinical trial, where selective 
depletion of B-lymphocytes in combination with methotrexate resulted in 50% 
improvement in clinical symptoms according to ACR criteria in 43% of RA 
patients at week 24 45.  
Many theories have been proposed to explain not only the mechanism behind the 
B cell depletion but also its efficacy in RA. It is currently assumed that the 
mechanism of action of B cell depleting agents could be through different 
pathways, one of them is antibody dependent cell mediated cytotoxicity (ADCC) 
or phagocytosis, which requires recognition of Fc portion of bound rituximab by 
Fcγ receptors and complement receptors 1 and 3 on macrophages 51, 52. Studies 
have demonstrated that rituximab binding causes activation of the complement 
cascade, generating membrane attack complex that leads to lysis of B cells 53, 54. 
Finally, rituximab bound B cells are recognised by natural killer cells via FcγRIII 
and complement receptor 3 that induces cytotoxicity of B cells 55.  
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Given that B cells are depleted it still remains for us to understand why the 
depletion of B cells actually leads to clinical improvement in RA patients. In 
explanation, B cells have various functions (Table 1.3), and various studies have 
been performed to investigate certain aspects of B cell biology is relation to RA. 
The autoantibody (Rheumatoid factor) secreting function of B cells in RA was 
recognised decades ago. Recently, the finding of autoantibodies to citrullinated 
peptide at an early stage of RA has resulted in enhanced diagnostic specificity 56. 
These autoantibodies can form immune complexes that mediate activation of B 
cells and follicular dendritic cells (FDCs) through complement receptor (CR1 & 
CR2) and Fc receptors 57.  Cytokine production is a known effector response of T 
cells and macrophages. Studies have shown that B cells can secrete IL-6, 
lymphotoxin and TNFα, which then amplify immune responses 58. However, 
further studies are required to properly characterize the cytokine producing 
ability of B cells in the synovium. Their ability as antigen presenting cells may 
also be important in the joints, as the B cell depletion therapy impaired ectopic 
germinal centre formation and the optimal activation of T cells 59. 
Antigen specific B cells are known to have the capacity to internalize and 
process antigens to peptides. Thereafter, antigen presentation of these peptides 
is executed normally through presentation on the major histocompatibility 
complex (MHC) class II molecule. Importantly, the involvement of HLA-DR4 in 
this antigen presentation through B cells signifies a link between B lymphocytes 
and arthritis pathophysiology 46. Adoptive transfer of CD4+ T cells into SCID mice 
induced disease only in the presence of B cells, depletion of B cells with anti-
CD20 mAb inhibited production of IFNγ and IL-1β suggesting a central role for 
viable B cells in the disease 59. In the diseased synovium, cellular infiltrates 
include T lymphocytes, B cells and macrophages. In fact a non lymphoid tissue 
like synovial membrane in patients contains the presence of germinal centres 
closely resembling the germinal centre characteristic of secondary lymphoid 
organs 60. Humby et al demonstrated that the ectopic germinal centres in RA 
synovium express activation induced cytidine deaminase (AID) an enzyme that 
influences somatic hypermutation and class switch recombination (CSR) of Ig 
genes. They also confirmed that these germinal centres are associated with 
ACPA producing plasma cells suggestive of functional aggregates of B cells in the 
inflamed synovium 61. In another study B cell activating factor (BAFF or BLys) of 
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TNFα family is produced by fibroblast like synoviocytes (FLS) in the lining layer 
of synovial membrane, which then supports the survival of B cells in the disease 
membrane. In fact TNFα and INFγ could influence the release of BAFF 62. 
1.2.2 Factors affecting B cell differentiation and survival  
Like every proliferating cell, lymphocytes also seek appropriate support from the 
environment via elaboration of growth and survival factors. Lack of these signals 
can result in inefficient performance and some of the cells may die. B cell 
activation factor (BAFF) also known as Blys (B lymphocyte stimulator) is a 
member of Tumor necrosis factor (TNF) family. As the name implies it is a 
survival factor for transitional and mature B-lymphocytes. Another factor closely 
related to BAFF that shares some of its receptors and functional properties is a 
proliferation inducing ligand (APRIL). 
1.2.2.1 B cell activation factor  
A member of TNF family, known as a potent stimulator of B lymphocyte survival   
has many designations like (Blys, BAFF, zTNF4, TALL-1 and THANK) 63-65 
Chromosomal mapping of BAFF gene revealed that it is located on chromosome  
13q34 66. BAFF expression is seen in macrophages, monocytes, T-cells and 
dendritic cells. In addition, non haematopoietic cells like osteoclasts, fibroblast 
like synoviocytes and adipocytes produce BAFF as well 67, 68.  
Structure: 
BAFF is a type II membrane bound protein, which has three domains. An 
intracellular TNF homology domain (THD), one transmembrane domain with a 
furin processing site and an extracellular domain 69. The extracellular domains of 
BAFF form a trimeric complex on the surface of cells and after proteolytic 
cleavage at the furin site a functional soluble trimeric complex. Unlike other 
TNF members, the BAFF trimer has an altered long loop conformation, a β strand 
and a long D-E loop, which is seen as negatively charged deep concave region 70. 
Stability of the trimeric structure is ensured by the presence of the magnesium 
ions that binds along the three fold axis 71, 72. 
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BAFF Receptors: 
BAFF has the ability to bind to three known receptors; B cell maturation antigen 
(BCMA) and transmembrane activator, cyclophilin ligand interactor (TACI) and 
BAFF-receptor. All of these receptors belong to the TNF receptor superfamily 
(Figure 1.2) 63. BCMA and TACI have a cysteine rich extracellular domain, a 
signature of TNF receptors, which contains two to eight cysteine residues 
stabilized by disulphide bonds. BAFF-R differs from the other two receptors 
because it only contains four cysteine residues in the extracellular domain, 
which makes it the smallest cysteine rich domain (CRD) in TNF receptor 
superfamily. Importantly, BAFF-r also differs from BCMA and TACI because it 
only binds to BAFF 73, whilst the other two receptors also interact with APRIL. 
The ligand-binding region in these receptors normally requires the participation 
of only two cysteine residues. All these receptors are type III membrane proteins 
with multiple transmembrane domains that span the entire membrane. 
However, they do have a similar orientation to type I membrane protein 74.  
As indicated above, BAFF shares the BCMA and TACI receptors with APRIL. BCMA 
was shown to be mainly expressed on mature B cells and was initially identified 
in cells of lymphoma patients with chromosomal translocation 75. TACI 
expression was confirmed on B lymphocytes and non resting T cells, TACI 
stimulation triggers calcium dependent transcription factor i.e. nuclear factor of 
activated T cells (NF-AT) 76.  
1.2.2.2 A Proliferation inducing ligand (APRIL) 
 APRIL, also known as TALL2, and is structurally related to BAFF i.e. a type II 
transmembrane protein with a trimeric assembly, with an extracelluar domain 
formed by 201 amino acids and a cytoplasmic domain consisting of 28 amino 
acids. APRIL has the unique ability to undergo maturation cleavage at the furin 
site inside the cell within the Golgi complex. This intracellular processing is 
carried out by furin convertase 77(Figure 4, adapted from Annual Review 
immunology78). 
The unique furin processing site is located towards the NH2 terminal region of 
the protein and is common to both the BAFF and APRIL extracelluar domains. 
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However, the cleaved APRIL containing the short NH2 consist of a unique cluster 
of amino acid (QKQKKQ) not found in BAFF. This unique sequence binds to 
glycosaminoglycan, which enables APRIL specifically bind to sydecan-1 on plasma 
cells and proteoglycan on non-haematopoietic cells 79.  
There is a wide range of immune cells that express APRIL including monocyte, 
macrophages, dendritic cells and T cells. In addition to haematopoietic cells, 
other cell types produce APRIL i.e. osteoclasts and tumour cells 68. In fact in 
breast cancer tissue APRIL and BAFF are expressed by infiltrating cells, epithelial 
cells and glands 67.  
 
 
 
Figure 1.2 Illustration of functions and receptors of BAFF and APRIL 
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APRIL Receptors: 
APRIL has a high affinity for the TNF receptors TACI and BCMA but does not 
interact with BAFF-R 68. However, APRIL binds preferentially to B cell maturation 
antigen (BCMA). It has been proposed that an APRIL specific receptor exists but 
it currently has not been identified 80.  
Different B cells at various stages express the receptors for APRIL and BAFF. 
Humans and mice both express BAFF-R on peripheral B cells and as B cells 
differentiation to plasma cells they lose the expression of BAFF-R. TACI is found 
on different B cell subsets like MZ, transitional T1 and T2 but not germinal 
centre B cells; whereas, BCMA is mainly expressed by the germinal centre B cells 
and plasma cells 81. 
 
Biological functions  
TNF receptors also called “Death receptor” have a signature death domain that 
contains TNF receptor associated factor (TRAFs) that upon stimulation can result 
in either apoptosis or survival. Receptors for BAFF and APRIL lack the death 
domains that are typical of TNF receptor family. It was established in BAFF 
deficient mice that secondary lymphoid organs lost 90% of marginal zone and 
follicular B-lymphocytes, which illustrates that BAFF plays a critical role as a 
survival factor 82. Transgenic mice over expressing Bcl-2 with BAFF deficiency 
failed to rescue B cells and showed their lack of ability to have B cell 
maturation, which suggested that BAFF promote B cell differentiation and 
prevents them from apoptosis as well 83. 
At a functional level, the antigen presentation ability of B cells is increased by 
APRIL. This is mediated through BCMA, whereby APRIL induces the up regulation 
of MHC class II and the co-stimulatory molecules CD80, CD86, CD40 and CD54. In 
addition APRIL binding to BCMA activates the NF-κB and JNK signalling pathways 
84. In another study lack of APRIL lead to an increased effector and memory T 
cells and impairment of IgA class switching recombination CSR 85. In vitro data 
suggests that APRIL can also induce megakaryocytopoeisis, which implies 
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delineation of progenitor cells to megakaryoblasts, megakaryocytes and finally 
to platelet fragments 86. Moreover, APRIL transgenic mice promote the formation 
of B-1 linked neoplasm, in fact high levels of APRIL in sera of patients suffering 
form B cell chronic lymphoid leukaemia (B-CLL) supported the notion 87. 
 
1.3 Rheumatoid Arthritis and vascular risk 
Rheumatoid arthritis primarily affects joints although around 15-20% of the 
patients exhibit extra-articular features; conventionally manifest as pericarditis, 
pleuritis, major cutaneous vasculitis, anemia, episcleritis and 
glomerulonephritis88. There is now extensive evidence based on observational 
cohort and case control studies that rheumatoid arthritis is strongly associated 
with cardiovascular morbidity and mortality 89-91. 
Many autoimmune diseases including; RA, systemic lupus erythematosis (SLE), 
antiphospholipid syndrome, systemic sclerosis and primary systemic vasculitis 
are associated with increased risk of cardiovascular morbidity and mortality 92. 
This can primarily be attributed to accelerated atherosclerosis 93. As we have 
already discussed RA as a chronic autoimmune arthropathy manifested by 
cartilage and bone damage resulting in deterioration of both social and physical 
abilities of the patients. In fact reduced physical activity of RA patient 
significantly increased CVD risk profile as compared to physically active patients 
94. However, RA is associated with accelerated atherosclerosis and reduced life 
expectancy. This overt rise in mortality cannot be explained with the classical 
risk factors like diabetes mellitus, dyslipoproteinemia, tobacco smoking, high 
blood pressure, advanced age and genetic abnormalities 95. In one study where 
RA patients were evaluated over a period of 20 years, it was revealed that the 
these patients had 50% mortality due to cardiovascular disease 96. Similarly, in a 
prospective cohort of female patients with rheumatoid arthritis it was 
demonstrated that they had a relative risk for myocardial infarction (3.10, 95% 
CI) 97. The cardiovascular events in RA patients equal that of DM2. This increased 
risk requires cardiovascular risk management as in DM2 98.  
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In Northern Sweden a cohort of seropositive RA patients were followed for 15 
years. This cohort showed that both sexes had an increased standardized 
mortality ratio of 1.46 in cardiovascular disease (CVD) and 1.54 in ischemic heart 
disease (IHD) 99. In an additional study in North America, a cohort of 236 patients 
revealed an approximate 4-fold rise in cardiovascular events. Importantly, 
analysis of the patients follow up over this 8 year period excluded traditional 
risk factors like smoking, hypercholesterolemia and diabetes mellitus as the 
underlying mechanism of cardiovascular diseases. These findings suggested that 
systemic inflammation in RA patients is the culprit 100. A similar observation was 
made in RA patients with a specific genetic constituent (HLADRB1) 101. 
The chronic systemic inflammatory milieu associated with RA sets a stage that 
accelerates the atherosclerotic disease102. A meta-analysis of observational 
studies by Avina-Zubieta et al substantiated the increased cardiovascular risk in 
RA patients, concluding that in comparison to the general population RA patients 
have a 50% higher CVD mortality 103. In a study to evaluate recent onset RA, 
patients were evaluated for sub-clinical atherosclerosis using ultrasonography to 
measure the carotid intima-media thickness (cIMT). The CRP level in these 
patients correlated with increased (cIMT) indicative of the presence of plaques 
in the vessel wall of the patients 104 105. Vincenzo pasceri et al in an editorial 
discussed the similarities between atherosclerosis and rheumatoid arthritis and 
argued that various cell types (CD3+, CD4+ CD28-), adhesion molecules (VCAM-1, 
ICAM-1, E-selectin, P-selectin), cytokines (TNFα, IL-6, IL-2), metalloprotienases, 
and autoantibodies (OxLDL, HSP) show striking similarity between RA and 
unstable angina 106. 
1.3.1 Atherosclerosis (a priori) 
Atherosclerosis is a chronic inflammatory response characterized by asymmetric 
focal thickening of the intima, resulting in luminal narrowing of blood vessels. 
Atherosclerosis is one of the major causes of cardiovascular diseases (CVD) 
worldwide, which is a principal cause of death and illness in the developed 
countries 107-109. CVD refers to a group of diseases that includes cerebrovascular 
accidents (stroke), coronary artery disease, myocardial infarction, congestive 
heart failure, angina, and aneurysms.  
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Atherosclerosis starts at an early age and gradually transforms into a complex 
structure. The atherosclerotic lesion undergoes transformation from an initial 
phase where lipid droplets and immune cells merely exist, to a state where lipid 
laden foam cells are dominant and called the fatty streak 110. This is followed by 
a more complex phase of atheroma 111, in this mature phase the plaque is 
composed of endothelial cells (ECs), leukocytes, foam cells, smooth muscle cells 
(SMCs), a necrotic core, accumulated modified lipids and calcified regions 112. All 
this takes place in the intimal layer of the vasculature and is accompanied by 
fibrous proliferation that marks the asymmetrical luminal narrowing of the blood 
vessels.  Over a century ago two pathologists proposed contrasting ideas 
regarding the initiation of this complex disease. Carl von Rokitansky proposed 
atherosclerotic inflammation to be a result of endothelial dysfunction caused by 
mechanical injury and toxins. Whereas, Rudolf Virchow believed that changes of 
cells were critical in atherosclerosis and coined the term cellular pathology 113.   
Almost two decades ago we started to appreciate a principal role for 
inflammation in atherosclerosis leading to major complications like myocardial 
infarction, stroke and vascular claudication. Steinberg postulated chemically 
modified lipoproteins to be the initiating factor, notably the oxidized low-
density lipoproteins (OxLDL), leading to the primary formation of foam cells in 
the intima 114. This was termed as the “altered lipoprotein hypothesis”. 
Alternatively, in 1993 Ross suggested “response to injury hypothesis”, which is 
an alteration of the endothelium and intima due to insults e.g. mechanical 
injury, toxins, and oxygen radicals that initiated the events leading to 
endothelial dysfunction 115. These two processes favour the “inside-out” theory 
(see section 1.3.2), the traditional concept of vascular inflammation. However, 
the growing evidence for functional significance of vascular adventitia in the last 
decade has resulted in a new concept of  “outside-in” hypothesis that will be 
discussed in a later section (1.3.3) 116. 
1.3.1.1 Structure of a normal Blood vessel 
It is important to know the basic structure of a normal blood vessel wall to 
understand the pathogenesis of atherosclerosis. A blood vessel is comprised of 
three layers, the intima, media and adventitia. The tunica intima is the inner 
most layer, which is comprised of a simple monolayer of endothelial cells 
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arranged on a basement membrane made of type IV collagen, laminin and 
sulphate proteoglycans. Finally, there is an internal elastic lamina made of 
insoluble protein polymer elastin that separates the tunica intima from media. 
The normal tunica media is the middle layer that contains exclusively vascular 
SMCs enclosed by basement membrane and embedded within an interstitial 
matrix. Whereas, the outer most layer is the tunica adventitia, a loose 
connective tissue comprised of fat cells, fibroblasts and capillaries separated 
from the tunica media by an external elastic lamina 117. 
1.3.2 The inside out phenomenon 
As the name implies the inside out theory begins at the tunica intima. An 
elevated level of lipid in the blood allows the low-density lipoproteins to diffuse 
into the tunica intima. This accumulation of LDL in the extracellular 
compartment leads to its modification, under the influence of enzymes and 
oxygen radicals, to OxLDL. This in turn results in the expression of vascular cell 
adhesion molecule 1 (VCAM1) and/or Intercellular adhesion molecule 1 (ICAM1) 
by endothelial cells, which promotes migration and invasion of monocytes and T 
cells into the intima 111.  
 
Figure 1.3 The focal intimal thickening of a blood.  
Tunica intima with plaque shows smooth muscle cells, foam cells formation and 
activated T cells. Leukocytes and platelets can be seen attached to lining 
endothelium. Tunica media (M) is a thick layer of smooth muscle cells and tunica 
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adventitia (A) the outer most layers of adipocytes (adapted from Hannson at el. 
Nat Rev Immunol 2006). 
 
The recruited monocytes, supported by the growth factor m-CSF, differentiate 
into macrophages. The resulting macrophages binds modified LDL through 
scavenger receptors (SR) that includes CD36, SR-A and SR-B1 118-120. Macrophages 
in human atherosclerotic lesions are shown to express TLR2 and TLR4 that can 
bind modified LDL whose uptake results in foam cell formation 121. Antigen 
presented by macrophages and dendritic cells (antigen presenting cells) activate 
lymphocytes, which produce Th1 cytokines (IL-12, IL-18, INFγ and Tumor necrosis 
factor-alpha) 111. The persistent inflammatory response is manifested as focal 
thickening of tunica intima with a core of cholesterol and cellular debris, 
surrounded by a fibrous cap of collagen fibre and smooth muscle cells, the set of 
events following the initiation of atherosclerosis at the tunica intima (Figure 1.3, 
taken form Ross, 1999). 
1.3.3 The outside in phenomenon  
The basic mechanism underlying the pathogenesis of atherosclerosis was 
revisited and an alternative hypothesis was proposed stating that the pathology 
of disease can be initiated at the outer most layer of a blood vessel (tunica 
adventitia).  Maiellaro et al has attempted to elaborate this new paradigm, 
focusing on the role of the tunica adventitia in vascular inflammation. The 
theory is that a phenotypic switch of fibroblast to myofibroblast is caused by 
either (a) a tear of the elastic laminae or (b) by the products of chronic 
inflammation, i.e., cytokines, chemokines and leukotrienes  (Figure 1.4, 
Adapted from Maiellaro et al) 116 shows the proposed order of events (from left 
to right) involved in the initiation of the vascular inflammation, starting with  
phenotypic switch of fibroblast to contractile myofibroblast, neovascularization, 
lipid oxidation leading to T cell and a humoral immune responses.   
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Figure 1.4 The development of atherogenesis beginning at the adventitial layer  
This begins in response to a tear in elastic lamina or as a result of chronic 
inflammatory cytokines, chemokines. These results in (from left to right) 
phenotypic switch of adventitial fibroblast to contractile myofibroblasts, neo-
angiogenesis (vasa vasorum), lipid oxidation leads to T cell and humoral immune 
responses.  
The myofibroblasts release MCP-1 that aids in the recruitment of cells into the 
adventitia. In addition to the myofibroblasts ability to recruit cells, the 
endothelium of the vasa vasorum starts to express molecules like P-selectin and 
VCAM-1 that assist in cellular trafficking towards the adventitia. To help 
perpetuate this disease process, un-switched fibroblasts in the adventitia 
secrete collagen thereby providing an extracelluar matrix for newly recruited 
cells. This is accompanied by neovascularization and modification and uptake of 
LDL by the macrophages leading to formation of foam cell 116. Thereafter, foam 
cells activate T cells (Th1), which are followed by cytokines release, formation 
of ROS and apoptotic bodies at the site of lesion.   
1.3.4 Inflammation in Atherosclerosis  
A classical marker of inflammation is C-reactive protein (CRP), which is 
synthesized in the liver. Elevated levels of CRP in patients of unstable angina 
suggested that inflammation is critical in the pathogenesis of the disease 122. 
Interestingly, significant levels of CRP in sub-clinical cases of myocardial 
infarction labelled it as an independent risk factor for this disease 123. More 
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recently, the measurement of CRP level has been found to be useful in 
predicting diseases like stroke, peripheral vascular disease and myocardial 
infarction124. 
1.3.5 Oxidized LDL triggers an inflammatory response 
Hyperlipidemia is defined as abnormally raised levels of lipids (LDL) in the blood 
and is thought to be the primary cause of atherosclerosis. The altered lipid 
levels are though to result in the transmigration of LDL across the vascular 
endothelial cells. Two decades ago, Witztum et al showed that in LDL receptor 
deficient rabbits atherosclerotic lesions contained modified oxLDL 125. In ApoE 
knockout mice, an animal model of atherosclerosis, it has been shown that 
endothelial activation in response to modified LDL, either through oxidation or 
enzymatic process, results in the expression of ICAM-1 and VCAM-1 that in turn 
recruits inflammatory cells to the site of hemodynamic strain 126.  
1.3.6 Monocyte recruitment to Macrophage activation 
The recruitment of monocytes by the activated vascular endothelial cells was 
first demonstrated in the pre-lesional intima 127. The differentiation of 
monocytes into long-lived macrophage takes place in the intima. The factor 
responsible for this differentiation is (MCSF), the osteopetrotic (op) deficient 
mice do not produce (MCSF), and in double knockout (op/ApoE-/-) reduction in 
lesion size demonstrated (MCSF) significance in atherosclerosis 128. 
Activated macrophages tend to express Pattern recognition receptor (PRRs), 
which includes scavenger receptors (SRs) and toll like receptors (TLRs). These 
SRs bind oxLDL, apoptotic particles, heat shock protein and bacterial endotoxins 
129. Accumulation of oxLDL in these macrophages results in the formation of 
foam cells, a classical feature of atherosclerosis. The atherosclerotic lesions also 
have a variety of immune cells including; T cells, macrophages, monocytes, 
vascular dendritic cells, mast cells and B cells 130, 131. 
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1.3.7 B-lymphocyte “A good guy” in Atherosclerosis? 
Studies in atherosclerotic lesions of ApoE-/- mice have established that B cells 
are involved in the inflammatory component of this disease. Their location was 
reported in the base of the lesion, which was associated with high levels of 
Immunoglobulin M (IgM) and vascular cell adhesion molecule-1 (VCAM-1) 132. B 
cell deficient LDL-/- mice on a western diet had a 30-40% increase in the lesion 
size, which imply an atheroprotective role for antibodies and B cells 133. Caligiuri 
et al established a similar finding, where removal of the spleen in ApoE-/- 
resulted in enhancement of plaque size. To confirm the subset of cells 
responsible for this effect, B lymphocytes were adoptively transferred into these 
splenectomized mice and the conferred protection was associated with an 
increase in anti oxLDL antibodies 134. Part of this protective effect stems from 
the production of natural antibodies by a specific set of innate-like B1 cells. 
These natural antibodies interact with both oxidized LDL and apoptotic cells and 
can protect mice from atherosclerosis 135, 136.  ApoE-/- mice in this chronic 
inflammatory disease exhibit high titres of antibodies against oxLDL 137. In vitro 
data showed that IgM autoantibodies can recognise phosphorylcholine (PC) on 
oxLDL, and their binding prevents oxLDL uptake and degradation by 
macrophages 138. These antibodies closely resemble the “natural” T15 antibodies 
to PC produced by B1 cells, and T15 IgM is known to protect against 
pneumococcal infection. Based on these facts pneumococcal immunization of 
LDL-/- resulted in reduced atherosclerosis 135. Immunisation of mice with MDA-
LDL an oxidation specific neo-epitope resulted in IL-5 dependent increased 
production of T15 IgM. This highlighted the fact that IL-5 can connect adaptive 
immunity to innate immunity 139. So far, little is known about natural antibody 
production or presence of B1 cells in atherosclerotic aorta.  
1.3.7.1 Lamina adventitia and B cells in vascular inflammation 
Zohu x et al provided indirect evidence for the involvement of B cells in the 
presence of moderate hypercholesterolemia in ApoE-/- mice. This altered lipid 
environment resulted in high titres of oxLDL specific IgG2a antibodies, typical of 
the Th1 response seen in ApoE-/- mice. Interestingly severe hypercholesterolemia 
switched the T helper phenotype to Th2, which was evident from the increased 
presence of oxLDL specific IgG1 antibodies 140. In a similar study increased levels 
        25                                                                          
of IgG1 antibodies to malondialdehyde-modified low-density lipoprotein (MDA-
LDL) and exogenous antigen keyhole limpet haemocyanin (KLH) were observed 
141. These observations, in an experimental model of atherosclerosis, made the 
link between the T lymphocyte dependent B cell responses and dyslipidemia. In 
more recent studies to further investigate dyslipidemia and B cell T cell 
interactions, ApoE-/- mice were fed a high fat chow for up to 78 weeks and the 
inflammatory response in tunica intima and adventitia were compared. This 
study demonstrated that not only were structures resembling tertiary lymphoid 
follicles present in the vessel wall but that they were predominantly present in 
the lamina adventitia. These lymphoid aggregates, formed under the influence 
of hyperlipidemia and old age, were comprised of dendritic cells, B cells, plasma 
cells and T cells 142. 
In a separate study where angioplasty mediated overstretch injury to porcine 
coronary artery were performed, cellular proliferation of myofibroblasts and 
production of PDGF was observed in the adventitia, suggesting that adventitial 
changes lead to the recruitment of cells into the neointima that eventually leads 
to luminal narrowing 143. Whereas, human adventitia were shown to have 
nodular aggregates, and these aggregates showed organised B cell dominance 
with few T cells, dendritic cells and macrophages suggesting resemblance to 
Mucosa associated lymphoid tissue (MALT) 144. Human coronary arteries 
examined for contributions from intima and adventitia in plaque stability 
revealed that inflammation in tunica adventitia is significantly responsible for 
the plaque rupture 145.  
1.3.8 Different T cell subsets in Atherosclerosis 
1.3.8.1 CD4+ T Lymphocytes 
Animal studies made it clear that immunocompetence was fundamental in 
atherosclerosis development. The lack of an immune component resulted in a 
dramatic 70% reduction in lesion size. Whereas, adoptive transfer of CD4+ T cells 
from atherosclerotic prone donors to immunodeficient mice aggravated the 
disease 146. Moreover, to confirm a link between CD4+ T lymphocytes and disease 
associated antigen oxLDL in atherosclerosis, CD4+ T cells from mice immunized 
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with oxLDL transferred to ApoE-/-/ SCID mice confirmed the proatherogenic 
potential of CD4+ T cells in aggravating the disease 147. 
In support of these murine studies and the importance of T cells in 
atherosclerosis, human studies have demonstrated that atherosclerotic plaques 
contain CD4+ T cells that recognise antigens presented through major-
histocompatibility-complex (MHC) class II molecules. These CD4+ T cells are 
reactive to antigens like oxidized LDL, heat shock protein 60 and Chlamydia 148. 
Helper T cells subsets 
T lymphocytes have different functional subsets and these include Th1, Th2 and 
a more recent addition the Th17 subset. It should also be appreciated that the 
role of B cells is not only related to their ability to produce antibodies but also 
their ability to present antigen and secrete cytokines that could potentially 
regulate the Th1/Th2 balance. Advanced atherosclerotic plaques in humans were 
reported to have a predominance of Th1 cells. This was based on the 
Immunohistochemical analysis of advance plaques showing the presence of 
increased levels of the Th1 cytokines, IFNγ and TNFα 149, 150.  
The proatherogenic potential of Th1 cells was demonstrated in the double 
knockout ApoE-/-/IFNγ-/- mouse. These mice were placed on a high fat diet and 
analysis of the model illustrated that the loss of IFNγ reduced lesion burden in 
male mice in particular 151. Furthermore, administration of exogenous IFNγ into 
ApoE-/- resulted in increased plaque formation 152. 
Different animal models have been used to show that atherosclerosis is an 
immune mediated response. In ApoE-/- mice pharmacological down regulation of 
Type 1 helper cell (Th1) with pentoxiphylline resulted in marked reduction in 
atherosclerosis 153. Conversely, the Type 2 helper cell subset (Th2) producing IL-
5, IL-4 and IL-13 have an ambiguous role in atherosclerosis. IL-5 has been shown 
to trigger B-cells to produce natural antibodies. These IgM antibodies have been 
shown to have an inverse relationship with carotid artery lesions suggestive of a 
protective role for these antibodies 154. However, this relation needs to be 
further investigated. In addition the idea that the spleen is a vital organ, where 
development of an immune response against atherogenesis takes place was 
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introduced in late 1970s, when splenectomized war injured patients were found 
to be at increased risk of ischemic heart disease 155. 
 
1.3.9 Mast cells in atherosclerosis 
Mast cells are granulocytes that are known major effector cells in allergy and 
anaphylaxis. They are known to release a wide range of vasoactive substances 
(histamine & serotinin), proteolytic enzymes (tryptase & chymase), granulocyte 
monocyte colony stimulating factor (GM-CSF) and cytokines like TNFα, INFγ and 
IL-6 upon activation. Usually mast cells are rare in blood vessel walls, however, 
they are present in the tunica adventitia and rupture prone shoulder region of 
the atherosclerotic plaque 156. 
 In an animal study, activation of perivascular mast cells resulted in weakened 
plaque, marked by vascular leakage, macrophage apoptosis, intraplaque 
haemorrhage and leukocyte recruitment 157. The mast cell deficient Ldlr-/- 
Kit(W-sh)(/W-sh) mice, show reduced lesions formation, which was associated 
with reduced T cells and macrophages. Moreover, introduction of wild type mast 
cells to mast cell deficient mice restored atherosclerosis progression, suggesting 
that IL-6 and IFNγ are provided by mast cells to promote atherogenesis 158. 
Apolipoprotein E and ApoA-II dependent cellular cholesterol efflux is effectively 
incapacitated by mast cell chymase, therefore apolipoprotien mediated removal 
of cholesterol from mouse macrophages promote foam cell formation and 
atherogenesis 159. 
1.4 Interleukin-1 (IL-1) superfamily cytokines in RA and Atherosclerosis  
Cytokines comprise a class of proinflammatory proteins implicated in the 
pathogenesis of many autoimmune diseases. Some known autoimmune diseases 
like RA, psoriatic arthritis (PsA) and some other spondyloarthropathies have 
responded well to cytokines blocking therapies as noted above. Many cytokine 
families have been described, including the IL-12 superfamily (IL-27 and IL-35), 
the IL-2 superfamily (IL-15 and IL-21) and one in which I became particularly 
interested namely the IL-1 superfamily - specifically (IL-18 and IL-33). IL-1 family 
members share homology of sequence, gene location, structural dimensions and 
binding to their receptors 160.  
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1.4.1 Interleukin 18 (IL-18) 
IL-18 is recognised as a cytokine of IL-1 superfamily, but was initially identified 
as an IFNγ inducing factor produced by murine splenocytes upon endotoxin 
stimulation. Within the family it has closest sequence homology to IL-33 161. A 
wide range of cells of both non haemopoietic or haemopoietic lineages express 
IL-18; these include dendritic cells, macrophages, kupffer cells, osteoblasts, 
adrenal cortex, intestinal epithelial cells, microglia, keratinocytes and synovial 
fibroblasts 161-166. IL-18 is synthesized as a 24-kDa inactive precursor, which is 
cleaved to a mature active 18-kDa form by IL-1β converting enzyme also know as 
caspase-1 167. Active mature IL-18 signals via heterodimer receptor complex, 
which includes IL-18Rα (IL-1RcP) the chain that has an extracellular binding site 
for IL-18; whereas, the non-binding IL-1Rβ (AcPL) is a signal transducing chain 
with an accessory cell surface protein and both these chains are vital for IL-18 
signalling 168. 
IL-18 receptor (IL-18R) is expressed on a variety of cells, including macrophages, 
natural killer (NK) cells, neutrophils, smooth muscles and endothelial cells. 
Stimulation by IL-12 up regulates IL-18R on Th1 cells and B cells; in fact IL-18Rα 
is a marker for Th1 cells. The IL-18 ligand binding to its receptor result in 
engagement of adaptor proteins like MyD88 and IL-1 receptor associated kinase 
(IRAK), to promote the NF-κB nuclear translocation 161. In vivo activity of IL-18 is 
regulated by a high affinity binding protein (IL-18BP) and also by a naturally 
occurring soluble IL-18Rα chain. 
IL-18 is present in synovial membrane of patients with rheumatoid arthritis as 
both precursor (24-kDa) and mature (18-kDa) forms. Its expression is seen in 
macrophages and fibroblast like synoviocytes (FLS) in situ and along with IL-12 
showed a synergistic property in supporting a Th1 inflammatory response 162, 169. 
IL-18 induces monocyte maturation and activation resulting in the release of 
cytokines; it also causes degranulation of neutrophils and enhances the release 
of chemokines and cytokines by them. In concert with IL-12 it inhibits 
osteoclasts maturation, which then retards bone erosion 170. IL-18 deficient mice 
are resistant to the development of collagen-induced arthritis; these mice 
exhibit both a reduction in inflammation and bone erosion.  
        29                                                                          
To establish the proinflammatory role of IL-18 in the context of rheumatoid 
arthritis, patients were treated with the recombinant IL-18BP in phase I study; 
this trial did not show clinical efficacy. The lack of efficacy in this study could 
be due to redundant downstream signalling of IL-18 in the synovium or perhaps 
the intrinsic properties of the blocking agent employed 171.  
In the experimental model of atherosclerosis i.e. ApoE-/- mice administration of 
IL-18 antibodies accelerated plaque formation. However, IL-18BP inhibits the 
proinflammatory effects of the IL-18 and not only resulted in a stable phenotype 
of the lesion but also caused reduction in size of the plaque 172. In another study 
atherosclerotic lesion size were markedly reduced in double knock out mice (IL-
18 and Apo-/-E) that further elaborated the proinflammatory role of IL-18; 
whereas, Immunoglobulin subclass analysis revealed a Th2 phenotype dominance 
and reduced INFγ production. Interestingly, the lipid profile established that     
IL-18 somehow reduces the serum cholesterol 173. To establish a mechanism for 
proatherogenic role of IL-18 in ApoE-/- exogenous administration exaggerated 
lesion formation and lack of INFγ in the same mice attenuated the response 
generated by IL-18; which strongly suggests that this is an INFγ dependent 
response 174. 
1.4.2 Interleukin 33 (IL-33)  
IL-33 a novel addition to the IL-1 superfamily (also abbreviated as IL-1F11) is a 
ligand for the IL-1 family receptor T1/ST2 found on mast cells and Th2 cells. IL-
33 is produced as a 30-kDa protein that can induce production of Th2 cytokines 
like IL-4, IL-5 and IL-13175. It was proposed initially that IL-33 has a full-length 
form that can be processed to a more active form like IL-1β and IL-18. 
Interestingly, it was subsequently shown that caspase-1 mediated cleavage 
caused inactivation of IL-33 176. A similar in vitro observation has demonstrated 
that it is actually the full length form which is biologically active 177. Moreover, 
apoptosis associated caspases like 3 and 7 caused inactivation of IL-33, which 
was seen as a reduction in NFκB activation 178. However, it should be 
appreciated that full length IL-33 is released from necrotic cells by damage 
through infection or trauma and this probably mediates its most important 
effector physiologic function.  
        30                                                                          
The biological effects of this cytokine are mediated when it binds to both the 
T1/ST2 and it’s co receptor IL-1 receptor accessory protein (RAcP) - both of 
them form a receptor complex 179. Interestingly, this co-receptor is common to 
other members of the IL-1 superfamily like IL-1α, IL-1β and IL-1F6 to IL-1 F9 for 
downstream signalling 180. Like other IL-1 family cytokines IL-33 upon binding to 
its receptor results in ERK, P38, mitogen activated protein kinase (MAPK), NF-κB 
and JKN activation 181 (Figure 1.5). IL-33 has the properties of a cytokine; 
however, the nuclear localization and transcriptional properties exhibited by 
this cytokine suggested a close link to IL-1α and High mobility group box 1 
(HMGB1) 182. 
  
Figure 1.5 A model for IL-33/ST2 signalling T1/ST2 Receptor 
 
ST2 is a member of toll like/IL-1 superfamily with several designations like 
IL1RL1, DER4, FIT-1 and T1). The IL-1 family receptors share a unique 
intracellular domain termed as Toll/Interleukin-1 receptor (TIR) domain, which 
comprises of a central core of five stranded β-sheets surrounded by 5 alpha 
helices. Beside the intracellular cellular TIR domain these receptors have a 
transmembrane fragment and an extracellular domain that contains three 
immunoglobulin like motifs. Since the initial discovery of ST2 in 1989 four 
isoforms of ST2 (sST2, ST2L, ST2V and ST2LV) have been identified 183-187. The 
membrane bound form ST2L (IL1RL1-b) has all three basic components i.e. 
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extracellular, transmembrane and intracellular domains (Figure 1.5, (modified 
from therapeutic targets and novel biomarkers) 188. The soluble form sST2 (also 
known as IL1R1-a) lack the intracellular domain and it has a unique nine amino 
acid sequence at the C-terminal 184, 189. Interestingly, the expression of both 
these variants differs from the membrane bound form ST2L that is constitutively 
expressed on surface of mast cells and Th2 cells. The sST2 is more of an 
inducible form expressed upon appropriate stimulation of fibroblasts, mammary 
tissue, retina and osteogenic tissue. Moreover, the human gastrointestinal organs 
like stomach, spleen, small and large intestine predominantly express the ST2V; 
whereas, ST2LV is found on various tissues like cerebral, ocular, pulmonary and 
cardiac in the second half of embryogenesis 188. 
1.4.2.1 IL-33 in RA  
Different experimental models have revealed that IL-33/ST2 signalling can have 
both inflammatory and protective properties, for example soluble ST2 (sST2) 
administration in mice reduces the mortality caused by LPS challenge by down 
regulating the proinflammatory cytokines 190. Yin H et al demonstrated a 
protective role for sST2 in a TLR4 mediated hepatic ischemic reperfusion injury 
191.  The administration of sST2 in mice cause reduction in joint erosions, 
synovial hyperplasia and cellular infiltration in a model of collagen-induced 
arthritis (CIA) supporting this notion 192. In addition, lack of ST2 receptor in mice 
attenuated disease in CIA; moreover, administration of IL-33 in ST2 deficient 
mice engrafted with wild type mast cells resulted in joint inflammation 
suggestive of IL-33 mediated mast cells activation 193. Mast cells are implicated 
in the pathogenesis of RA in fact mast cell deficient mice are resistant to the 
development of disease and implanting mast cells restored joint inflammation 
194, which might suggest that mast cell activation occurred through IL-33 
activity. 
1.4.2.2 IL-33 in CVD 
Human and animal data suggest that IL-33/ST2 signalling has an imperative role 
in the pathophysiology of cardiovascular diseases. Serum concentration of sST2 
are elevated in patients with acute heart failure 195. High levels of serum sST2 
were strongly correlated with increased future mortality in patients of acute 
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destabilized heart failure 196. The potential of ST2 as a biomarker was 
highlighted when myocardial injury caused ST2 release in the patients; both the 
transmembrane form and the soluble form was induced, with soluble form 
dominating 197. Therefore serum sST2 levels were analyzed in about 800 patients 
presenting with acute myocardial infarction, which predicted mortality and 
heart failure in the patients 198. 
In an experimental model of atherosclerosis mice on high fat diet were treated 
with IL-33, which markedly reduced the plaque size through Th2 cytokines like 
IL-5; whereas, the administration of sST2 blocked this regulatory loop and 
increased atherosclerotic plaque 199. In fact immunisation of mice with MDA-LDL 
an oxidation specific neo epitope resulted in an IL-5 dependent increased 
production of T15 IgM natural antibodies. This highlighted the fact that IL-5 can 
connect adaptive immunity to innate immunity 139. So if IL-33 is mediating its 
cardioprotective effects through IL-5 then there seems to be a link between IL-
33 and natural antibodies, which need to be investigated. Sanada et al 
demonstrated that biomechanical stress induced IL-33 release by cardiac 
fibroblasts resulted in reduced cardiac hypertrophy and fibrosis. In contrast ST2 
deficient mice observed ventricular hypertrophy and impaired survival, in a 
volume overload model with aortic constriction compared with untreated 
controls 200.  
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1.5 Hypothesis and Aims 
The immunopathological process in RA is characterised by ongoing immune 
responses that result in joint destruction. This autoimmune condition is strongly 
linked with cardiovascular morbidity. How the vascular environment influences 
the RA immune response and vice versa, contributing to high cardiovascular risk 
in RA, remains unclear. Some of the questions to be addressed in this thesis are 
detailed below. 
a) Citrullinated protein is an RA associated self-antigen. Due to the high 
specificity (>98%) of ACPA in diagnosing RA patients, we must consider the 
significance of CP in the aortic adventitia. 
• Does the inflammatory environment associated with CVD and RA alter 
the level of RA associated self-antigens in the aortic adventitia? 
b) B lymphocytes have been documented in the aortic adventitia but we do not 
know whether the presence of B cells is different between CVD patients with or 
without RA. In addition, the factors mediating B cells survival in this disease-
associated site remain obscure. 
• Is the presence of B cells altered in RA vs. non-RA and are survival 
niches present in the aortic adventitia? 
C) Atherosclerotic plaques contain inflammatory cells and cytokines 
(predominantly T cells, macrophages, IL-18) that appear to contribute to lesion 
formation.  
• What is the difference in macrophages and IL-18 expression between 
RA and non-RA patient’s vascular adventitia?  
d) The IL-1 family cytokine IL-33 is reported to reduce lesion size in the 
experimental model of atherosclerosis.  
• Which cells express IL-33 in human atherosclerotic lesions, and how is 
it different in RA patients? 
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e) B lymphocytes are atheroprotective, whereas, the clinical efficacy of B cell 
depletion therapy in RA identifies a pro-inflammatory role for B-lymphocytes.  
• What will be the impact of B cells depletion therapy on 
atherosclerosis? 
The aims of the study were to  
• Examine the presence of citrullinated protein, a potential auto-antigen of 
rheumatoid arthritis, in human aortic adventitial biopsies and correlate 
this to B-lymphocytes and their survival niches (BAFF & APRIL) in 
rheumatoid patients. 
• To investigate the effects of hypoxia and oxLDL on BAFF and APRIL in 
cultured vascular endothelial cells. 
• To establish the expression of Interleukin 33 (IL-33) in human aortic 
adventitia and murine vascular endothelial cells and explore the impact of 
Oxidized LDL and hypoxia on its protein and gene expression. 
• To investigate the impact of B cells depletion therapy with Rituximab (a 
monoclonal antibody against CD20 receptor) on lesion development in the 
experimental model of Atherosclerosis. 
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2 Methods and Material 
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2.1  Human Biopsy samples 
The human aortic adventitia and Internal mammary artery (IMA) samples were 
from the Feiring Heart Biopsy study; biopsies were obtained from Patients 
undergoing coronary artery bypass graft (CABG) surgery. On the ventral aspect of 
the ascending aorta 1–3 punch holes were made from areas with less 
atherosclerotic lesions through the vessel wall; these areas were selected for 
proximal aortico-coronary anastamoses. Subsequently, part of the adventitia 
covered by the epicardium was removed from the biopsies, fixed in formalin and 
paraffin embedded. A total of 40 aortic adventitia and 33-matched internal 
mammary artery biopsies were used in the present study. All the patients gave 
written informed consent. Regional Ethics committee for Medical Research 
Norway approved the Feiring Heart Biopsy study.  
2.1.1  Immunohistochemistry  
The architecture of AA is primarily composed of adipocytes; which are signet 
rings shaped fat cells. The issue with these tissue samples was there limited 
number and they would pick lot of back ground staining. Therefore, the stainings 
were first established on RA synovium or human tonsil using different antigen 
retrievals, secondary antibodies and blocking systems and then the adventitias 
were stained with established protocols. These biopsies were stained for 
different cytokines, proteins and receptors; details of the primary antibodies, 
retrieval system and secondary antibodies are listed (Table 2.1). 
Table 2.1. Details of antibodies and antigen retrieval system used in staining of 
human biopsy samples 
Antibody  Clone Source  Antigen Retrieval  Staining system 
Citrullinated 
peptide 
07-377 Upstate, Lake 
placid, NY, 
USA 
Trypsin, 37C, 15 min Horse anti Rabbit 
ImmPRESS 
CD20  L-26 DAKO 
Cytomation 
MW* 500w 15 min Horse anti mouse 
ImmPRESS 
        37                                                                          
Plasma cells Vs38c DAKO MW* 500w 15 min Horse anti mouse 
labeled with FITC 
BAFF Buffy-2 Alexis 
Biochemical 
MW* 500w 15 min ABC§ 
APRIL Aprily-8 Alexis 
Biochemical 
MW* 500w 15 min Horse anti mouse 
ImmPRESS 
 CD68 MO 876 DAKO 
Cytomation 
MW*, 500w 15 min ABC§ 
 IL-18 11.51 E3E1  
 
MW*, 500w 15 min ABC§ 
IL-33 Nessy-1 Alexis 
Biochemical 
MW* 500w 15 min Horse anti mouse 
ImmPRESS 
 
MW*: microwave citrate buffer, pH 6.0 for antigen retrieval  
ABC§: Biotinylated horse Pan-specific secondary antibody (Avidin biotin complex staining system) 
Impress: Peroxidase linked secondary antibody, Vector laboratories. 
The RA synovium, human tonsil and biopsy samples were stained using the 
following steps.  
2.1.1.1 Deparaffination and hydration 
Paraffin embedded sections cut 4-5 µm thick were mounted on electrostatically 
or Polysine coated microscope slides (BDH), which were then used for 
immunohistochemistry. Initially, the slides were incubated at 650C for 1 hour to 
soften the wax. Then the sections were deparaffinised in Xylene for about 10 
minutes. After this the tissues were hydrated by sequential incubations at 100%, 
90%, 70% ethanol 3 minutes each and then into distilled water for 5 minutes. The 
endogenous peroxidase activity was blocked with 0.5% hydrogen peroxide 
(Appendix 1, a) for 30 minutes at room temperature.  
2.1.1.2 Antigen Retrieval 
Two antigen retrieval methods (citrate or trypsin) were used depending on the 
stainings performed. Antigen retrieval by citrate buffer (Appendix 1, b), was 
performed by microwaving 500-600ml of buffer into a suitable container for 5 
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minutes. The slides were added to the container with buffer already heated to 
boiling. The sections were heated further in the microwave at high power for 8 
minutes. Then they were allowed to cool down for another 15 minutes. (2) the 
antigen retrieval used for citrullinated peptide staining was done with the 
enzyme trypsin. In trypsin retrieval the sections are covered with the trypsin 
working solution (Appendix 1, e) and incubated for 15 minutes at 37OC and then 
left for 5 minutes at room temperature. This was followed by 5 minutes wash 
twice in the TBS buffer (Appendix 1, c). 
2.1.1.3 Non specific binding block  
 Subsequently, for every staining procedure non-specific binding was blocked 
with 5% normal horse serum for 30 minutes at room temperature. The optimum 
concentrations of primary antibodies and subtle changes in the order of the 
steps explained so far and different retrieval systems adapted are listed in (table 
2.1 & 2.2). However, the incubation period for the primary antibodies for all the 
stainings performed was at 4 OC overnight. 
2.1.1.4 Secondary antibody and mounting of section 
On the second day the sections were brought to room temperature. After 
washing the sections in the TBS buffer (Appendix 1, c) they were incubated for 
half an hour with an appropriate secondary antibody. The secondary staining 
system mostly used (table 2.2) was an antibody coupled to peroxidase (Immpress 
kit, Vector laboratories). Finally, the staining was developed with Impact DAB 
(Diaminobenzidine) and after washing the slides in running water the sections 
were counter stained with hematoxylin and after the final wash in TBS buffer 
(Appendix 1, C) sections were mounted with a cover slip using DPX (Di-N-Butyle 
Phthalate in xylene). 
2.1.1.5 Additional steps performed for Pan specific Biotinylated secondary 
antibody 
Whenever the secondary antibody was not conjugated directly to HRP, a 
biotinylated antibody was used as a secondary; this was associated with 
additional steps, including the blocking of endogenous avidin, and a 30 minutes 
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incubation with avidin biotinylated horseradish peroxidase macromolecular 
complex (ABC Vector labs) was performed after application of secondary 
antibody for some of the stainings as listed in (Table 2.1).  
2.1.1.6 Sequence of major staining steps for all the stainings 
All the immunohistochemistry as well as the immunofluorescent staining 
performed on the human AA and IMA was slightly different depending on the 
stainings done. As their antibody dilutions, antigen retrieval and the staining 
systems were specific for each staining. The sequence of major steps was 
specific with subtle differences; details of the order of steps, antibody dilutions, 
Isotype control and positive tissue used for all the stainings performed are listed 
in (table 2.2). 
 
Table 2.2. Sequence of major steps performed for all the different stainings. 
 
Antibody 
dilution 
Isotype 
control  
    Order of primary steps Positive 
tissues 
Citrullinated 
peptide/Protein 
1/500  
Monoclonal 
rabbit anti 
human  
 
a) Antigen retrieval with Trypsin. 
b) Non-specific binding block with horse serum. 
c) Overnight primary antibody incubation at 
4OC. 
d) Endogenous peroxidase block.  
e) Incubation with peroxidase linked secondary 
antibody. 
f) Staining developed with Impact DAB. 
RA synovium 
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CD20 
1/100  
Monoclonal 
mouse 
IgG2a 
a) Endogenous peroxidase block. 
b) Antigen retrieval with citrate buffer. 
c) Non specific binding block with horse serum. 
d) Overnight primary antibody incubation at 
4OC. 
e) Incubation with peroxidase linked secondary 
antibody. 
f) Staining developed with Impact DAB. 
RA synovium 
Plasma cells 
1/75  
Monoclonal 
mouse 
antihuman  
IgG1 
a) Endogenous peroxidase block. 
b) Antigen retrieval with citrate buffer. 
c) Non specific binding blocked with horse 
serum. 
d) Primary antibody incubation for one hour at 
room temperature. 
e) Incubation with peroxidase linked secondary 
antibody. 
f) Staining developed with Impact DAB. 
RA synovium 
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BAFF 
1/500 
Monoclonal 
Rat anti 
human IgG 
a) Antigen retrieval with citrate. 
b) Endogenous peroxidase block. 
c) Non specific binding blocked with horse 
serum. 
d) Overnight primary antibody incubation at 
4OC. 
e) Secondary antibody incubation with 
biotinylated rabbit anti rat immunoglobulin. 
f) Avidin/Biotin complex. 
g) Staining developed with Impact DAB. 
RA synovium 
APRIL 
1/500 
Monoclonal 
mouse 
antihuman 
IgG1 
a) Antigen retrieval with citrate buffer. 
b) Endogenous peroxidase block. 
c) Non specific binding blocked with horse 
serum. 
d) Overnight primary antibody incubation at 
4OC. 
e) Incubation with peroxidase linked secondary 
antibody. 
f) Staining developed with Impact DAB. 
Human 
Tonsil 
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 CD68 
1/100 
Monoclonal 
mouse IgG1  
a) Endogenous peroxidase block 
b) Antigen retrieval with citrate. 
c) Incubation with non-specific binding block 
plus Avidin. 
d) Incubation with primary antibody and the 
biotin block. 
d) Secondary antibody incubation with 
Biotinylated Pan specific horse immunoglobulin 
e) Incubation with Avidin/Biotin complex. 
f) Staining developed with impact DAB 
RA synovium 
 IL-18 
1/500 
Monoclonal 
mouse IgG1 
a) Endogenous peroxidase block. 
b) Antigen retrieval with citrate. 
c) Incubation for non-specific binding block plus 
Avidin. 
d) Incubation with primary antibody and the 
biotin. 
d) Secondary antibody incubation with 
Biotinylated Pan specific horse immunoglobulin 
e) Avidin/Biotin complex. 
f) Staining developed with Impact DAB. 
RA synovium 
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2.1.2 Preparation of Modified fibrinogen  
Human fibrinogen was modified to citrullinated protein as previously described 
23, 201.  Plasminogen depleted human fibrinogen (calbiochem; EMD Biosciences) 
was incubated at 0.86mg/ml with 10U/ml of rabbit skeletal muscle peptidyl 
arginine deiminase (sigma Aldrich) in 0.1 M Tris-HCl (pH 7.4), 10mM CaCl2, and 
5mM DTT for 2 hours at 50oC. The reaction was stopped by adding 2% SDS and 
finally heated to 100oC for 3 minutes. Citrullinated fibrinogen was washed with 
0.01 M carbonate buffer in Amicon spin column (millipore); this column had a 
molecular cut off (100kDa) and was centrifuged at 2500g for 10 minutes. 
2.1.2.1 Biotinylation of native and modified fibrinogen 
Citrullinated fibrinogen and native fibrinogen were both biotinylated using the 
NHS-LC biotinylation kit (Pierce Biotechnology). A concentration of 10mM sulpho-
NHS-LC-Biotin was prepared by dissolving 2.2mg in 400µl ultra pure water. Then 
as per manufacturer’s guidelines, the correct volume of biotin solution was 
added to the citrullinated fibrinogen and native fibrinogen and they were 
IL-33 
1/200 
Monoclonal 
mouse 
antihuman 
IgG1 
a) Endogenous peroxidase block. 
b) Antigen retrieval with citrate buffer. 
c) Non specific binding blocked with horse 
serum. 
d) Primary antibody incubation for one hour at 
room temperature. 
e) Incubation with peroxidase linked secondary 
antibody. 
f) Staining developed with Impact DAB. 
Human 
Tonsil 
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incubated on ice for two hours. Biotinylated fibrinogen was later used as 
negative control in staining of antibodies to citrullinated protein.  
2.1.2.2 Preparation of “a citrulline rich sample” cornified skin cell lysates  
Human cornified skin is known to have CP; to generate a positive control for 
western blot analysis of citrullinated fibrinogen, we processed cornified skin 
cells that were collected from the forearm using a 12.5cm long scotch tap. 
Scotch tape was pasted on the forearm and rubbed 3-5 times along the length. 
The tape was placed in a Petri dish with both ends secured, cells were lysed by 
addition of 200µl of SDS-PAGE lysis buffer (Appendix 1, f). The cells were rubbed 
with a cell scraper. Cell lysates were collected into an eppendorf and heated at 
95oC for 5 minutes; this was then allowed to cool down. The lysates were 
centrifuged at 10,000rpm for 5 minutes to get rid of the cell debris. Finally, 
protein concentration was determined with the nano drop (Thermo scientific) 
and stored at -20 oC.  
2.1.3 Western Blotting  
2.1.3.1  Sample preparation 
The cell lysates or proteins prepared as explained above were quantified using 
nanodrop (Thermo scientific) and equal concentrations of each protein sample 
were then used in the later stages. The samples were made by mixing LDS 
sample buffer (Appendix 2, c), reducing agent (Nupage, Invitrogen) as per 
manufacturer instructions and then heated for 10 minutes at 70oC.  
2.1.3.2 Electrophoresis 
The Novex 4-12% Bis-Tris gels (Invitrogen) were used for the electrophoresis. 
After setting the gel cassette in the cell, both the upper and outer buffer 
chambers of cell were filled with appropriate volume of the running buffer 
(Appendix 2, a). Then an appropriate molecular weight marker for proteins and 
similar concentrations of the sample proteins were loaded onto the gel. The gel 
was run for 35 minutes at 200 volts.  
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2.1.3.3  Coomassie staining 
To confirm the electrophoresis of different proteins used; coomassie staining 
was done to see various bands for each protein. After electrophoresis the gel 
was put in a fixative solution (Appendix 2, d) for 10 minutes. The gel was then 
stained with Coomassie blue (invitrogen) for 10 minutes with gentle shaking. A 
series of washing was carried out using destain solution (Appendix 4, f). This was 
followed by an overnight destain; which resulted in visualization of distinct 
bands for a variety of proteins. The solutions mentioned were prepared using the 
recipes stated in the appendix. 
2.1.3.4 Transfer of Proteins to PVDF membrane 
The western transfer followed the electrophoresis; which is completed using the 
invitrogen Blot module (as per manufacturers instructions). After carefully 
removing the gel from cassette, the gel and methanol soaked PVDF membrane 
was put together. It was ensured that there were no bubbles between the gel 
and membrane. Subsequently, the gel membrane was sandwiched between filter 
paper and blotting pads. The gel-membrane assembly within the blot module 
was tightly locked in the cell. The inner buffer chamber was filled with transfer 
buffer (Appendix 2, b); whereas, the outer chamber was filled with distilled 
water. Finally, the transfer of protein was carried out at a continuous 30 volts 
for 1 hour. 
2.1.3.5  Immunostaining for proteins 
The Immunostaining of the proteins on the PVDF membrane was started with a 
non-specific binding block. An incubation of one hour at room temperature with   
a blocking buffer; which was prepared by adding 5% non-fat milk marvel 
(premier International Foods, Lincs, UK) in TBST buffer (Appendix 1, c) The 
blocking buffer was removed and the detection antibody (pooled sera from RF 
positive RA patients) was added to the membrane. Patients sera was diluted to 
1:100 in 5% dried skimmed milk/TBS plus 0.05% Tween; the PVDF membrane was 
incubated with patient’s serum for overnight at 40C with gentle agitation. Next 
day the PVDF membrane was washed thrice with TBS plus 0.05% Tween for 5 
minutes; then an HRP conjugated goat anti-human IgG (Southern biotech) was 
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used as a secondary antibody. This antibody was used at a dilution of 1:8000 in 
5% dried skimmed milk/TBS plus 0.1% Tween and incubated for one-hour at room 
temperature. This was followed by a 3 times wash with TBS plus 0.05% Tween. 
Finally, the staining was developed for 5 minutes with chemiluminescent super 
signal (Pierce) and visualized by developing x-ray film (Kodak) using the 
developer (Konica Minolta, SRX101). 
2.1.4 Double Fluorescent staining of RA synovium and Aortic adventitia 
To establish the presence of plasma cells secreting antibodies to citrullinated 
proteins a double fluorescent staining was performed on paraffin embedded RA 
synovium. Initially the slides were incubated in the oven at 650C for one hour to 
soften the wax. The sections were deparaffinised in xylene and serially passed 
through graded alcohol i.e. 100%, 90%, 70% and finally to distilled water for 
properly hydrating the samples. Explained in detail (section 2.1.1). 
The antigen retrieval was performed using citrate buffer (Appendix 1, b), which 
was done by microwaving 500-600ml of buffer into a suitable container for 5 
minutes. After heating the buffer, sections were added to it. The slides were 
heated further in the microwave at high power for 8 minutes. Then the sections 
were allowed to cool down for about 15 minutes, slides were then washed in 
TBST twice for 5 minutes. 
Subsequently, the sections were blocked for non-specific binding by incubating 
them with 2.5% goat serum for 30 minutes at room temperature. This was 
followed by a two-step Avidin/biotin block of 15 minutes each. After this the 
tissues were incubated with biotinylated-modified citrulline (10µg/ml) overnight 
at 4oC. 
The following day slides were left at 250C for half an hour to bring them to room 
temperature. To identify the binding of biotinylated modified citrulline in the 
tissues, staining was performed using a straptavidin conjugated QDOT 605 
(invitrogen) at a 1:250 dilution. After this the tissues were blocked again but this 
time with 2.5% horse serum for 30 minutes at room temperature. This was 
followed by a two times wash in TBS plus 0.05% Tween for 5 minutes each. 
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Sections were further incubated with monoclonal anti-plasma cell antibody 
(Vs38c, DAKO) for 2 hours at a concentration of 2µg/ml in a humidified chamber  
(Table 2.1). The secondary antibody was selected carefully to make sure that 
the spectra of the fluorophore used in the double staining do not overlap, which 
might complicate the analysis. Therefore, slides were incubated with FITC 
labeled anti mouse IgG (15µg/ml, Vector); this resulted in green colored staining 
of the plasma cells. To stain the nuclei sections were mounted with medium 
containing 1.5µg/ml DAPI (Vectashield).  
Finally, the staining was analyzed with the laser scanning cytometer (LSC, 
Compucyte). First the antibodies reactive to citrulline (red color) were located 
in the stained sections and images were captured. Then the plasma cells staining 
(green color) and nuclear staining with DAPI (blue color) was confirmed. 
Subsequently, all the images were merged to establish antibodies secreting 
plasma cells in the tissues. A similar sequence was followed for the Isotype 
controls; importantly, the exposure time and contrast enhancement were kept 
constant for both the positive and Isotype controls. 
2.1.5 Scoring and statistical analysis 
2.1.5.1 Scoring of stained tissues 
A blinded observer scored all the stainings performed on 40 human aortic 
adventitia and 33 paired IMA. Visually counting number of cells per high power 
field for stainings of surface markers or intracellular staining; whereas, if 
staining was not only confined to cell surface and involved extracellular 
compartment then scores were recorded as percentage area per high power 
field. The raw data for scores was analyzed for normality. The normally 
distributed data (Citrullinated protein) staining in Aortic adventitia was further 
analyzed by calculating the mean percentage area. However, for all other 
stainings i.e. CD20, APRIL, BAFF, IL-18 and CD68 there was a non normal 
distribution so a median percentage area/HPF was calculated to complete the 
analysis. 
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2.1.5.2  Statistical analysis 
The data was statistically analyzed by student’s t-test to determine the 
statistical significance, when comparing two groups for normally distributed 
data. However, the data not following a normal distribution were analyzed for 
differences in quantitative variables by Non parametric Mann Whitney U test to 
determine the statistical significance, with a P value of <0.05 considered 
significant. Graphs are displayed as dot plots to clearly illustrate the details of 
scores for individual specimen. Finally, the associations between CRP vs. ACPA  
were analyzed using Fisher’s exact test. All the statistical analyses were 
performed using GraphPad Prism version 4 for Mac (GraphPad Software). 
2.2 Effects of Oxidized LDL on cultured cells 
2.2.1  Human endothelial cell culture 
Primary cultures of human sephenous vein endothelial cells HSVEC passages 3 
were kindly provided by Professor Andrew Baker, University of Glasgow. Cells 
were maintained in T-75 flasks in endothelial cell basal medium MV2 and 
supplement pack (Promocell) included; Fetal Calf Serum 5%, Epidermal Growth 
Factor 5.0ng/ml, Hydrocortisone 0.2µg/ml, Vascular Endothelial Growth Factor 
0.5ng/ml, basic Fibroblast Factor 10ng/ml, R3 IGF-1 20ng/ml, Ascorbic Acid 
1µg/ml. The endothelial cells were cultured to full confluence, as checked by 
light microscopy and were then split; the media was taken off and cell 
monolayer was rinsed with 1x PBS (Sigma) at room temperature. The monolayer 
was trypsinized with 5ml of 1x of 0.5% trypsin EDTA (Sigma) at 370C for 5 
minutes. The flask was banged a couple of times and 10 ml of media MV2 was 
added to stop the enzymatic action of Trypsin EDTA. To wash the collected 
trypsinzed cells they were put in a universal and spun at 1500rpm for 10 
minutes. Cells were washed again in fresh media.  Media was again taken off and 
cells were resuspended in 10ml of media MV2. Approximately 20% of the cells 
were used to seed a T-75 flask. Cells were used for experiments between 
passage 3 and 5. 
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2.2.2  Murine endothelial cell culture 
A mouse lymphoid vascular endothelial Cell line SVEC4-10 202 was also generously 
provided by Professor Andrew Baker, University of Glasgow. The Mouse lymphoid 
endothelial cell line, Immortalized by simian virus 40, were grown in T-75 flasks 
in Minimum essential medium Eagle MEM (Sigma) supplemented with 200 mM L-
Glutamine (GIBCO), Pen-strep 10,000 units (GIBCO), sodium pyruvate (Sigma) 
100mM and 10% FCS (Sigma). Media was changed twice a week. Cells were split 
as required and passaged as discussed above for human endothelial cells.  
2.2.2.1 Murine cell culture in T-25 flasks 
To look for the effects of OxLDL on IL-33/sST2 expression, cells were grown in 
vented T-25 flasks (Corning); for all the treatment groups T-25 flasks were 
seeded with equal number of cells and the confluence of monolayer was 
confirmed under light microscopy. After taking off the media the cells were 
washed 1xPBS at room temperature. This was followed by the monolayer harvest 
using the cell scraper (Corning). The scraped cell were washed with media and 
collected in a 15ml tube.  They were then used to extract RNA as described in 
the following section. 
2.3 Polymerase chain reaction (PCR) 
2.3.1 RNA isolation 
Human saphenous vein endothelial cells (HSVEC) and mouse endothelial cell line 
SVEC4-10 were grown in Endothelial cell basal medium MV2 and MEM 
respectively. They were exposed to oxLDL and nLDL at a concentration of 80 
µg/ml in the relevant media for different time points i.e. 6hrs, 12hrs, 18hrs and 
24hrs in T-25 flasks; cells were harvested from these tissue culture flasks as 
explained earlier in (section 2.2.2) and transferred to RNAase free 1.5 ml 
eppendorf. They were spun for 5 minutes at 1000 rpm and supernatant was 
discarded. To isolate intact RNA from HSVEC and SVEC4-10, 350 µl RLT buffer 
(supplied with RNeasy mini column kit by QIAGEN) was added to cells pellet in 
the eppendorf. RLT buffer is used for lysis and homogenisation of biological 
samples in the presence of highly denaturing guanidine isothiocyanate [GITC] 
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containing buffer that immediately inactivates RNases to ensure isolation of 
intact RNA.  To purify RNA from the samples, the protocol of RNeasy minicolumn 
kit (QIAGEN) was followed as per manufacturer instructions. 
Purified RNA samples were quantified on an eppendorf biophotometer. Uniform 
RNA concentration in each sample was confirmed by agarose gel electrophoresis. 
Samples were loaded on 1% agarose gel stained with Ethidium Bromide. Gel 
scanning with alphaimager Mitsubishi P91D (FujiFilm) was performed to ensure 
that all samples were similar in terms of intensity of fluorescent signals from 
each band. 
2.3.2 First strand cDNA synthesis 
The complementary DNA (cDNA) was synthesised according to the protocol 
described by manufacturer (Invitrogen) using reagents supplied with the 
Superscript™ III First-Strand Synthesis System. 1µl of RNA was diluted in 4µl of 
RNase-free H2O and was adjusted to 2µg/µl RNA by mixing calculated volumes of 
diluted RNA and RNase-free H2O. 1µM oligo dt and 1µl dNTP were added to each 
sample. Samples were placed in the thermocycler  (BIO-RAD) for 5 minutes at 
650 C and then on ice for 1 minute. The cDNA synthesis mix was prepared on ice 
by mixing 2µl of 10x RT buffer, 4µl 25mM MgCl2, 2µl 0.1M DTT, 1µl RNaseOUT 
and 1µl SuperScript III Reverse Transcriptase. 10µl of cDNA Synthesis mix was 
added to each sample. For the control samples Superscript III Reverse 
Transcriptase was replaced by equivalent volume of RNase-free H2O. 
Samples were placed in the thermocycler for 50 minutes at 500C.  Afterwards, 
raising the temperature to 850C for 5 minutes terminated the reaction. 1µl 
RNase H was added to each cDNA sample to remove any RNA and finally placed 
at 370C for 20 minutes. cDNA was stored at -20°C. 
2.3.3 PCR 
The PCR amplification was carried by using 2µl of cDNA of different genes. The 
cDNA was added to each PCR reaction, containing 10µl of PCR master mix 
(promega), 1µl of forward and reverse primers, 2.5mM dNTP (Biolab) and 35µl of 
RNAase free H2O.  
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The PCR reaction was initiated with 1 cycle of denaturation for 5 minutes at 
940C. The reaction was further programmed to 940C for 30sec, 550C for 30 
seconds and at 720C for 30 seconds. Finally, a single cycle for extension of the 
product was set for 10 min at 720C. This standard thermal profile was used for 
the PCR performed for different genes in the study; except for the annealing 
temperature that were specific for most of the genes and are listed in (Appendix 
6). 
2.3.4 Quantitative PCR  
2.3.4.1 Normalisation of cDNA samples 
To allow effective comparison of gene levels between samples, normalisation of 
cDNA levels was undertaken. The amount of cDNA between samples can 
inadvertently be varied by multiple factors including: variation introduced 
during RNA extraction, differential RNA degradation, the amount of RNA used in 
the reverse transcription reaction and the reaction efficiency of the reverse 
transcription. This variation was reduced by; 1) Using exactly 5 µg of non-
degraded total RNA (as determined by OD); 2) All samples that were directly 
compared within a quantitative PCR were reverse transcribed using the same 
master mix to avoid inter-day and inter mixture variability in reverse 
transcriptase activity; and 3) Housekeeping genes like GAPDH and β actin were 
used to normalise samples. 
The cDNA samples were diluted 1 in 5 in nuclease free water and used as 
template for QPCR. Samples that were to be directly compared within a 
quantitative PCR were reverse transcribed using the same master mix to avoid 
inter day and inter mixture variability in reverse transcription activity.  
2.3.4.2 Primer Design 
A set of “inner” primers was designed for use in the quantitative PCR machine 
and an “outer” set of primers was designed for creating PCR products to act as 
standard templates. All primers were designed using the Primer3 software (Steve 
Rozen and Helen J. Skaletsky). 
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QPCR Primer specification were as follows: 
• between 18 and 23 base-pair (bp) in length 
• between 40 and 65% GC content (50% optimal) 
• Tm of primers within 59.5oC and 61oC  (60oC optimal) 
• Maximum self complementarity: 2 
• Maximum 3’self complementarity: 1 (most important) 
• Amplicon size less than 150bp 
• Not more than two G or C bases in last 5 at 3’ end of each primer (i.e. 
don’t include a GC clamp) 
• Avoid stretches of 4 or more G or C bases in a row 
If this did not generate any primers then the max self-complementarity was 
relaxed from 2 to 3 and the primer Tm down to 59oC. The only condition that 
was never relaxed was maximum 3 self-complementarity. 
Outer primers were then designed to amplify the region in which the QPCR 
primers bind. These primers were designed with similar parameters although 
they could possess higher self-complementarity levels if the software could not 
suggest suitable primers using the above criteria. 
BLAST analysis was used to ensure primer that primer sequences were specific to 
gene of interest alone and that no splice variants exist that could complicate the 
analysis. 
2.3.4.3 Generation of DNA standards for QPCR 
The generation of a standard curve is essential for quantifying the levels of the 
gene of interest in the test samples. A standard DNA template for each gene 
assayed was generated by taking the PCR product using the “outer” primers, 
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purifying the PCR product on a PCR purification column as per manufacturer’s 
instructions (Qiagen QIAquick columns) and diluting this product to generate 
serial dilutions. Each of these dilutions was used as a template for a QPCR using 
the “inner” QPCR primers for amplification. A range of standards dilutions was 
used in each QPCR assay. The standard was diluted in nuclease free water and 
serial dilutions were given arbitrary values that were later used for calculating 
copies of the target gene.  
2.3.4.4 SYBR QPCR protocol 
Each sample/standard was performed in triplicate on the QPCR machine. A 
master mix was prepared for the total number of samples per reaction 
contained:  
• 10µl Power SYBR green mix (Applied Biosystems, or similar mix from 
Roche) 
• 0.8µl of primer mix (each primer mixed together at 50pmol /µl) 
• 8µl nuclease free water (Ambion) 
6µl of cDNA or standard as appropriate was placed in a “mixing” well, along with 
54.5 µl master-mix. This was mixed by pipetting (for the full 54µl); at least 
three times. Around 19.8µl of this resulting mix was placed in each of the three 
wells (triplicate) on the QPCR plate. A non-template control (NTC) was included 
to determine the level of contamination and show the detection limit of the 
assay. Plate was spun for 20 seconds at 400g to place all contents at bottom of 
well. Using the 9700HT QPCR machine a standard run was performed, which uses 
the following reaction conditions: 
• Initial 10 minutes at 94oC not repeated 
• 3 seconds at 940C then 30 seconds at 60oC repeated 40 times (measuring 
fluorescence at the end of each 60oC elongation step) 
• Melt/ dissociation stage* 
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*At the end of the PCR a melt curve analysis was always performed. This 
measured the fluorescence during an incremental increase in temperature from 
65oC to 94oC. This was to establish whether the PCR was specific. At the end of 
the run to confirm whether the PCR was successful the following things were 
looked at, the standard curve should have a correlation of r2>0.97, preferably > 
0.98. Additionally, the slope should be equal to 3.3 (which means that the PCR 
product was amplified by a factor of 10 every 3.3 cycles, which implies that the 
reaction was 100% efficient). 
2.3.4.5 Analysis of QPCR data and stats 
Levels of a housekeeping/reference gene were assayed via QPCR to determine 
the level of cDNA present within a specific sample. Each sample was allocated a 
ratio of its GAPDH content in relation to the 75th percentile of GAPDH levels of 
all samples assayed. This ratio was subsequently used to normalise the levels of 
target gene. 
2.4 Lipoprotein isolation and oxidative modification 
Blood was taken from 8 healthy volunteers (50ml each) for lipoprotein isolation. 
The blood was collected in 0.4mmol/l EDTA after 12hrs of fasting. To obtain 
plasma, blood was centrifuged at 3000rpm at 100C for 30 minutes.  LDL was 
isolated using density adjustment of plasma (Plasma volume 150 ml) with sodium 
bromide (NaBr. Alfa Aesr) and four days of discontinuous ultracentrifugation at 
50,000rpm, 100C in a Beckmen L-80 ultracentrifuge, using a Ti 70 rotor. The first 
day the background density of plasma was assumed 1.006 and was adjusted to 
1.022 by adding 1.0gm dry salt NaBr to 50ml of plasma. This adjusted plasma 
was centrifuged at 50,000rpm at 100C for 18hrs. On the second day plasma 
density was adjusted to 1.020 by adding 28.31gm/L solution of NaBr and again 
spun at 50,000rpm at 100C for 18 hrs. On third day plasma density was adjusted 
to 1.065 by adding 3.24gm of NaBr dry salt and again centrifuged at 50,000rpm 
at 100C for 24 hrs.  On day four LDL was carefully taken off and 1gm of NaBr was 
added to it and finally centrifuged at 50,000rpm at 100C for 24hrs. LDL isolated 
as described, was dialysed against 5 litres of PBS (with 0.25mM EDTA to protect 
from oxidation) using a dialysing tube with a molecular cut off (12000-14000 
KDa). It was dialysed overnight at 40C three times. After dialysis the preparation 
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was passed through an Acrodisc filter (0.45um pore size) to sterilize and remove 
aggregates. 100µl was set aside for a modified Lowry protein determination. To 
oxidize the LDL, a final concentration of 10uM CUSO4 was added to LDL (w/o 
EDTA) at 1mg/ml and incubated for 16-18 hours; EDTA was then added at a final 
concentration of 0.25mM to stop and protect from re-oxidation. Oxidized LDL 
was sterilized by passing through Acrodisc filter (0.45mM pore size) and stored at 
40C in the dark. 
2.4.1 Modified Lowry protein assay 
LDL was prepared as explained earlier and to measure its concentration we used 
the modified Lowry protein assay. A 2x Lowry concentrate was prepared by 
mixing 3 parts copper reagent (Appendix 3) 1 part (1% sodium dodecyl sulphate) 
and 1 part (1 M NaOH). Just prior to mixing of these three stock solutions. The 
LDL sample was diluted to an estimated 0.025-0.25mg/ml with a buffer. A 
standard was prepared from 0.25mg/ml bovine serum albumin (pierce). 400µl of 
2x Lowry concentrate was added to every 100µl of sample and mixed thoroughly 
before incubating at room temperature for 10min. After this 200µl of 0.2N folin 
reagent (VWR) was added quickly and incubated for 30min. Finally, the samples 
were analysed using an ELISA plate reader at 500nm (DYNEX revelation 3.2) to 
obtain OD readings; a standard curve was prepared from the BSA samples and we 
extrapolated the concentration of LDL samples.  
2.4.2 Lipoprotein (Lipo) Electrophoresis 
The lipoproteins produced from fasting human blood from healthy donors was 
modified using copper sulphate. Electrophoresis was performed to confirm that 
the above-explained process resulted in two separate entities i.e. oxidised LDL 
and native LDL. A freshly drawn specimen from an overnight fasting individual 
was used as a control. Assuming that fasting human plasma will show distinct 
bands for LDL and HDL. 
This Agarose electrophoresis was performed using the paragon LIPO Gel kit 
(Beckman). All the samples to be tested were loaded on to the Lipo gel, 3-5µl of 
each sample was applied and allowed to diffuse for 5 minutes. This paragon gel 
was then placed onto the Gel Bridge assembly, in the Paragon Electrophoresis 
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cell with 45ml of Barbital buffer (Appendix 4). The gel was run at a set voltage 
of 100 volts for 30 minutes.  
The gel was fixed and stained with paragon lipo stain (Appendix 4) for 5 minutes. 
After serial destain steps the gel was finally dried in a fume hood. The gel was 
scanned with an alphaimager Mitsubishi P91D (FujiFilm). 
 
2.5 Animal study 
2.5.1 Mouse Model 
Human CD20 (huCD20+) transgenic mice were kindly provided by Professor Mark J 
Shlomchick (Yale University, New Haven) 203. These mice were crossed with 
Apolipoprotein E knockout mice (ApoE-/-)  (Jackson laboratory) to produce 
“huCD20+/ApoE-/- mice”. The breeding and maintenance was done by Biological 
services at the University of Glasgow. Litters were weaned at 3 weeks and tissue 
samples (tail) were taken and used to determine the genomic expression of the 
huCD20+ and ApoE genes.  
2.5.2 Mouse Genotyping 
2.5.2.1  Mouse tail sample preparation 
Mouse tissue samples (tails) were placed in thin walled 0.2ml PCR tubes. 75µl of 
alkaline lysis buffer (Appendix 5) was added and incubated at 95oC for 1 hour. To 
neutralise and stop the reaction 75µl of neutralizing buffer (Appendix 5) was 
added to the samples. The prepared DNA was used in Polymerase chain reaction 
(PCR) as described in (section 2.3.3) and stored at -20 oC. 
2.5.2.2 PCR reaction conditions for genotyping 
The PCR reaction was started with an initial incubation at 940C for 3 minutes. 
The reaction proceeded with 35 cycles of; 94°C for 20sec, 640C for 40 seconds 
and 720C for 2 minutes. Four set of PCR were done to ensure the presence of the 
entire bacterial chromosome in the transgenic mice. Two of these PCRs amplify 
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regions within the hCD20 gene (exon 2 and 3' untranslated region), and the other 
two amplify sequences near the two ends of the BAC (5' BAC and 3' BAC) 203. The 
sequences of oligonucleotides are as follows: exon 2, F, 5'-CACAAGGTAAGACTG 
CCAAAAATC-3' and R, 5'-ATATACAAGCCCCAAAACCAAAAG-3'; 3' untranslated 
region, F, 5'-GGCCTTTGCATGGAGTGAC-3' and R, 5'-AGCCCTGTAGAAAGATAA 
ATGGA-3'; 5' BAC, F, 5'-ATTGTTTGAGTGCTCAGCATG-3' and R, 5'-GGGAAAAACAAT 
ATTGCCTCC-3'; 3' BAC, F, 5'-GTTGGAGGT TCTGGTTG CAT-3' and R, 5'-AATTGGCT 
TAGGATTGGGCT-3' conditions were similar for 3 UTR and 3 BAC; whereas, for 
Exon 2 and 5 BAC the annealing temperature was different i.e. 580C for 50 
seconds x35 cylces. In addition 3 primers were used to confirm ApoE-/- and the 
sequences of oligonucleotides are as follows: ApoE IMR0180 F 5’ GCCTAGCC 
GAGGGAGAGCCG 3’; ApoE IMR0181 R 5’ TGTGACTTGGGAGCTCTGCAGC 3’; ApoE 
IMR0182 R 5’ GCCGCCCCGACTGCATCT 3’. 
2.5.3 Flow cytometric analysis of mouse blood samples 
2.5.3.1  Blood sampling  
To determine B cells (huCD20+) in Rituximab/IgG treated (huCD20+/ApoE-/-), 
mice were bled by venesectioning of the tail. This was performed by placing 
them in a heatbox maintained at 38oC for approximately 10 minutes to allow 
dilation of blood vessels in the tail. Mice were restrained; the tail sterilized with 
70% ethanol and a sterile scalpel was used to make a small nick in the tail. 70-
100µl of blood was obtained using heparinised capillary tubes (Hawksley) and 
transferred into 1.5ml eppendorf tubes. The whole blood was centrifuged at 
4000rpm for 10 minutes and serum was recovered that was stored at -20 oC. The 
remaining pellet was resuspended in an equal volume of sterile PBS (Appendix 1, 
d) to compensate for the volume of serum taken from each sample. The blood 
pellet collected was used for extracting peripheral blood mononuclear cells; the 
pellet was first mixed with PBS and then with ammonium chloride solution (stem 
cell technology) at a 9:1 ratio. This RBC lysis solution is buffered and optimized 
for gentle lysis of erythrocytes, with minimal effect on leukocytes. The sample 
was mixed by vortexing and incubation for 10 minutes on ice. The remaining 
cells  (PBMCs) were washed twice in FACS buffer (Appendix 1, g). These cells 
were resuspended in 100µl of FACS buffer with Fc Block (i.e. anti-Mouse 
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CD16/CD32 or FcγRIII/II, BD bioscience) added as 1µl per 100µl of FACS buffer 
and then incubated the cells for 5 minutes on ice.  
2.5.3.2  PBMC staining  
PBMCs from hCD20+/ApoE-/- were stained for different cell surface antigens; 
CD19-APC (ID3, BD pharmingen), CD3-PE (145-2c11, BD pharmingen), B220-PerCP 
(RA3-6B2, BD pharmingen), CD21-FITC (7G6, BD pharmingen), CD23-PE (2G8, 
southern biotech), CD24-PE (BD pharmingen, M1.69), IgM-PE (BD pharmingen), 
CD11b-PerCP (BD pharmingen, M1.70), IgM-FITC (BD pharmingen, II/41), IgD-FITC 
(bioscience, 11-26c), CD43-FITC (BD pharmingen, S7) and huCD20-FITC (L-27, BD 
bioscience). All the staining antibody solutions were prepared by adding 1µl of 
antibody per 100µl of FACS buffer (Appendix 1, g) except for huCD20, which was 
made by adding 15µl per 100µl of the buffer. The cells from blood samples were 
resuspended in 50µl of FACS buffer and to stain these cells 50µl of the staining 
solution was added to every sample making the final concentration of antibody 
to be 1:200 and the cells were incubated with these antibodies for 20 minutes at 
4oC. After incubating the cells the buffer was decant off and cells were washed 
twice in 1ml of FACS buffer each time centrifuged at 1600rpm for 5 minutes. 
Cells were then fixed for later analysis with a 250µl of paraformaldehyde-
containing buffer cytofix (BD Biosciences), for 15 minutes at 4oC. Following 
fixation, 1ml of permeabilization buffer (BD Bioscience) was added to each 
sample, centrifuged at 1600rpm for 5 minutes, decanted and samples 
resuspended in 300µl of FACS buffer. Finally, these fixed and stained cells were 
resuspended in 300µl of FACS buffer and acquired on a FACS calibur (BD 
biosciences). The resulting data was analyzed using Flowjo (Treestar). 
2.5.4 High-fat diet and B cell depletion 
High Fat diet 
The cardiovascular literature refers to high fat diet as a western diet. The 
individual components of the diet are; 17.3% protein, 48.5% carbohydrate and 
21.1% fat by weight. When the high fat diet is given to genetically susceptible 
mice (ApoE-/-) it results in atherosclerosis. In this study high fat diet (Harlan) was 
given to huCD20+/ApoE-/- at 6-7 weeks of age until the animals were sacrificed 16 
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weeks later. The body weight of the mice was regularly monitored during the 
study to ensure that high fat diet resulted in increase in the body weight of 
these mice. 
2.5.4.1 B cell depletion in huCD20+/ApoE-/- mice 
HuCD20+/ApoE-/- mice were given 100µl of 100µg intravenous (iv) injections of 
Rituximab (Rituxan), or chromopure human IgG (Jackson Immunochemicals) 
every 4 weeks. To perform iv injections, mice were placed in a heat box at 38oC 
to ensure dilation of tail vessels. Warmed mice were placed in a restrainer; tails 
were swabbed with 70% ethanol and injections given in the tail veins. Pressure 
was applied to the injection site for approximately a minute to prevent further 
bleeding. 
2.5.4.2  Animal euthanasia 
At the end of 16 weeks the huCD20+/ApoE-/- mice on a high fat diet were 
euthanised by a rising concentration of carbon dioxide (CO2), in accordance with 
UK Home Office regulations. Mice were transferred to the cleaned plastic 
chamber connected to a carbon dioxide cylinder. The CO2 was turned on and the 
CO2 concentration gradually increased over several minutes resulting in 
euthanasia. To ensure that mice were successfully euthanised, we carefully 
noted that there were no reflexes before doing dissection. 
2.5.4.3 Mouse dissection    
Euthanised mice were pinned on a dissection board in a supine position so that 
the ventral aspect of the mice was easily accessible. Their skin was sprayed with 
70% ethanol and a small nick was made in the skin with a pair of scissors. The 
skin was carefully folded to the side to expose the thoracic and abdominal 
regions. The anterior abdominal muscles were cut using the scissors and the cut 
was further extended vertically upwards towards the sternum and on both the 
flanks as well. This resulted in a clean surgical field with all the abdominal 
organs exposed. A terminal bleed was obtained via the vena cava and the needle 
was left for perfusion and fixation. Blood samples were used to obtain serum and 
PBMCs for Flow cytometric analysis as already explained (section 2.5.3) 
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2.5.4.4 Mouse tissue harvesting 
2.5.4.5 Spleen  
Spleen was carefully removed by cutting the vessel at the hilum. A single cell 
suspension was achieved by passing the spleen through a 70-micron cell strainer 
into 3ml of complete RPMI. Cells suspensions were increased to 10ml with 
complete RPMI and centrifuged at 400g for 5 minutes. The media was decanted 
and red blood cells present in spleen samples lysed with 2ml of ACK lysis buffer  
(Lonza) and incubated for 2 minutes and the cell suspension was increased to a 
volume of 10ml with complete RPMI and centrifuged at 400g for 5 minutes. The 
media was decanted and the cell pellet was resuspended in 10ml with complete 
RPMI. To determine the number of total lymphocytes present in the sample, 50µl 
of the cell suspension was taken off and mixed with 200µl of media. 50µl of this 
mix was added to 50µl of trypan blue and placed on a heamocytometer. All 
together 16 squares were counted (8 from the top left and 8 from the bottom 
right) and the number of cells corresponded to the total number of million cells 
in the 10ml cell suspension. The cell suspensions were centrifuged at 400g for 5 
minutes, media was decanted and the cell pellet resuspended in FACS buffer 
(Appendix X) so that cells were at a density of 20 x 106 cells/ml. Cells were 
stained for different cell surface antigens; CD19-APC (ID3, BD pharmingen), CD3-
PE (145-2c11, BD pharmingen), B220-PerCP (RA3-6B2, BD pharmingen), CD21-
FITC (7G6, BD pharmingen), CD23-PE (2G8, southern biotech), CD24-PE (BD 
pharmingen, M1.69), IgM-PE (BD pharmingen), IgM-FITC (BD pharmingen, II/41), 
IgD-FITC (bioscience, 11-26c), CD43-FITC (BD pharmingen, S7) and huCD20-FITC 
(L-27, BD bioscience). All the staining antibody solutions were prepared by 
adding 1µl of antibody per 100µl of FACS buffer (Appendix 1, g) except for 
huCD20, which was made by adding 15µl per 100µl of the buffer. The cells from 
blood samples were resuspended in 50µl of FACS buffer and to stain these cells 
50µl of the staining solution was added to every sample making the final 
concentration of antibody to be 1:200 and the cells were incubated with these 
antibodies for 20 minutes at 4oC. After incubating the cells the buffer was 
decant off and cells were washed twice in 1ml of FACS buffer each time 
centrifuged at 1600rpm for 5 minutes. The cells were fixed for later analysis 
with a 250µl of paraformaldehyde-containing buffer cytofix (BD Bioscience), for 
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15 minutes at 4oC. Following fixation, 1ml of permeabilization buffer (BD 
Bioscience) was added to the each samples, centrifuged at 1600rpm for 5 
minutes, decanted and samples resuspended in 300µl of FACS buffer. Finally, 
these fixed and stained cells were resuspended in 300µl of FACS buffer and 
acquired on a FACS calibur (BD biosciences). The resulting data was analyzed 
using Flowjo (Treestar).  
2.5.4.6 Lymph nodes  
Different pairs of regional lymph nodes were removed such as popliteal, axillary, 
mesenteric and cervical. A single cell suspension was achieved by passing the 
lymph node fragments through 40-micron cell strainer. Cells were resuspended 
with total of 10ml of complete RPMI and centrifuged at 400g for 5 minutes. Cell 
pellets were resuspended in 10ml of complete RPMI and aliquot of resuspended 
cells were taken and manually counted on a chamber slide. Finally, the cell 
densities were adjusted to 20 x 106 cells/ml in warm RPMI and were stained (see 
spleen details above).  
2.5.4.7 Bone marrow 
The long bone like femur and tibia of the hind limbs were used for extracting 
bone marrow. Bones were cleared of tissues completely to avoid contamination 
with other cells. Then bones were cut at both ends using sharp scissors. The 
bone marrow was extracted using hydrostatic pressure. In brief, 1ml of media in 
a syringe with a 25g needle is used to flush the bone marrow out of the bone. 
The needle and syringe are then used to create a single cell suspension. Cells 
were resuspended with total of 10ml of complete RPMI and centrifuged at 400g 
for 5 minutes. Cell pellets were resuspended in 10ml of complete RPMI and 
aliquot of resuspended cells were taken and manually counted on a chamber 
slide. Cells were then stained for; CD19-APC (ID3, BD pharmingen), CD3-PE (145-
2c11, BD pharmingen), B220-PerCP (RA3-6B2, BD pharmingen), IgM-PE (BD 
pharmingen), CD11b-PerCP (BD pharmingen, M1.70), IgM-FITC (BD pharmingen, 
II/41), IgD-FITC (bioscience, 11-26c) FCM as described in (see spleen details 
above) 
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2.5.4.8 Heart and aorta  
After removal of the spleen, lymph nodes and hind limbs the needle in the vena 
cava was used to perfuse the circulatory system with PBS for 5 minutes, followed 
by 10 minutes with paraformaldehyde. The organs like spleen, lymph nodes, 
bone marrow and blood were harvested for staining and FACS analysis.  As the 
mice were already fixed they remained in the cold room for 6 days. Later, the 
diaphragm was carefully removed to access the thoracic cavity. The sternum was 
cut up the midline till the upper end; which is at the nape of the neck and the 
ribcage was pinned on sides. Viscera within the thoracic cavity were carefully 
removed to avoid damage to heart and aorta. The heart was firmly held at the 
base with a pair of forceps and by applying some tension to the aorta it was 
carefully dissected off its attachments with the posterior wall of the thoracic 
cage. The aorta was cut proximal to the branch of the brachiocephalic artery 
and then dissected out from above downwards, up to the bifurcation into the 
common iliac arteries. The dissected heart and aorta were fixed in formalin for 
24 hours and then transfer to 70% alcohol prior to processing tissue (tissue 
processing machine Shandon); finally the tissues were paraffin embedded. 
Sectioning of the heart 
Dissected heart with the attached aorta was cut using a sharp blade in a plane 
parallel to the cross sectional plane of aortic lumen as shown in (figure 2.1). 
Paraffin embedded formalin fixed sections were cut, Tissue block was pared into 
the aorta with the microtome set to (20µm) until the tissue was visible at this 
point the cutting scale is changed to 7µm. Thereafter, sections are cut serially 
and two sections were placed on each slide. All the aortas were cut till the atria 
were clearly visible. The sections are heated on a hot plate 600C for an hour to 
dry the sections and then stored at 40C. 
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Haematoxylin & Eosin staining  
Heart sections were selected for Haematoxylin & Eosin (H & E) staining; after 
every two sections a slide was stained. The selected slides were heated in an 
oven for 35 minutes at 600C. Heated slides were dewaxed twice in xylene for 3 
minutes. Thereafter, sections were hydrated in graded alcohol (100%, 90% and 
70%) 6 minutes each and finally to running cold water for 3 minutes.  
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Figure 2.1 A guide to sectioning the heart for cross sectional analysis 
The heart was cut at an angle of around 35 degree to the aortic origin as shown in 
the top left panel. Serial section (7µm) of formalin fixed paraffin embedded aorta 
were cut from the end where aortic valves were visible towards the ascending 
aorta as demonstrated in the top right panel. The aortic lumen with valves is 
demonstrated in (1) as more sections are cut the aortic valves starts to disappear. 
(2) Finally the aortic lumen can be seen without valves (3), the atherosclerotic 
lesion is marked  
Dehydrated sections were stained with haematoxylin 2 minutes and then washed 
in running water for 3 minutes. To reduce background, sections were put in 1% 
acid/alcohol for few seconds and quickly rinsed in running water. Then the slides 
were placed in tap water for 30 seconds. Thereafter, sections were 
counterstained with 1% eosin for 2 minutes; excess stain was washed in running 
water. Tissues were dehydrated through (70%, 90% and 100%) alcohol 1 minute 
each. Sections were then placed in xylene for 3 minutes and finally mounted 
with DPX and a coverslip. 
 
Quantification of lesion size  
Heart sections stained with H & E were analysed using microscope (Carl Zeiss) 
mounted with a camera, and pictures were captured with the imaging system on 
5x magnification. Lesions were examined in a blinded fashion. Morphometric 
analysis of the lesions was performed on cross sections through aortic origin by 
using image analysis software (Axio vision 4.4). The lesions were marked on top 
of the internal elastic lamina (see Figure 2.1). The aortic lumen and lesion area 
measurements from 5 sections were then used to calculate the percentage of 
luminal area obliterated by the lesion. This percentage area was than 
represented for demonstrating the extent of lesions longitudinally. Some lesions 
may have sheared off and be in the lumen, those were also measured and used 
in further analysis. The atherosclerotic lesion area is expressed as the mean of 
the lesion areas from 5 sections.  
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3 The cellular composition of human aortic adventitia from 
coronary bypass patients with rheumatoid arthritis  
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3.1 Introduction 
Rheumatoid Arthritis (RA) is a chronic, progressive, systemic autoimmune 
disease characterized by joint destruction. This chronic inflammatory ailment 
results in poor quality of life and also an increase in the development of life-
threatening outcomes, such as cardiovascular diseases (CVD). This is evident 
from the fact that RA patients have a strong association with cardiovascular 
morbidity and mortality 99, 204.  The underlying disease mechanism of RA is not 
known but post transitional modification of arginine to citrulline is proposed to 
be a potential auto antigen, which might be crucial in initiation of this chronic 
autoimmune disease. In fact the discovery of antibodies to citrullinated 
peptide/protein (ACPA) has augmented the diagnostic specificity of RA to 90-98% 
56. These disease specific antibodies can appear at early stages of the disease. 
Therefore, detection of ACPA has greatly improved early diagnosis of RA.  
However, the presence of ACPA alone is not enough to explain disease onset, 
therefore additional factors such as citrullinated protein, infections, genetic and 
environmental factor are all considered important for explaining the underlying 
disease mechanism. Klareskog et al proposed an etiological model, where an 
individual with genetic susceptibility and exposure to environmental factors are 
prone to develop ACPA. If at this point an unspecific stimulus such as trauma and 
infection leads to citrullination of proteins within the joints, then these target 
proteins are primed to be bound by circulating ACPA. As a result of this immune 
complexes are formed that aggravate joint inflammation. (reviewed 205)  
 Although ACPA antibodies are associated with RA, citrullinated proteins have 
been detected in disease-associated tissues in numerous inflammatory conditions 
30, 206. Citrullination is a posttranslational modification of arginine to citrulline 
that occurs under the influence of PADI a calcium dependent deiminating 
enzyme. This phenomenon is specific to apoptosis and inflammation. In fact 
there is evidence of PADI 2 and 4 associated with severity of inflammation in RA 
synovium; with activation of PADI occurring at calcium concentration 100 times 
more than physiological levels 207. Nevertheless, to date the presence of 
citrullinated protein has not been reported in aortic adventitia of animals or 
humans.  
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The tunica intima, of the aorta, has been accepted as the classical site of 
initiation in atherosclerosis, however, there is supporting data that cellular 
infiltrates are present in both intima and adventitia. The pathological 
mechanisms that result in inflammatory infiltration of both the layers is 
unknown, perhaps there are disease-associated mechanisms in both the tunica 
intima and adventitia. Recent studies have demonstrated that inflammatory 
rheumatic disease patients undergoing coronary artery bypass graft (CABG) have 
more pronounced chronic inflammatory infiltration in the media and inner 
adventitia of the aorta208. 
 
In 1962 Schwartz et al established adventitial infiltrates in three different blood 
vessels i.e. iliac, cervical and coronary arteries; these infiltrates were mainly 
distributed around the vasa vasorum. Further analysis demonstrated that 
infiltrating cells in the adventitia strongly correlated to atheromatous lesions 
suggesting a role in the disease pathogenesis 209. The type of cells present among 
the infiltrates are very important to know in order to understand the principal 
mechanism of the disease. The blood vessel of atherosclerotic patients were 
reported to have plasma cells with immunoglobulin IgM and IgD in the adventitial 
layer of the blood vessel210. Interestingly, B-cell presence is not only reported in 
human atherosclerotic lesions, in fact the aorta of ApoE-/- has been 
demonstrated to have B-lymphocytes even before the disease develops. 
Moreover, adoptively transferred lymphocytes homed to the aortic adventitia 
through a mechanism involving L-selectin211. Recently, Grabner et al established 
in ApoE-/- mice that lymphotoxin beta (LTβ) induces lymphoid aggregate 
formation and termed it adventitial aortic tertiary lymphoid organs (ATLOs); 
which contained B cell follicles, high endothelial venules (HEV), plasma cells and 
T cell areas212. Human aortic adventitia from patients with advanced 
atherosclerotic lesions showed lymphoid follicle like structures composed of 
macrophages, B cells and follicular dendritic cells144.  A brief report on B 
lymphocytes in two patients with co existing RA and coronary artery disease 
(CAD) revealed a predominance of B cells in both the plaque and adventitia; this 
preliminary observation deviates from the dogma of T lymphocyte predominance 
in atherosclerotic lesions 213. The presence of B cells in the aortic adventitia lead 
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us to hypothesize that the aortic adventitia of RA patients favours B cell 
proliferation and survival.  
 
There is evidence that RA is strongly associated with cardiovascular morbidity 
and mortality 99, 204. However, it is not clear how the vascular environment 
affects the immune component of RA. It has previously been shown that 
inflammatory rheumatic disease patients have more pronounced chronic 
inflammatory infiltration in the media and inner adventitia of the aorta 214. To 
address whether vascular environment of diseased vessel in terms of cellular 
composition and cytokine expression differ, and whether this is affected by the 
immune component of RA, the aortic adventitia from patients with CVD and 
coexisting RA would be a good resource to explore. Aortic adventitial biopsy 
samples were obtained in the Feiring heart biopsy study from patients with 
advanced atherosclerosis of their coronary arteries who underwent CABG. A full 
medical history was taken from all patients and samples were sub-divided based 
on co-morbid diagnoses. During surgery, Internal mammary artery (IMA) was used 
as the grafting vessel, due to its decrease susceptibility to atherosclerosis; a 
biopsy sample of IMA was taken and used as internal control for our study. 
The objective of this chapter was to compare the cellular composition and 
cytokine expression in 20 RA patients with coexisting CVD to CVD patients 
without RA. Importantly, the biopsy samples of IMA from 33 matched patients 
were considered non diseased and used as an internal control. The main aims of 
the study were:   
1. To investigate the expression of an RA-associated self-antigen, 
citrullinated protein, in the aortic adventitia removed from patients with 
coexisting Rheumatoid arthritis and cardiovascular disease. 
2. Investigate the presence of B cell aggregates and plasma cells in these 
lesions associated vessel and related them to expression of citrullinated 
protein. 
3. Examine whether the aortic adventitia of RA patients with coronary artery 
disease had any association with B cell survival factors like BAFF and 
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APRIL, which might provide a supportive niche for the differentiation and 
survival of B cells. 
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3.2 Results 
3.2.1 Patients characteristics  
The human aortic adventitia and Internal mammary artery (IMA) samples were 
from the Feiring Heart Biopsy study; biopsies were obtained from Patients 
undergoing coronary artery bypass graft (CABG) surgery. A total of 40 AA and 33-
matched IMA tissue samples were obtained. These 40 CVD patients had 
coexisting diseases and were divided into subgroups of RA (n=20) and non-RA 
(n=20). The demographic data and prevalence of traditional risk factors were 
similar in the RA and non-RA subgroups as shown below (Table 3.1). 
Table 3.1. Characteristics of patients in the group 
Characteristics   RA n=20 # Non RA n=20 # 
Age, years  70 ± 8.8 69 ± 9 
Male sex, no. (%) 13 (20) 14 (20) 
Duration of coronary artery 
disease, years 
8 ± 10 9.4 ± 7.9 
Time from angiography to 
CABG surgery, days  
17 ± 29 32 ± 61 ∗ 
Acute coronary syndrome, 
no (%) 
9 (20) 4 (20) 
C- reactive protein mg/litre 12 ± 40 3 ± 3 ∗ 
Diabetes mellitus, no (%)  3 (20) 1 (20) 
Smokers, no (%)  12 (20) 13 (20) 
Hypertension, no (%) 14 (20) 9 (20) 
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Unless stated otherwise, values are mean ± SD. RA= rheumatoid arthritis; Non 
RA= non rheumatoid arthritis; CABG = coronary artery bypass graft. # Based on 
clinical diagnosis. ∗  P< 0.005 versus Non-RA  
3.2.2 Citrullinated proteins are increased in the aortic adventitia of patients 
with rheumatoid arthritis  
Citrullinated proteins have previously been detected in tissues (rheumatoid 
synovium, skin epithelium, glial fibrillary acidic protein, myelin basic protein) 
and in inflammatory conditions (RA, multiple sclerosis and Alzheimer’s disease) 
30, 206. To investigate the presence of CP in the aortic adventitia of CABG patients 
with or without RA we first had to establish the technique for detection in our 
laboratory. The initial experiments were performed on sections from RA synovial 
biopsies, as we had a limited number of aortic adventitial sections. To 
determine the optimal antigen retrieval for citrulline staining we performed a 
series of standard antigen retrieval protocols.  
3.2.2.1 CP staining established in RA synovium 
RA biopsies that had previously been fixed (paraformaldehyde), embedded in 
paraffin, cut and placed on standard glass slides were subjected to different 
antigen retrieval procedures. After antigen retrieval the sections were stained 
with an anti-citrullinated protein antibody and the quality of staining 
determined. A citric acid retrieval (pH6) method was the first retrieval buffer 
used, due to a boiling step this retrieval method is known to be harsh. Our 
results demonstrated that under these retrieval conditions, the negative control 
staining was at a level that rendered this retrieval method unsuitable (figure 
3.1A). The next retrieval method attempted was a milder system utilising Tris 
EDTA. Although, there was an improvement with decreased background staining, 
it was still not negligible and confounded any interpretation of positive control 
biopsies (Figure 3.1B). Finally, Trypsin retrieval was used and this did result in 
much cleaner negative controls. In addition, a further modification in the 
staining procedure was implemented; Instead of performing the peroxidase-
blocking step prior to primary antibody incubation, it was performed before the 
secondary antibody incubation.  
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Figure 3.1 CP staining using different antigen retrieval systems 
To establish CP staining different retrieval systems were used A) is the citric acid 
retrieval showing strong background (brown colour) of the Isotype control (top left 
panel). B) this staining was performed using EDTA, which is a mild retrieval 
system that resulted in some improvement in negative control but still there was a 
lot of background staining seen as (brown colour) in the middle left panel. C) 
Finally, trypsin was used as an antigen retrieval that resulted in clean negative 
(bottom left panel) and strong staining (brown colour) on the positive sections. The 
sections were counter stained with Haematoxylin to highlight the nuclei and 
cytoplasm. All the stainings both negative and positive were photographed at 40x 
magnification 
In summary, trypsin retrieval and peroxidase block after primary antibody 
resulted in clean negative controls and the positive staining that was distinct 
and plausible based on prior publication and our expectations of expression 
(Figure 3.1, C). This optimised protocol was therefore used to stain all aortic 
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sections. All of the human aortic adventitia from patients with advanced CVD 
had observable levels of citrullinated proteins. It should also be noted that 9 out 
of 33 matched internal mammary arteries had moderate levels of citrulline 
staining. The CP stain was observable in mononuclear cells, interstitium and 
adventitial adipocytes (Figure 3.2, A-B). 
 
 Figure 3.2 Citrulline staining in aortic adventitia 
Citrullinated protein staining (brown) in the aortic adventitia can be noted in  (A & 
B); especially the signet ring shaped fat cells of the tunica adventitia. The lower 
panel (C & D) represents the Isotype control for the CP staining. The sections 
were counter stained with haematoxylin to highlight nuclei and cell structure. A & C 
10x magnification, B & D 40x magnification. 
The level of CP staining was quantified in an observer-blinded manner; 5 high 
power fields per section were scored for the percentage area of positive 
staining. Since the raw data were normally distributed, mean of percentage area 
was analyzed as already explained (section 2.1.5). The results shown (Figure 3.3, 
A) clearly indicate that Aortic Adventitia has high levels of citrullinated protein 
as compared to matched IMA, the mean ± SD of AA vs. IMA were (3.81% ± 1.956%) 
and (0.35% ± 0.73%), respectively (p = 0.0001). As we confirmed that AA has 
more citrullinated protein the next objective was to see if the staining was 
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different in aortic adventitia of patients subgroups, with and without RA. 
Interestingly, we observed significantly more CP in RA patients, the mean ± SD in 
RA vs. non-RA were 4.78% ± 2.6% and 3.2% ± 1.4%, respectively (p = 0.017, T 
test; Figure 3.3B).    
 
Figure 3.3 Scores for CP staining in aortic adventitia and IMA. 
In each graph circles and triangles represents different groups that are compared 
with each other A) Matched samples of IMA were compared with aortic adventitia 
from the same patients stained for citrullinated proteins; a massive increase in CP 
was seen in comparison with the non diseased IMA. B) RA represented with a 
circle are shown to have significantly increased level of CP expression in 
comparison with Non RA patients. A p-value of <0.05 was considered statistically 
significant and was represented as an (∗) 
In addition, all the forty patients in the Feiring heart biopsy study were also 
subdivided into smokers (n=25) and non-smokers (n=15). As citrullination of 
proteins is associated with smoking and inflammation, we analysed CP in aortic 
adventitia of patients in this subgroup for any interesting associations. However, 
the analyses showed that smokers mean ± SD 4.47% ± 0.56% vs. non-smokers 
5.15% ± 1.276%, was not significantly different (p = 0.086) as shown in the 
(Figure 3.4). 
        75                                                                          
 
Figure 3.4 CP in aortic adventitia of smokers and non-smokers  
In each graph circles and triangles represents different groups that are compared 
with each other. CP staining in smokers represented with a circle is shown to have 
almost similar level of CP as compared with Non-smokers 
 
3.2.3 B lymphocytes are present in the aortic adventitia from patients with 
CVD 
The literature on B cells presence in relation to atherosclerosis supports the fact 
that majority of their expression is in the AA rather than tunica intima in both 
humans and animals models116, 142, 215.  Now that we confirmed the presence of 
CP an RA associated antigen in AA, we sought to further validate the presence 
and any possible link between B-lymphocytes and CP in RA. We set out to 
establish B cell staining in RA synovium and human tonsil with an antibody 
against CD20, which is a pan B cell marker. To optimise this staining we tried 
both citrate and Tris EDTA antigen retrieval methods. Citrate retrieval with a 
pan specific secondary antibody was not successful. Staining with both these 
retrieval systems had background staining of negative control.  To optimize the 
staining method we tried an enzyme coupled secondary antibody system 
(Vector).  This resulted in specific staining of the aortic adventitia with no 
background staining of the adipocytes in the Isotype control. Thereafter, the 
surgical biopsies of Aortic adventitia (n=40) and matched IMA (n=33) were 
stained for the presence of B-lymphocytes using the established protocol as 
discussed in (section 2.1.1). Discrete membrane staining of CD20 can be seen 
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among the infiltrating mononuclear cells in the aortic adventitia (Figure 3.5, A & 
B).  
 
Figure 3.5 CD20 staining in aortic adventitia. 
In these sections a small aggregate of inflammatory cells can be seen, surrounded 
by signet ring shaped fat cells. CD20 a B cells marker has a discrete membrane 
staining of cells seen within the small follicle (A & B). Sections were counter 
stained with haematoxylin that resulted in nice nuclear staining as seen in the 
lower panel, which is the negative control (C & D), original magnification 10x in A 
& C; 40x B & D 
 
We were able to detect B-lymphocytes in 70% of the AA samples, whereas there 
were no B cells detected in IMA. In addition the aortic adventitial biopsies were 
sub grouped as RA (n=20) and non RA (n=20). When the percentage of B cell 
positive (72%) AA samples with coexisting RA were compared with non-RA 
samples (65%), a significant increase was seen in AA of RA patients (p 
value=0.03) (Figure, 3.6). 
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Figure 3.6 B cell presence limited to aortic adventitia                                            
The staining of all the biopsy samples for B cells (CD20) showed that their 
presence is limited to AA (both black and brown column), as none of the IMA had 
detectable B cells. The percentage of samples positive for B cells among RA 
patients (black column) were significantly more 75% vs. non RA around 60% 
(brown column) p value = 0.03 shown with an * asterisk 
Thereafter, the AA positive for B cells were scored in a blinded manner to 
determine level of B lymphocyte expression; CD20 positive cells were counted in 
a total of 5 HPF, as the raw data was non normally distributed it was therefore 
analysed by using median number of B lymphocytes/HPF already explained 
(section, 2.1.5). 
We observed that only Aortic Adventitia had B lymphocytes, whereas, matched 
IMA adventitia had no B cells, the mean ± SD in AA vs. IMA were 0.65 ± 1.65 and 
(0), respectively (p<0.05, Wilcoxon rank test; Figure 3.7). Half of the aortic 
adventitia samples from these CVD patients had coexisting RA. Therefore, we 
also compared B cells positive aortic adventitia among the sub groups of RA vs. 
non-RA, the mean ± SD 0.65 ± 1.3 and 0.68 ± 1.91, respectively (p = 0.816). 
Furthermore, CVD patients (n=40) had another subgroup based on whether the 
patients smoked or not.  We therefore also examined B cells staining scores 
between smokers and non-smokers, and the mean ± SD 6.8 ± 14 vs. 10 ± 22, was 
insignificant (p = 0.58). 
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  Figure 3.7 Scores for CD20 staining in aortic adventitia and IMA. 
 In the graph circles and triangles represents different groups, B cells were only 
seen in the aortic adventitia, the distribution of CD20 positive B cells between 
Aortic adventitial (n=33) and matched IMA (n=33) was statistically seen as (p-
value of <0.05, Wilcoxon rank test). 
3.2.4 B-cell aggregates in rheumatoid arthritis patients with advanced 
atherosclerosis 
The aortic adventitia of patients with advanced atherosclerosis have follicle like 
structures composed primarily of B cells (Figure 3.5) Interestingly, in the 
adventitia of RA patients, 7 out of 20 had these follicles whilst in non-RA 
patients we only saw 3 out of 20, because of small sample size this interesting 
observation needs to be addressed in future studies. 
3.2.5 Detection of plasma cells in the aortic adventitia of patients with 
advanced cardiovascular disease. 
We have confirmed the presence of an RA associated auto-antigen i.e. 
citrullinated protein in adventitia of both RA and IMA. Predominance of B-
lymphocyte and follicles in the diseased vessel made plasma cells an obvious 
choice for further investigation. Plasma cell staining has previously been 
demonstrated in RA synovium61. We used previously reported protocols to 
establish this staining not for in Immunohistochemistry by light microscopy, but 
also  immunofluorescent staining of plasma cells. This was done so that we could 
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perform double staining of plasma cells secreting antibodies to modified 
citrulline (section 3.3.8). The plasma cells were stained for (p63) with a 
monoclonal antibody (Vs38c); this was detected as discrete membrane staining 
(Figure 3.8, A & B) of cells with characteristic phenotype (e.g. clock face nuclei 
and acentric nuclear distribution). 
 
 Figure 3.8 Plasma cell staining in RA synovium 
The top panel shows a large number of plasma cells within the lymphocyte 
aggregates as intense discrete membrane staining (brown staining). The staining 
showed at different magnifications (A & B); while the lower panel (C & D) 
represents the Isotype control. The sections were counter stained with 
haematoxylin. Original magnification 10x  A & C; 40x B & D  
After establishing the plasma cell staining method on RA synovium, a number of 
adventitial biopsy tissues were stained for plasma cell presence. We found 
plasma cells presence in the aortic adventitia and next attempted to co localize 
these cells with citrulline reactive antibodies (Figure 3.11, A). This again 
required the generation of a novel tissue detection assay. 
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3.2.6 Generation of citrullinated fibrinogen 
So far three important components of an immune response were identified in 
these biopsy tissues including citrullinated protein as a target antigen, B-
lymphocytes along with aggregates as a source of plasma cells and presence of 
plasma cells seen in one biopsy sample. Now the next step was to generate 
citrullinated protein and then use it further as a ligand (bait) in the RA synovium 
to identify citrulline reactive antibodies secreted by plasma cells. 
Human fibrinogen modified to citrullinated fibrinogen. 
Human fibrinogen was modified based on enzymatic deimination using rabbit 
peptidyl arginine deiminase (PADI) as explained in the (section 2.1.2). The newly 
prepared citrullinated fibrinogen was run on an electrophoresis gel and then 
stained to confirm presence of the altered proteins (Figure 3.9) 
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Figure 3.9 Coomassie staining for citrullinated fibrinogen  
After electrophoresis of freshly prepared proteins, Coomassie staining confirmed 
all samples; lane 1 is a protein standard ladder, lane 2 is citrullinated fibrinogen, 
lane 3 is native fibrinogen and lane 4 is human cornified skin as a positive control. 
Multiple bands seen for all three proteins between 50-80 kDa 
3.2.7 Reactivity of modified fibrinogen confirmed with sera from RA 
patients   
To establish the reactivity of the freshly generated modified fibrinogen, fresh 
serum was collected from RA patients. Western blot membranes containing 
modified and non-modified fibrinogen and cornified skin extract were probed 
with sera from both Rheumatoid factor (RF) positive and negative Patients. The 
western blots probed with sera from healthy donors did not show any reactivity 
to citrullinated fibrinogen. However, the use of pooled sera from RA patients 
confirmed reactivity of citrullinated fibrinogen and skin (Figure 3.10, A).  
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Figure 3.10 Western blot analysis for citrullinated proteins  
A) Western blot using pooled sera from RF positive patients; Protein bands 
corresponding to molecular weight of 60-80 kDa represent citrullinated fibrinogen. 
Non-citrullinated fibrinogen was used as a negative control (lane 2) and human 
cornified skin as a positive control for citrullinated protein (lane 3). B) Western blot 
to confirm the biotinylation of proteins produced; lane 1 is citrullinated fibrinogen 
conjugated to biotin, lane 2 is biotinylated fibrinogen and lane 3 is skin, which was 
non-biotinylated and used as a negative control. 
Citrullinated fibrinogen and native fibrinogen were biotinylated to be used as 
bait for ACPA antibodies and a western blot was performed to demonstrate that 
the proteins were biotinylated (Figure 3.10, B). 
3.2.8 Plasma cells secreting antibodies to citrullinated protein in RA 
synovium  
It has recently been established that plasma cells producing anticitrulline 
protein antibodies (ACPA) are present in the synovium of patients with RA61. We 
have reproduced this finding in RA synovial samples from patients by using 
citrullinated fibrinogen.  As discussed above, the reactivity of newly prepared 
human citrullinated fibrinogen was confirmed on western blot. A biotinylated 
version of this reagent was used as a ligand to identify plasma cells secreting 
antibodies against citrullinated proteins. Autoantibody producing plasma cells 
were detected RA synovial samples by immunofluorescent staining. As can be 
seen in Figure 3.11 A-D, plasma cells (green)  antibodies reactive to citrullinated 
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protein (fibrinogen in this case red) are co localized as (green & red)  in the 
synovial tissue of RA patients.  
Once the ACPA producing plasma cells were established in RA synovium the next 
step was to investigate their presence in the aortic adventitia. This was 
important because presence of RA associated antigen (CP) and presence of B 
cells foci make it highly likely that there might be antibody selection/maturation 
going on. A thorough analysis of all the aortic adventitial sections illustrated that 
although we could find plasma cells in the aortic adventitia (5 out of 40 samples) 
we could not detect any that exhibited citrullinated fibrinogen reactivity (figure 
3.11, E & F). 
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 Figure 3.11 Plasma cell secreting antibodies to citrullinated fibrinogen 
To confirm plasma cells producing antibodies to citrullinated proteins. RA synovial 
membrane was stained green with anti p63 for plasma cells green (A) biotinylated 
CFb was used to stain citrulline reactive antibodies shown with white arrows (red) 
(B) Double immunofluorescence staining for plasma cells with immunoreactive 
antibodies to citrullinated protein can be seen green & red together (D). Sections 
were countered stained with DAPI for nuclear staining. (original magnification 40x). 
Plasma cell stained (green) in aortic adventitia (E & F). 20x magnification 
Details of the patients that were positive for plasma cells are given below (Table 
3.2). Interestingly, these 5 patients have a mixed profile from age group to 
smoking. However, four out of five are females and are non-RA. 
Table 3.2. Details of patients positive for plasma cells 
SNo Patient ID    Gender       Age Smoker/Non 
smoker 
Disease 
Profile 
1. 3178 Male  81 years  Smoker RA 
2. 9897 Female  67 years Smoker Non RA 
3. 2582 Female  78 years Smoker Non RA 
4. 10508 Female  76 years  Non smoker Non RA 
5. 3183 Female  66 years  Non smoker Non RA 
 
3.2.9 ACPA and CP together affect the cardiovascular outcome of RA 
patients 
The high specificity of ACPA in diagnosing RA patients at early stage, where 
patients do not have any overt signs of disease is an established fact. In fact 
ACPA expression persists at the end stage of disease and we wanted to validate 
any link between ACPA levels and CP in CVD patients with coexisting RA. Our 
data so far have demonstrated B cells and CP in the aortic adventitia of these 
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CVD patients (n=40), these patients also had coexisting RA (n=19) and remaining 
patients were considered non RA; however, the ACPA levels were not measured 
previously in this cohort. We therefore obtained the Axis Shield ELISA kit and 
determined the levels of ACPA in our RA cohort. The levels reported here for the 
RA cohort are from an ELISA kindly done by Susan Kitson in our lab. Out of 19 
patients in our cohort that were diagnosed with RA, we were able to obtain 
serum samples from 17 patients. We were also able to obtain serum from CVD 
patients without RA as some of these patients had high CP staining in their aortic 
adventitia. Serum samples from controls (non-RA patient’s) along with RA (n=17)  
were used in a standardized ELISA kit (Axis shield) to determine the levels of 
ACPA; 20U/ml is the cut off for a positive response in this assay. Importantly, we 
found that non-RA sera had no detectable levels of ACPA titres. However, ACPA 
levels were detectable in 70% of RA patients (12 out of 17), the mean ± SD 
(124.5 ± 61.89). The ACPA levels of patients examined are shown (Figure 3.12, 
A). 
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Figure 3.12 ACPA and CRP in RA patients 
 The ACPA levels were determined in the patients A) it was observed that all non-
RA  (red bars)  had non-detectable levels of ACPA (ELISA). However, 12 out of 17 
RA patients (brown bars) were found positive for ACPA levels, the mean ± SD 
(124.5 ± 61.89). The ACPA levels were further correlated with CRP and CP 
staining scores. To do the correlation subgroups were made, CP staining <5.5 was 
one group. B) the ACPA of these patients were correlated with their CRP levels, 
which was not significant (p=0.469) ( C) Thereafter, ACPA level for the remaining 
patients (CP> 5.5) was correlated with the CRP, which resulted in a strong 
correlation (∗∗p value=0.0067 with r2 0.9286).  
All RA cohort samples were analysed for correlation between ACPA and CRP, this 
was because elevated levels of CRP are associated with increased incidence of 
ischemic heart disease216. In addition, the patient’s characteristics for our 
cohort (Table 1) show that CRP is significantly increased in RA patients. When 
we examined all RA patients there was no-significant correlation seen between 
ACPA levels and CRP. Although in the present study we detected CP in the AA of 
non-RA patients similar to other inflammatory conditions. However ACPA was not 
detected in serum of non-RA patients, as this antibody reactivity is highly 
specific for RA.  
To determine a relationship between patients with both (ACPA plus CP) vs. CRP 
levels we had to identify a subgroup based on the maximum CP staining scores in 
non-RA patients. When the cohort of RA patients was sub-divided based on CP 
expression level in the AA, we had two groups one with (CP<5.5) and the other 
(CP>5.5).  The cut off point of (CP>5.5) was chosen, as this was the maximum 
seen in non-RA patients. This subgroup of RA patients with (CP>5.5) was 
correlated for ACPA vs. CRP levels. A linear regression analysis revealed no 
significant correlation for the RA patient’s subset with (CP<5.5) (see Figure 3.12, 
B). As expected a strong correlation was confirmed for the subset with (CP>5.5), 
with a p value of 0.0067 and r2= 0.9286 (Figure 3.12, C). 
So far we have confirmed that both AA and IMA express CP, an RA associated 
autoantigen. Which is notably more in the AA as compared to IMA. In addition, 
CP the proposed RA autoantigen was expressed more in the CVD patients with 
coexisting RA (n=20) as compared to non-RA. Furthermore, B-lymphocytes were 
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only detected in AA and 75% of these tissues samples were from CVD patients 
with RA. B cell aggregates and autoantigen presence was an impetus to 
investigate plasma cells in the AA. Interestingly a total of 5 AA were positive for 
plasma cells. We then confirmed an anticipated association between CP 
expression and serum ACPA levels in CVD patients. The serum analysis of the 
patients showed that ACPA was detectable in RA subset of the CVD patients. 
Importantly, patients with CP>5.5 score showed a significant association 
between serum ACPA levels and CRP as anticipated.  
3.2.10 Dominant B-lymphocyte survival factor (BAFF) expression in the 
smokers aortic adventitia 
The aortic adventitia samples express a known auto-antigen, B cells and plasma 
cells. Assuming the fact that B cells survival in any tissue is dependent on B cell 
survival factors. The next step was to address whether there are any survival 
factors in these biopsy samples.  
Unlike B cells BAFF staining was achieved using an avidin/biotin-based method. 
Using the established protocol BAFF was identified in the RA synovium. As 
explained in (section 2.1.1) it was seen that BAFF was expressed by infiltrating 
cells and non-haemopoietic cells like adipocytes and vascular endothelial cells. I 
then moved on staining AA and cytosolic staining of BAFF was prominent among 
mononuclear cells, adipocytes and vascular endothelial cells of vasa vasorum 
(Figure 3.13, A & B) 
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 Figure 3.13 BAFF staining in human aortic adventitia 
 Lymphocytes in and around the vasa vasorum show cytoplasmic staining (brown 
colour) for BAFF (arrowheads) - in fact distinct staining of vascular endothelial 
cells of vasa vasorum is also shown (A & B); whereas, the lower panels represent 
the negative control for BAFF (C & D). The sections were counter stained with 
hematoxylin. Original magnification 10x in A & C; 40x B & D 
Blinded observers scored the stained sections; these showed a non-normal 
distribution despite the fact that scoring was determined from 5 random high 
power fields. Therefore, the median percentage area was calculated for further 
analysis as already discussed (section 2.1.5). BAFF was present in 97% of AA vs. 
27% of IMA (p < 0.0001, OR 85). The increased expression of BAFF in diseased 
adventitia suggests some interesting relation with the underlying disease. The 
data of matched AA vs. IMA revealed a mean ± SD 3.57 ± 3 and 0.63 ± 1.24 
respectively, with a (p values<0.0001, Wilcoxon rank test; Figure 3.14, A). 
Interestingly, we also found a significantly higher expression of BAFF in the 
adventitia of the smoking patients, the mean ± SD for the subgroups are 4.8 ± 
2.50 vs. 3.6 ± 2.93 and a (p value = 0.03, Mann-Whitney; Figure 3.14, B). These 
results suggests that the survival niche can be related with both smoking an 
independent risk factor for vascular diseases and underlying mechanism of 
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atherosclerosis. The staining score of BAFF were also analysed for another 
subgroup of RA vs. Non RA patient’s, the mean ± SD 4.3 ± 3.17 vs. 4.4 ± 2.2 was 
not significant (p value = 0.81, Mann-Whitney) 
 
  Figure 3.14 BAFF staining score in human aorta and IMA 
In each graph circles and triangles represents different groups that are compared 
with each other (A) Scores for BAFF staining were significantly high in Aortic 
adventitia as compared to the matched IMA (p<0.0001, Wilcoxon rank test) B) 
Smoking patients had significantly more BAFF expression than non-smokers 
mean ± SD, 4.8 ± 2.50 vs. 3.6 ± 2.93 p = 0.03. A p-value of <0.05 is represented 
with an (∗). 
3.2.11 A proliferation inducing ligand (APRIL) specific to aortic adventitia 
from CVD patients 
We next probed the adventitia for another member of the TNF superfamily, 
APRIL, which also has potential role in B cell survival. Human tonsil was used to 
establish this staining protocol. Unlike BAFF in this staining method we used an 
enzyme coupled secondary antibody (Immpress vector). All the biopsy sections 
were stained for APRIL using the established protocol (section 2.1.1).  
Staining for APRIL was observed in the adventitia, particularly in inflammatory 
cells resembling monocytes and lymphocytes in which discreet punctate staining 
was noted(figure 3.15, A & B). Importantly, non-haemopoietic cells were also 
observed to express APRIL. These cells include adipocytes and vascular 
        90                                                                          
endothelial cells of the nutrient artery of aortic adventitia called vasa vasorum.  
Evaluating 5 high power fields for the percentage area of positive staining was 
done for scoring APRIL staining. Analysis was performed in both diseased aortic 
adventitia and the IMA specimens.  Comparison of scores revealed that APRIL is 
extensively expressed in diseased vessels (figure 3.15, c); compared with IMA 
comparators. 
 
Figure 3.15 APRIL staining in aortic adventitia 
The typical punctate and discreet APRIL staining is seen in this massive infiltrating 
area in the aortic adventitia (A & B), lower panel (C & D) are negative controls for 
the same area. Original magnification 10x & 40x respectively;  
APRIL was present in 68% of AA vs 6.5% of IMA (p < 0.0001, OR 30.5; Figure 3.16). 
The staining pattern and level of expression did not completely mirror that of 
BAFF.  For example, APRIL expression in smoking vs. non-smoking patients was 
not different, with the mean ± SD 1.4 ± 3.39 vs. 2 ± 5.2 (p value = 0.97, 
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Wilcoxon rank test). Similarly, comparison of RA vs. non-RA showed no 
difference as suggested by the figures for mean ± SD 2.5 ± 5.5 vs. 0.7 ± 1.8 p 
value = 0.52.  
 
Figure 3.16 APRIL staining scores in human samples 
In the graph circles and triangles represents AA compared with matched IMA. A 
significant difference was observed reflected by the mean ± SD 0.9 ± 1.9 vs. 0.12 
± 0.48 and a p value < 0.0006 (Wilcoxon rank test) represented (∗).  
 
3.3 Adventitial B-cells correlate with citrullinated protein 
and APRIL in patients with rheumatoid arthritis 
We next wished to explore further the possible role for these B cell survival 
niches in the context of RA pathogenesis. In RA patients, we noted a significant 
correlation between the presence of B cells and CP expression in AA tissues; 
r2=0.56, p value = 0.0001 (Figure 3.17, A). As expected we also observed an 
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association between B cells and APRIL r2=0.566, p value = 0.0017 (Figure 3.17, 
B). In addition, a significant correlation was noted for CP vs. APRIL, r2=0.295, p 
value = 0.29 (Figure 3.17, C). Intriguingly, when we looked for similar 
correlations for CP, B cells and their survival factors in non-RA patients there 
were no significant correlation seen.  
 
Figure 3.17 Associations observed in RA patients between citrullinated proteins B 
cells and APRIL.  
The staining scores of RA patients were analyzed for any significant associations 
using fisher exact test. The significant associations observed were A) between B 
cells and CP (r2 = 0.56; p = 0.0001), the second was B) among B cells and APRIL 
as (r2 = 0.655; p = 0.0017), and C) APRIL and Citrullinated protein (r2 = 0.29; p = 
0.295) in RA patients. There was no significant association with smoking. 
 
3.3.1 Macrophages in aorta of patients with advanced 
atherosclerotic lesions 
 Moving from B cells to macrophages and macrophage-derived cytokines AA were 
now probed for cytokine IL-18 and macrophages. Several prior studies have 
demonstrated the presence of macrophages in human atherosclerotic lesions. 
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Indeed, their presence is reported in aortic adventitia of human samples 13, 14, 21. 
I elected therefore to perform a complete analysis of my AA samples cohort in 
order that I could examine potential cytokine expression of monokine derivation. 
Given the prominence of macrophages in RA pathogenesis it seemed reasonable 
to focus on macrophage biology particularly in trying to elucidate a contribution 
to accelerated vascular disease in RA. Therefore, we initially looked for the 
presence of macrophages in aortic adventitia of patients with coexisting 
rheumatoid arthritis, as their presence in the context of RA has not previously 
been reported. All the aortic adventitias were stained for CD68 a well-
established macrophage marker; this demonstrated that these cells are present 
in the infiltrating areas and around the adipocytes (Figures 3.18, A&B).  
 
  Figure 3.18 Macrophage staining in aortic adventitia  
 The aortic adventitial staining for macrophage marker CD68 can been seen 
(brown colour) in the periphery of this lymphocyte aggregate seen as a small 
follicle (A & B) and the Isotype control showed no background staining (C & D). 
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The sections were counter stained with hematoxylin. Original magnification 10x in 
A & C; 40x B & D      
Analysis for the presence of macrophages in the aortic adventitia revealed 
similar representation in RA and non-RA patients, with mean ± SD 5.31 ± 4.36 
and 4.1 ± 3.91 respectively (p value = 0.42, Mann-Whitney; Figure 3.19 A); 
comparison between smokers and non-smokers also showed no difference, the 
mean ± SD 4.17 ± 3.89 vs. 5.5 ± 4.4 and a (p value = 0.346, Mann-Whitney; 
Figure 3.18, B). 
 
 
Figure 3.19 Macrophages in aortic adventitia 
In each graph circles and triangles represents different subgroups that are 
compared with each other. A) The comparison between the RA and Non- RA 
group is not significantly different with mean ± SD 5.31 ± 4.36 and 4.1 ± 3.91 
respectively (p value = 0.42, Mann-whitney). The other subgroup of the patient’s 
cohort is that of smokers and non-smokers and there was no significant difference 
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observed B) smokers vs. non-smokers mean ± SD 4.17 ± 3.89 vs. 5.5 ± 4.4 and a 
p value = 0.346, Mann-Whitney. 
The internal control (IMA) used through out the study was insufficient in quantity 
to examine macrophage staining. Therefore, we could not determine if there 
was any difference between the AA and matched IMA adventitia.  
Given the presence of macrophage lineage cells, I next wished to examine the 
presence of pro-inflammatory monokine that might play a role in pathogenesis.  
I focused initially on the IL-1 superfamily member IL-18 
3.3.2  Interleukin 18 a proatherogenic cytokine of IL-1 family 
The proatherogenic potential of IL-18 has been demonstrated in experimental 
model of atherosclerosis.22 IL-18 is known to have a synergistic effect with IL-12 
and the combination of these cytokines is demonstrated to generate Th1 
effector cells, which are known to accelerate the atherosclerosis. We 
investigated the presence of IL-18 in aortic adventitia and analyzed the 
difference between RA and non-RA patients. The staining of IL-18 was observed 
around the vasa vasorum as seen in (figure 3.20, A & B). 
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 Figure 3.20 IL-18 staining in aortic adventitia 
IL-18 positive cells can be seen in and around vasa vasorum expressed by 
infiltrating cells present at the margin of adventitial adipocytes (A & B); the lower 
panel represents the Isotype control with no staining of the infiltrating cells around 
the same vasa vasorum (C & D) sections were counter stained with hematoxylin 
original magnification 10x in A & C; magnification 40x B & D 
 
The IL-18 staining was scored in the aortic adventitia in a blinded manner, 
number of cells was scored for 5 HPF and as the raw data was skewed therefore, 
median cells/HPF were used to analyse the data. IL-18 expression in these 
adventitial samples was different in RA and non-RA patients but statistically not, 
as the mean ± SD 8.3 ± 7.3 and 4.6 ± 3.9 respectively (p value = 0.10, Mann-
Whitney; Figure 3.20, A). Whereas, the comparison of smokers vs. non-smokers 
showed a similar pattern, mean ± SD 7.1 ± 7 vs. 5.53 ± 4.2 respectively (p value 
= 0.91, Mann-Whitney; Figure 3.21, B). There was no control blood vessel (IMA) 
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available to stain for IL-18, therefore no data to shown differences between AA 
and IMA.  
 
 Figure 3.21 IL-18 staining scores in aortic adventitia and IMA 
In each graph circles and triangles represents different subgroups that are 
compared with each other. A) The cytokine IL-18 was found in aortic adventitia 
and there was no significant difference seen between RA and Non RA patients, as 
the mean ± SD 8.3 ± 7.3 and 4.6 ± 3.9 respectively p value = 0.10; B). In fact 
smokers vs. non-smokers revealed no significant difference, as the with mean ± 
SD 7.1 ± 7 vs. 5.53 ± 4.2 respectively p value = 0.91  
 
3.3.3 BAFF and APRIL expressed by mouse vascular endothelial 
cell line (SVEC4-10) 
In human aortic adventitia we found that vascular endothelial cells of the vasa 
vasorum, which are the tiny nutrient artery of great vessels, expressed both 
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BAFF and APRIL. We established a culture system of mouse vascular endothelial 
cells to verify expression of APRIL and BAFF transcripts. 
 DNAase free RNA was extracted from mouse vascular endothelial cells and 
reverse transcribed to cDNA, which was further used to determine what the 
levels of these transcripts are in the samples as seen below. Vascular endothelial 
cell line (SVEC4-10) expresses both BAFF and APRIL transcripts (Figure 3.22). 
 
Figure 3.22 BAFF and APRIL expression  
BAFF seen as (305 bp) band & APRIL as (220 bp) in vascular endothelial cell line 
(SVEC4-10) Lane 1 is 1 kb ladder, lane 2-3 represents the vascular endothelial 
cells expression of BAFF; where as lane 4-5 is BAFF expression in peritoneal 
macrophages, which were used as a positive control. Whereas, APRIL expression 
in mouse vascular endothelial cell is seen in lane (6-7) and mouse peritoneal 
macrophage expression of APRIL is lane 8-9. 
The presence of these transcripts in the vascular endothelial cells supports our 
finding of their protein expression seen in AA and IMA. Moreover, vasa vasorum is 
present in the deeper layer i.e. the adventitial layer of large blood vessels; 
which is subject to hypoxic environment.  As we confirmed the over expression 
of both the survival factors in the AA. In addition BAFF expression was found 
significantly more in the AA of smokers. It was intriguing to address the 
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expression levels of these transcripts under hypoxia because smoking is known to 
cause vasoconstriction of end arteries (vasa vasorum), which can induce hypoxia 
of vascular endothelial cells. To validate if, this phenomenon affects the 
transcripts of B cells survival factors experiments were carried out. 
To initially investigate the effect of hypoxia on SVEC4-10 expression of BAFF and 
ARPIL transcripts we performed semi quantitative PCR. The expression of APRIL 
seemed to have some subtle changes when kept under hypoxic conditions. The 
subtle changes in the semi-quantitative analysis provided a rationale to perform 
quantitative PCR using SYBR green chemistry. The assay is shown by a product 
dissociation graph confirming the product specificity by a single peak and the 
standard curve was to extrapolate number of gene copies (Figure 3.23)   
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Figure 3.23 Mouse APRIL QPCR  
The CDNA was used to quantify APRIL expression using the SYBR green; the 
dissociation curve on the left panel confirms product specificity and on the right is 
the standard curve generated using the outer primers to extrapolate the transcript 
copies. 
We then went on and tried different set of conditions to establish the impact of 
hypoxia (1% oxygen) on transcript levels of APRIL. Cultured SVEC4-10 cells were 
seeded in T-25 flask and grown till confluence. Then each treatment was in 
triplicate and treated for 6 and 12 hours under both hypoxia and normoxia, 
which were compared with the base line APRIL expression at 0hr time point. 
Moreover, one set of cells were first kept in hypoxic for 6 hours and then 
brought to normoxia for another 6 hours to explore if reoxygenation effects the 
APRIL expression. After repeating the experiment several times it was confirmed 
that there was no effect of hypoxia or reoxygenation upon APRIL expression as 
shown in the (Figure 3.24) 
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Figure 3.24 Quantitative analysis of APRIL expression in vascular endothelial cells 
Cultured cells were harvested untreated at 0hr shown as black column; there were 
cells that were kept under hypoxic conditions for 6 and 12hrs seen as grey 
columns and at similar time points cells were incubated under normoxia shown 
with white columns. The last group of cells was first incubated for 6hrs in hypoxia 
and then reoxygenated for another 6hrs. Every single group was as a biological 
triplicate. No significant differences were observed between the base line level and 
all the treatments. 
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3.4 Discussion 
The salient findings of the present study are that the aortic adventitia of 
rheumatoid arthritis patients, with coronary heart disease, is associated with an 
environment that is conducive to B cell survival and harbours a known RA-
associated self-antigen. Importantly, these insights provide a rationale for the 
perpetuation of B cell auto-reactivity outside of both lymphoid tissue and the 
joint in RA.  
The presence of citrullinated protein is significantly more in RA aortic adventitia 
but a reasonable number of non-RA diseased vessels demonstrated CP presence 
as well, which confirms that citrullination is an inflammation-associated 
phenomenon rather than an RA specific. In addition the conversion of arginine to 
citrulline is Peptidylarginine deiminase (PADI) dependent deimination, which 
occurs under high calcium concentration; physiological calcium level does not 
support this enzymatic conversion 36. However, under stress full conditions like 
apoptosis, terminal differentiation of skin cells and inflammatory responses the 
calcium concentrations are increased to levels that support citrullination. 
These findings were broadened, as we correlated serum ACPA levels in our 
patients to the CP staining scores. To do this analysis we sub defined only RA 
patients on account of maximum CP staining score in non RA patients and 
therefore we had a group of patients with (CP>5.5) this was selected as a cut off 
because this was the maximum CP score observed in non RA patients. The serum 
ACPA levels of this subgroup (CP>5.5) of patient correlated to the CRP levels. A 
strong correlation was observed between ACPA levels and raised CRP levels. 
Which implies that CP and ACPA might be working synergistically in aggravating 
the inflammatory response in the blood vessels.   
 Our attempt to characterize plasma cells with citrulline reactive antibodies was 
ineffective, which may perhaps be because of inappropriate reactivity of the 
citrulline used but this is quite difficult to confirm as only one RA patient had 
plasma cells. In addition, Klareskog et al proposed two subtypes of RA patients 
APCA positive and ACPA negative patients 217. If this stands true then even in 
suitable number of specimens we might have ACPA negative samples, as out of 5 
patients positive for plasma cells 4 patient were non-RA; theoretically these 
samples should not be positive for citrulline reactive antibodies. At the time of 
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analysis the scorer was blinded to the samples and having noticed no citrulline 
reactive antibodies is genuine. 
 
Studies to date have focused on intimal lesion in atherosclerosis and role of 
adventitial tissue has not yet been extensively elucidated.  Lymphoid follicular 
structures in advanced atherosclerotic aortic adventitia were reported to have B 
cells 144 215, 217. More recently ApoE deficient mice were shown to have lymphoid 
follicle like structures with B cells, which were diet and age dependent 142. 
However, we are showing for the first time that a B cell survival niche exist in 
the aortic adventitia that provide the microenvironment for B cell survival and 
maturation.  Here we report not only CP presence in AA from CVD patients but 
also significantly increased levels in RA patients. In addition there were more 
macrophages, plasma cells and B cells in aortic adventitia then IMA along with 
its survival factors BAFF and APRIL. There were significant associations observed 
between CP, B cells and APRIL in RA patients.  
BAFF expression was increased in smokers with CVD. The expression of both 
BAFF and APRIL was further confirmed at mRNA message level in vitro in a 
mouse vascular endothelial cell line (SVEC4-10). However, at a message level 
these survival factors were not affected with danger signal hypoxia. 
There is increasing evidence to support the fact that cigarette smoking is an 
individual risk factor for both atherosclerosis and rheumatoid arthritis. 
Moreover, accumulating data from the past decade has indicated that 
citrullination is strongly associated with smoking and rheumatoid arthritis (RA).  
However, we could not observe any association between CP and smoking in 
patients of rheumatoid arthritis. Perhaps there are other unknown 
environmental factors involved in the citrullination of proteins that were not 
persistent within our groups. 
 Our study does have limitations as we have shown all the differences by 
comparing aortic adventitia from CVD patients and their matched IMA (non 
diseased vessel); which is not the best vessel to compare with aortic adventitia. 
Replacement of aortic adventitia with coronary artery with dimensions similar to 
IMA was one possible option.  Secondly, matched saphenous vein adventitia is 
closer to aorta in size and calibre, so as a negative control it would have 
provided a better option for comparison. Moreover, the severity of inflammation 
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in these atherosclerotic plaques would have been underestimated as the 
specimens were selectively taken (for some surgical reasons) from areas with 
less severe disease.  
The characteristic of IMA to resist atherosclerosis is established but it is not fully 
understood why it behaves different. However, Ferro et al showed that the 
lesions are ten times greater in coronary artery then the IMA. This was seen in 
the inner most layer i.e. intima but not in the tunica media 218. The IMA have 
high antioxidant capacity compared to coronary artery SMC; IMA smooth muscle 
cells also express low tenascin and decorin that are involved in the LDL binding 
and SMC migration. Apart from these factors there are extrinsic features like 
axial stretch, sheer stress and small number of side branches that might play a 
role in the IMA resistance to atherosclerosis 219. The underlying mechanism for 
resisting atherosclerosis might not be unfolded yet but there is some unknown 
attribute that makes IMA unique. 
 
This study suggest that the aortic adventitia of rheumatoid arthritis patients, 
with coronary heart disease, is associated with an environment that is conducive 
to B cell survival and harbours a known RA-associated self antigen. Importantly, 
these insights provide a rationale for the perpetuation of vascular inflammation 
in RA patients with presence of both CP and ACPA in these patients. 
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4   IL-33 in Vascular Biology 
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4.1 Introduction 
In atherosclerosis the balance between the Th1 and Th2 immune response is 
altered and studies have demonstrated that atherosclerosis is predominately a 
Th1 mediated disease. In fact, atherosclerotic lesions from patients with 
cardiovascular disease show a predominance of the Th1 cytokines IFNγ and IL-2 
149. Moreover, the pharmacological down regulation of the Th1 response with 
pentoxiphylline, in a murine model of atherosclerosis, significantly reduces 
atherosclerotic burden 153.  
One cytokine and its receptor that was recently hypothesized to have a role in 
the pathophysiology of cardiovascular diseases was IL-33, a novel cytokine of the 
IL-1 family and a mediator of Th2 responses 175. It is expressed by synovial 
fibroblasts, macrophages, endothelial cells and cardiac fibroblasts 200, 220.The 
receptor for IL-33 is ST2 and this membrane bound form is constitutively 
expressed on mast cells, fibroblasts and Th2 cells. The secreted form (sST2) is a 
soluble inhibitory receptor also known as IL1R1-a. This is induced upon 
appropriate stimulation of fibroblasts, mammary tissue, retina and osteogenic 
tissue (reviewed 188). IL-33 has dual properties that of a cytokine and a 
chromatin associated transcription repressor suggesting its close link to IL-1α 
and high mobility group box 1 (HMGB1) 182. The release of this cytokine from the 
cells has not been convincingly shown. However, apoptosis associated caspases 
like 3 and 7 cause inactivation of IL-33, which was seen as a reduction in NFκB 
activation 178. Interestingly, in our lab some unpublished work has shown that 
necrotic damage to cells with UV light cause release of full length IL-33; Gerard 
et al have reported a similar observation in endothelial cells 176.  
Human and murine studies have suggested that the levels of soluble ST2 (sST2) 
are indicative of a role for it in cardiovascular disease. In support of this role, 
serum concentration of sST2 were found to be elevated in patients with acute 
heart failure 195 and the levels of serum sST2 strongly correlated with increased 
future mortality in patients of acute destabilized heart failure 196. The potential 
of ST2 as a cardiovascular biomarker was highlighted when it was observed that 
myocardial injury induced the release of both sST2 and transmembrane ST2. 
sST2 was demonstrated to be increased one day after myocardial infarction and 
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was associated with creatine kinase (standard marker for myocardial infarction) 
and had an inverse association with ventricular function 197. In addition the 
potential of sST2 as a biomarker of mechanical overload was investigated in a 
larger patient cohort where 800 patients presenting with acute myocardial 
infarction were tested for serum sST2. The serum levels of sST2 at the time of 
presentation in hospital correlated with 30 day mortality 198. 
In juxtaposition to the detrimental role of ST2 in cardiovascular disease, Sanada 
et al demonstrated that biomechanical stress induced the production of IL-33 by 
cardiac fibroblasts, which resulted in reduced cardiac hypertrophy and fibrosis 
200. The beneficial role of increased levels of IL-33 was further demonstrated in 
vivo in an experimental model of atherosclerosis. The supplementation of 
recombinant IL-33 in ApoE knockout mice, fed on a high fat diet, resulted in a 
significant reduction in plaque size.  This protective effect was specifically 
inhibited by the administration of sST2 199. The underlying mechanism of this IL-
33-mediated protective effect was a shift from a predominantly Th1 mediated 
response to a Th2, which was associated with increased levels of 
atheroprotective anti-oxLDL IgM antibodies 139. In support of this mechanism, the 
protective effects of IL-33 were lost upon inhibition of IL-5 with a blocking 
antibody.  
The great vessels have thick muscular wall and the adventitia of these vessels 
need continuous supply of nutrients, which is achieved by tiny vessels called 
vasa vasorum (a single layer of vascular endothelium). Vasoconstriction (due to 
smoking) of this nutrient supply can result in hypoxia and increased wall 
thickness, which can further deteriorate the metabolic supply to the adventitia 
221, 222. Endothelium from blood vessels of chronically inflammed tissues like RA 
synovium and Crohn’s disease intestine has marked expression of the cytokine IL-
33 182. In addition IL-33 expression is demonstrated to be more in the resting 
endothelium and down regulated upon angiogenic stimulation. Therefore, it is 
hypothesised that vascular endothelial cells of the vasa vasorum in the aortic 
adventitia might express IL-33. An interesting question is whether or not co-
morbid RA, smoking or levels of oxLDL will modulate this expression. It would be 
interesting to examine IL-33 expression in AA of smoking patients with that of 
non-smokers. Moreover, IL-33 is regarded as a novel alarmin, which can respond 
to danger signals and can function as an extracellular cytokine by mediating Th2 
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response through IL-4, IL-5, IL-13 and IL-33 also has nuclear repressor properties 
223. Cytokines like IL-5 can induce IgM production that can neutralize oxLDL. We 
proposed that if IL-33 expressing cells were subjected to danger signals (oxLDL 
and hypoxia) that are thought to play fundamental role in the progression of 
atherosclerosis, then we might be able to show interesting association between 
IL-33/sST2 system and risk factors of atherosclerosis.  
 
4.2 Aims 
In view of the role of IL-33 and ST2 in cardiovascular disease the aims of the 
present study are  
1. Examine IL-33 expression in AA and IMA. 
2. Verify IL-33 expression in mouse vascular endothelial cell line. 
3. Investigate the effects of danger signals (oxLDL and hypoxia) on IL-33 
expression in vascular endothelial cell line. 
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4.3 Results 
4.3.1 IL-33 expressed by vascular endothelial cells of AA and IMA 
To investigate the expression of IL-33 in the aortic adventitia of patients with 
advanced atherosclerosis, with or without coexisting RA, we performed 
immunohistochemistry on paraffin embedded sections from our cohort of 40 
aortic adventitia and 33 matched internal mammary artery (IMA). Analysis of 
staining by light microscopy revealed that IL-33 was detectable in both aortic 
adventitia and IMA (Figure 4.1 and 4.2). We were able to detect pronounced 
staining of IL-33 in the vascular endothelial cells of the vasa vasorum of aortic 
adventitia (Figure 4.1). The staining observed in the vascular endothelial cells of 
the vasa vasorum had a distinct nuclear localisation pattern (figure 4.1B), 
implying that IL-33 is synthesised in these cells and transported to the nucleus as 
a transcriptional regulator. This pattern of staining was also observed in the IMA, 
where the predominantly positive cells were endothelial cells (lining monolayer) 
of IMA (figure 4.2B). The semi-quantitative scoring was performed to determine 
the mean number of IL-33 positive cells per high power field (40x) in the aortic 
adventitia mean ± SD (2.80 ± 2.5) vs. IMA (4.1 ± 4.36) demonstrated that there 
was no significant difference in their IL-33 staining (p=0.36, paired t test).  The 
presence of IL-33 expressing endothelial cells is not necessarily a feature of 
cardiovascular disease but rather a component of normal physiology (Figure 4.1 
and 4.2).  
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Figure 4.1 IL-33 expressed by vasa vasorum of aortic adventitia 
Paraffin embedded aortic adventitial sections underwent deparaffination, antigen 
retrieval and were stained with either an anti-IL-33 antibody 5µg/ml (A & B) or an 
isotype control antibody (C&D) and localized with DAB (brown. A & B, illustrate 
that the monolayer of vascular endothelial cells of vasa vasorum are positive for 
IL-33 staining and that this staining is predominately nuclear. No positive staining 
was observed in the isotype control sections (C & D). Original magnification 10x (A 
& C) and 40x (B & D) 
        111                                                                          
 
Figure 4.2 IL-33 expressed by vascular endothelial cells of IMA. 
IMA tissue section showing lining layer and the adjacent interstitium were stained 
with either an anti-IL-33 antibody 5µg/ml (A & B) or an isotype control antibody 
(C&D) and localized with DAB (brown. A & B, illustrate that the monolayer of 
vascular endothelial cells lining IMA are positive for IL-33 staining (arrows) and 
that this staining is predominately nuclear. Original magnification 10x (A & C) and 
40x (B & D) 
4.3.1.1 IL-33 is down regulated in aortic adventitia of smokers 
Previous studies have shown that cardiovascular disease is associated with many 
risk factors including; diabetes mellitus, smoking, dyslipidemia, high blood 
pressure, advanced age and genetic abnormalities 95. Our study cohort of 
patients with advanced atherosclerosis could be sub-divided into smokers (n=21) 
and non-smokers (n=14). In addition, patients had co-morbidity (RA with CVD, 
n=20) and only CVD (n=20).  
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The expression of IL-33 in aortic adventitia of smokers (n=21) and non-smoking 
patients (n=14) showed that smokers had a significantly reduced level of IL-33 
expression than non-smoking patients (p=0.03, t test, Figure 4.3, A). To confirm 
if this was specific to AA, the IMA tissues were also analyzed for IL-33 expression 
in smokers (n=19) vs. non-smokers (n=9), and there was no significant difference 
seen (Figures 4.3, B).  
 
 
Figure 4.3 IL-33 expression reduced in smokers AA 
IL-33 staining was specifically observed in endothelial cells of vasa vasorum. 
Analysis was performed using mean cells per high power field to demonstrate 
differences between the subgroups. The circles and triangles represents groups 
compared A) AA of smoking patients had significantly less IL-33 expression than 
non-smoking patients (p=0.03, T test). B) The staining scores for (IL-33) in control 
vessel IMA as mean cells (per HPF) between smokers vs. non-smokers was found 
to be insignificant. 
The results for IL-33 expression in AA of smokers were quite intriguing. To 
validate if this observation that smoking affects IL-33 expression is specific to 
diseased vessel (AA) we compared the scores between AA and IMA. There was a 
marked reduction observed in IL-33 expression in AA (n=21) of smoking patients 
(p=0.0036, Figure 4.4, A).  As smoking is a well know risk factor in cardiovascular 
diseases; we anticipated no effects on IL-33 expression in vascular adventitia of 
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non-smoking patients, this was confirmed by analysis shown in graph (Figure 4.4, 
B).  
 
Figure 4.4 IL-33 expressions in Aortic adventitia and IMA  
The staining score were quantified using light microscopy and mean cells per 
(HPF) were used to analyse differences between the groups. The circles and 
triangles represent the groups compared. A) IL-33 staining scores in smoking 
patients AA (n=21) compared with IMA (n=19) demonstrated significant reduction 
(p=0.0036, paired t-test), whereas, B) Non smokers AA (n=14) and IMA (n=9) 
showed no significant difference.  
In addition, the sub-division of patients into those with or without RA co-
morbidity demonstrated that RA did not affect the levels of IL-33 in either 
endothelial cells of vasa vasorum (AA) or lining layer of IMA (figure 4.5). 
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Figure 4.5 IL-33 expressions in RA and non-RA patients 
IL-33 staining was specifically observed in endothelial cells of vasa vasorum. 
Analysis was performed using mean cells (per field) to demonstrate differences 
between the groups. The circles and triangles represents groups compared A) AA 
of RA patients (n=16) had a similar IL-33 expression as non-RA patients (n=19). 
B) The staining for IL-33 was specifically seen in endothelial lining layer of control 
vessel (IMA) and no significant difference was observed between RA (n=13) vs. 
non-RA (n=14) patients. 
These data clearly suggest that in the vasculature IL-33 is expressed primarily in 
endothelial cells and that smoking can contribute to decreased cellular 
expression/nuclear localisation of IL-33 in small vessels in an inflammatory 
environment. Subsequent experiments addressed the possible functional 
significance of this observation. 
4.3.2 IL-33/sST2 mRNA transcript under oxLDL and Hypoxic conditions 
Previous studies have demonstrated that IL-33 is expressed in vascular 
endothelial cells of chronically inflammed tissues 182. Whilst other studies have 
shown factors such as oxLDL and hypoxia can induce endothelial dysfunction or 
damage. It has been previously shown that in vivo effects of IL-33 can be altered 
by the use of decoy receptor sST2. Interestingly we looked at these two 
transcripts in parallel because the vascular endothelial cells express them so if 
one goes up then the other is down regulated. It was therefore important to look 
at these two transcripts in parallel to demonstrate the impact of different 
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treatments (oxLDL, hypoxia) on their transcript levels. To test this hypothesis we 
established a culture system to examine the mRNA expression of IL-33 under the 
influence of oxLDL and hypoxia. Our initial experiments were performed to 
demonstrate that mouse vascular endothelial cells (SVEC4-10) expressed 
detectable levels of IL-33 and sST2 transcripts. A PCR was designed and 
optimised to evaluate the expression of IL-33 and sST2.  An example of the PCR 
can be seen in Figure 4.6. This illustrates that the IL-33 transcript (270bp) is 
expressed in SVEC4-10, where smooth muscle cells were used as a positive 
control (Figure 4.6, A). In addition, sST2 (600bp) was also detectable in SVEC4-
10 cells (Figure 4.6, B). Studies have shown that non-haemopoietic cells like 
fibroblasts, retinal cells and mammary tissue express the inducible isoform sST2 
(reviewed 188). However, the expression sST2 by vascular endothelial cells have 
not previously been reported. Our experiment demonstrates that mouse vascular 
endothelial cells express sST2 transcript. 
 
Figure 4.6 PCR for IL-33 and sST2 in vascular endothelial cell line (SVEC4-10) 
PCR was performed to detect mouse IL-33 and sST2 mRNA expression in 
vascular endothelial cell line. A) Lane 1 is 1 kb ladder, lane 2-3 represents 
vascular endothelial cells and lane 4 is positive control (mouse smooth muscle 
cells); whereas, B) is sST2 PCR, lane 2-3 represents vascular endothelial cells 
and lane 4 is positive control (mouse Fibroblast) 
Having established that both IL-33 and sST2 are expressed in the murine vascular 
endothelial cell line SVEC4-10, we designed a quantitative PCR procedure to 
evaluate the specific levels of both IL-33 and sST2. Using primers for IL-33/sST2 
QPCR was performed and the data was normalized with the house-keeping gene 
GAPDH, we generated gene specific standards (purified products) using an outer 
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set of primers. Inner primers were then used to detect the specific gene in the 
samples and in the generation of a standard curve for quantification. A QPCR 
was performed to evaluate the standard curves, generated from outer primers, 
for the housekeeping GAPDH (ct 19) and IL-33 (ct 24, Figure 4.7, B & C). A 
melting curve was performed to ensure product specificity, which can be seen as 
single peaks for both the genes. (Figure 4.7, A) 
This data shows that mouse vascular endothelial cells (SVEC4-10) express IL-33 
that can be quantified using the method explained for evaluating changes in 
transcript levels under different conditions (oxLDL or hypoxia).  
 
Figure 4.7 QPCR for IL-33 and house keeping gene (GAPDH) 
This QPCR was performed using SYBR green; (A) The product specificity was 
confirmed by dissociation curve showing two peaks one for the housekeeping 
gene GAPDH (Red) and other for IL-33 (blue). (B) The graph represents the 
standard curve for IL-33 using the outer primers; this is to extrapolate the number 
of copies of the sample gene. (C) Using the outer primer, the product of house 
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keeping gene (GAPDH) is serially diluted to generate the standard curve; which 
helps to normalize the number of copies of the sample gene (IL-33). 
4.3.2.1 Lipoprotein isolation and oxidative modification 
To investigate the effect of oxLDL on IL-33 and sST2 transcript levels in SVEC4-10 
we used the method of Binder et al to generate native LDL from fasting human 
serum collected from healthy individuals. This involved the isolation of LDL 
lipoproteins by consecutive ultracentrifugation of fasting human serum. After 
isolating native LDL, it was quantified using the modified Lowry protein assay, a 
standard curve was generated using bovine serum albumin (BSA) and the 
concentration of LDL samples was determined by extrapolation from the 
standard curve. The OD value for LDL was 0.14, which was used to calculate the 
LDL concentration (12.4 mg/ml) using the formula shown in the graph (Figure 
4.8). The modification of native LDL to an oxidised LDL was achieved by the 
addition of copper sulphate using a previously published protocol 224. To stop the 
oxidization of native LDL and additional oxidization of oxLDL the lipoproteins 
were stored in PBS containing 0.25mM EDTA. 
 
Figure 4.8 Modified Lowry assay 
This standard curve was generated using known concentration of BSA; which was 
used to extrapolate the LDL concentration in mg/ml. 
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4.3.2.2  The effect of ox-LDL on the level of IL-33 transcript in SVEC4-10 
Thus far, the IL-33 transcript is confirmed in endothelial cell line and to 
investigate the hypothesis that danger signals (oxLDL or hypoxia) could affect IL-
33 transcript levels. We treated SVEC4-10 cells at 75% confluence, as confirmed 
by light microscope, with either, oxLDL (80µg/ml) and native LDL at the same 
concentration, or vehicle (PBS-EDTA). The freshly isolated modified LDL and 
oxLDL were prevented form oxidation by adding 0.25mM EDTA. Therefore, 
because of the addition of EDTA to our low-density lipoprotein samples a vehicle 
(PBS) containing EDTA was included as a control treatment. Cells were treated 
for 24 or 48h and RNA harvested for determining IL-33 transcript level. To 
establish a baseline value for IL-33 transcript cells were harvested when the 
treatment was started at time (0hr). As can be seen in (Figure 4.9), at 24hr both 
native LDL and vehicle resulted in an increase (<2 fold) in IL-33 transcript, while 
oxLDL did not affect the IL-33 transcript. 
 
Figure 4.9 QPCR analysis of IL-33 expression in mouse endothelial cell line 
(SVEC4-10).  
Cells were treated for 24hrs with LDL, oxLDL and PBS-EDTA (in triplicate) and 
every single square represents a treated sample. Transcript levels are represented 
as mean fold change relative to base line levels (untreated 0hr). DNA-free RNA 
was extracted from mouse cell line, which was reverse transcribed and used in a 
quantitative PCR (SYBR Green chemistry). A trend was observed in IL-33 
expression (up regulated) at 24hr with LDL and PBS-EDTA treatment as 
compared to the untreated (0hr) levels. However, the expression is close to the 
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base line (untreated 0hr), and was almost similar for all the treatments after 
48hours. 
As these findings show a trend at 24hr time point in the level of IL-33 transcript  
and not at 48hr, it was important to investigate the change in IL-33 transcript 
prior to 24hr. The treatment groups were kept same as the pervious experiment. 
Unfortunately, in this experiment there was no difference seen within the 
groups at any time points. However, there was a fluctuation observed for all the 
samples at three different time points, At 6hr IL-33 baseline levels were below 
baseline and  at 12hr and 24hr remained above the base line. However, all the 
values were very close to base line and hence nothing significant (Figure 4.10). 
 
Figure 4.10 IL-33 expression at earlier time points (6hr, 12hr, 24hr) 
The IL-33 transcript were looked under different treatments at earlier time points 
like 6hr, 12hr and 24hrs; cells were treated with (PBS-EDTA, PBS, LDL, and 
OxLDL) at each time point; each treatment was in triplicate and every single 
square represents a sample. Transcript levels are represented as mean fold 
change relative to base line levels (untreated 0hr). None of the treatment showed 
any significant differences within the groups.  
To verify that oxLDL did not affect IL-33 transcript levels another experiment 
was set, this time apart from the three different treatment groups an additional 
group of untreated cells was added at each time point. This was to confirm if 
the baseline level of IL-33 transcript remains consistent for the untreated cells. 
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In addition this time we also looked at the sST2 expression in the same settings 
as explained above.  
There was no difference seen in IL-33 mRNA fold change with or without 
treatment within the groups at any time point. (Figure 4.11, A). Moreover, the 
sST2 transcript levels were not significantly affected at any time point (6hr, 
12hr, 24hr), and no considerable changes were observed within the groups with 
any treatment (Figure 4.11, B). 
 
Figure 4.11 A) IL-33 mRNA expression at 6hr, 12hr and 24hr time point 
The gene expression was looked under different conditions at earlier time points; 
6, 12 and 24hr; The cells were treated with (PBS-EDTA, LDL, OxLDL and an 
untreated group was also included) at every time point; each treatment was in 
triplicate and every single dot represents a mean fold change relative to baseline 
line level. None of the treatment showed any significant differences within the 
group; however, IL-33 showed slight increase at 24hr in comparison with cells 
harvested at any other time point. B) sST2 mRNA expression shows a trend at 6hr 
time point in vascular endothelial cells 
4.3.2.3 Synchronized SVEC4-10 and IL-33/sST2 mRNA 
In the experiments performed to this point it was not clear whether the IL-33 
transcript level fluctuation at different time points were because of cell cycle or 
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any other factor. Previous studies have shown that serum starvation synchronize 
cells cycle of the cultured cells. Therefore, mouse vascular endothelial were 
serum starved (0.2% FCS) 225, as this would result in synchronization of the cells 
in culture. After 12hr of serum starvation with 0.2% FCS; fully confluent cells 
were harvested at 0hr, 6hr, 12hr and 24hr. The semi quantitative PCR (Semi 
QPCR) showed consistent levels of IL-33 transcript levels at all time point as 
demonstrated (Figure 4.12), indicative of no effects of cell cycle on the IL-33 
expression. 
 
Figure 4.12 IL-33 mRNA expression in synchronized mouse vascular endothelial 
cells 
Murine vascular endothelial cells were serum starved with (0.2% FCS) for 6hr, 
12hr and 24hr.  Top panel is IL -33 level at 4 different time points (in triplicate); 
which were analyzed relative to the house keeping gene (GAPDH). IL-33 transcript 
levels were consistent across all time points. 
4.3.2.4 Confluence of cultured cells and IL-33 expression 
As there was no effect seen with serum starvation, which suggest that cell cycle 
is not affecting IL-33 gene expression; another interesting factor to examine was 
confluence of the cultured cells. To investigate the impact of confluence on 
cultured cells, an experiment was set with fully confluent cells, which were 
treated with oxLDL and native LDL. When cells were fully confluent untreated 
cells were harvested to confirm baseline levels and also at each time point (6hr, 
12hr, 24hr) to see the impact of different treatments. This demonstrated that 
the IL-33 baseline levels were increased with confluence because this time the 
mean fold change relative to baseline levels dropped for all treatment close to 
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zero. Therefore, in these settings IL-33 transcript levels are almost same (Figure 
4.13, A). 
 
 
Figure 4.13 IL-33 mRNA upregulated with confluence  
Fully confluent cells were treated for different time points (6hr, 12hr, and 24hr) with 
oxLDL and native LDL. Every treatment was performed in triplicate. Each single 
sample is represented with a square. A) There were no significant change 
observed in IL-33 transcript with different treatments within each individual group 
relative to the expression of untreated cells at 0hr. B) The base line expression 
level of sST2 with full confluence was quite low and this got significantly 
upregulated at 6hr (p<0.05, Mann-Whitney) for all the treatments. However, this 
was followed by a decrease in the expression level at later time points of 12hr and 
24hr. 
In this experiment with fully confluent cells in culture assuming that the IL-33 
transcripts would be stable for untreated (0hr) These confluent cells were 
treated with oxLDL and native LDL for 3 different time points. Interestingly the 
same exact triplicate was also analyzed for sST2 transcript to confirm IL-33/sST2 
relationship under the influence of stress factors in cells expressing both these 
transcripts together. IL-33 transcripts did not show a change with any treatment 
within the groups at 6hr, 12hr and 24hr (Figure 4.13, A). However, the transcript 
levels of sST2 were looked at in parallel and there was a significant up 
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regulation seen at the 6hr time point with all the different treatments (p<0.05, 
Mann-Whitney). 
Thus far, it was observed that fluctuations seen in IL-33 mRNA was due to 
change in confluence and this was confirmed by a recent study, where resting 
confluent vascular endothelial were shown to have high IL-33 expression and it 
was lost upon angiogenic proliferation 220. 
4.3.2.5 Validation of generated lipoproteins 
In our culture system oxLDL treatment did not alter the levels of IL-33 
transcript. To validate whether lipoproteins generated from fasting human 
serum were properly oxidized with copper, we ran a lipogel (Beckman coulter) 
for different batches of both oxLDL and native LDL. To our surprise all the 
batches of modified and non-modified LDL used in the present study were found 
to be oxidized, which seemed a spontaneously oxidation (Figure, 4.14), despite 
the fact that they were kept in dark in a buffer containing EDTA to prevent 
spontaneous oxidation. 
 
Figure 4.14 Gel electrophoresis for lipoproteins 
The native LDL and oxLDL isolated from healthy donors were confirmed for their 
oxidation status on the lipogels. Lane 1 is serum from fasting donor (a positive 
control for LDL and HDL) that shows two bands top one is HDL and the bottom 
one is LDL. Lane 3 is OxLDL (Batch 1), Lane 4 is native LDL (batch 1). Lane 5 is 
also oxLDL; thereafter lane 7 is oxLDL (Batch 2) and lane 8 is native LDL (Batch 
2) This gel, therefore, confirms that both batches of native and modified LDL are 
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oxidized, which implies a spontaneous oxidation despite the fact that they were 
stored in dark at 40C.  
Henceforth, fasting serum from healthy donors was used again to generate fresh 
native LDL. After 4 days of ultracentrifugation a fresh batch of LDL was 
produced, which was oxidized using copper sulphate. This time samples were 
immediately run on a lipogel with human serum as a control that contains both 
LDL and HDL. Surprisingly, the freshly prepared LDL was not oxidized using the 
published protocol (Figure 4.15)224. Therefore, all the experiments  
 
 
 
 
 
 
Figure 4.15 Gel electrophoresis for lipoproteins 
Lane 1 is human fasting serum (positive control) that has two bands a top faint one 
is HLD and the bottom one is LDL. Lane 2 is native LDL. Lane 3 is spontaneously 
oxidized LDL (positive control, previous batch). Lane 4 is fresh LDL. Lane 5 is new 
oxidized LDL, which is not oxidized. Lane 6 is HDL extracted from fasting serum. 
Lane 7 is native LDL. 
Performed in the present study to examine the impact of oxLDL on IL-33/sST2 
system are inconclusive and needs to be repeated with properly oxidized LDL.  
4.3.2.6 Hypoxia and IL-33/sST2  
Previous studies have shown that smoking can cause vasoconstriction of nutrient 
vessels (vasa vasorum) of aortic adventitia, resulting in hypoxia of vascular 
endothelium. Together both smoking and hypoxia are implicated in the 
underlying disease mechanism of atherosclerosis 226. In addition, this present 
study confirms that IL-33 expression in vascular endothelial cells of AA was down 
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regulated in smoking patients. Therefore, it was important to investigate the 
expression of IL-33 and sST2 under the influence of hypoxia. 
As we were unaware of the fact that oxLDL used in the system was not properly 
oxidized, we initiated a parallel set of experiments to investigate the impact of 
hypoxia and/or oxLDL on IL-33/sST2 transcript levels. Murine vascular 
endothelial cells in the established culture system were kept under hypoxia (1% 
oxygen) and normoxic conditions at 75% confluence. No significant difference 
was seen in comparison to cells at normoxia at both 6hr and 12hr (Figure 4.16, 
A). The IL-33 fluctuation observed with full confluence in the earlier 
experiments was not seen this time. sST2 transcript levels were also same for all 
the samples. (Figure 4.16, B) 
 
Figure 4.16 QPCR for IL-33 & sST2 gene expression under hypoxia 
A) IL-33 mRNA in murine SVEC4-10 treated with PBS, oxLDL, LDL in triplicate 
under normoxia and hypoxia (1%) for 6hr and 12hrs. No significant effects were 
seen in the expression level of IL-33 at both 6hr and 12hrs. B) Soluble ST2 
transcript levels in similar settings showed a trend of reduction in transcript level, 
which was not significant. 
It came to our attention at this point that a published study has demonstrated in 
the past that the house-keeping gene (GAPDH) was affected by hypoxia. This was 
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particularly relevant, as all of our previous studies had used GAPDH as a house-
keeping gene to normalise our specific genes. We, therefore, investigated the 
effect of hypoxia on GAPDH in our culture system. We designed a new set of 
primers for beta actin gene to perform QPCR. The data with beta actin showed a 
clear 5 fold up regulation of GAPDH level at 6hr and a 9-fold up-regulation at 
12hr. The reoxygenation of the cells at 6h resulted in stabilisation of the GAPDH 
levels, as can be seen in Figure 4.17. These finding were consistent with the 
data published for GAPDH up regulation under hypoxia 227. Therefore in all 
subsequent hypoxic experiment beta actin was used as the house-keeping gene.  
 
 
Figure 4.17 Hypoxia upregulates expression of house keeping gene GAPDH  
Mouse vascular endothelial cell line (SVEC4-10) was looked for GAPDH 
expression under hypoxic conditions; the white columns represents cells exposed 
to normoxia; whereas, the grey column show expression of cells under hypoxia. 
The GAPDH expression is significantly up regulated after 6hr treatment (5 fold) 
and it further increases to around 10 fold (p<0.0001, T test) after 12 hours of 
exposure to hypoxic conditions in comparison to cells exposed to normoxia. The 
last column shows that cells that were kept in normoxia for 6hr and then in hypoxia 
for 6hr had an up rise as well. 
To investigate the effect of hypoxia on IL-33 transcript levels in murine vascular 
endothelial cells line. Cultured cells were exposed to normoxia; hypoxia (1% 
oxygen) and one group of cells were reoxygenated by incubation in hypoxia for 
6hr and then in normoxia for another 6hr. The data was analyzed with both 
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GAPDH and Beta actin (Figure 4.18 A, B) respectively; which look completely 
different and knowing that it is the house keeping gene GAPDH that gets up 
regulated under hypoxia. In this experiment again the expression levels 
increased at 12hr time point and no important variation seen with the different 
treatment; which is consistent with previous results for IL-33/sST2. 
 
 
Figure 4.18 IL-33 transcript levels, hypoxia and house keeping genes. 
Mouse vascular endothelial cells were treated with vehicle (PBS), LDL and oxLDL 
under hypoxia (1% oxygen) and normoxia for 6hr and 12hr. Another group was 
added where treatments were carried out for 6hr under hypoxia and then the 
cultured cells were reoxygenated for the last 6hrs. The IL-33 transcript levels were 
normalized with two different house keeping genes GAPDH and beta actin. A) 
QPCR data for IL-33 transcript levels normalized with GAPDH show some random 
variation that are due to changes in the house keeping gene (GAPDH) B) The 
transcript levels normalized with beta actin as house keeping gene shows a trend 
of up-regulation at 12hr. 
As we understand from the results so far, that IL-33 transcript levels have 
fluctuation in baseline level depending on cells confluence at the time of 
harvest. Moreover, the effects of oxLDL cannot be investigated because the 
modification of LDL did not yield oxLDL form. Therefore, a Final experiment was 
designed to determine the impact of hypoxia on IL-33/sST2 transcript levels. 
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Murine cells were cultured and once fully confluent SVEC4-10, exposed to 
hypoxia (1% oxygen) for 6hr and 12hr. Cell were also kept in normoxia as a 
control group for the same length of time, lastly a group of cells were kept 
under hypoxia for 6hr and then brought back to normoxia for the last 6hr to 
examine the affects of reoxygenation on IL-33/sST2 expression. The QPCR data 
was normalized with beta actin as a house keeping genes. IL-33 transcript level 
at 0hr was considered as baseline therefore all the other treatment are 
presented as mean fold change calculated relative to the baseline, which 
showed that all treatment samples had almost similar transcript levels (Figure 
4.19, A). Whereas, the sST2 transcript levels up regulated at 12hrs under both 
normoxia and hypoxia, which were not significant (<2.5 fold), Figure 4.19, B) 
 
Figure 4.19 Fully confluent SVEC4-10 under hypoxia 
Murine endothelial cells were exposed to normoxia, hypoxia (1% oxygen) and 
reoxygenation for 6hr and 12hr. Cell were harvested when fully confluent at 0hr 
and IL-33 ct was normalized with β actin and fold change was calculated. A) IL-33 
expression at 0hr is base line and it was used to calculate relative fold change for 
all the samples treated under different conditions.  B) sST2 fold change at 12hr 
show an increase of (<2.5), which is not significantly different. 
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4.4 Discussion 
It has been shown previously that IL-33/sST2 is important in cardiovascular 
system. The protective effects of IL-33 in the murine model of atherosclerosis 
are shown to exist through Th2 cytokines IL-5 and IL-13. Importantly, the 
blockade of IL-5 results in augmented plaque size despite IL-33 treatment 199. 
Moreover, IL-5 is known to exert its anti atherosclerotic response through 
natural antibodies against oxLDL 139. This suggests that IL-33 has an 
atheroprotective role through B-lymphocytes and antibodies.  
The salient findings of this study are that there is down regulation of IL-33 
expression in vascular endothelial cells of human AA of smokers. In non-smoking 
patients the level of IL-33 was comparable between the AA and IMA, and it was 
similar for both the vessels. It can be hypothesized that IL-33 is released with 
damage to vascular endothelium, which then stimulates the production of 
natural antibodies against oxLDL through IL-5; the antibodies then perhaps block 
the uptake of oxLDL by macrophages. Most likely this smoking associated down 
regulation of IL-33 expression is suggestive of failed protective mechanisms of 
this Th2 cytokine, however, this could be an indirect effect of smoking on IL-33 
expression in AA. 
A culture system was established to confirm the impact of hypoxia and 
reoxygenation on IL-33/sST2 transcripts in vascular endothelial cells. Initially the 
expression of IL-33/sST2 was confirmed in vascular endothelial cell line. In the 
process of optimization of the culture system for gene quantification, it was 
observed that GAPDH (house-keeping gene) is significantly up regulated with 
hypoxia at 6h and 12hrs. It was also established that other house keeping gene, 
Beta actin is not affected by hypoxia. Therefore, in the experiments towards the 
end, the data was normalized with Beta actin, which confirmed that IL-33/sST2 
is not affected under hypoxia or reoxygenation. Interestingly, it was observed 
that IL-33 transcript fluctuate with proliferation/confluence of cells; whereas 
fully confluent cells in culture resulted in stable level of IL-33 transcripts 220. 
Therefore, fully confluent cells were treated under hypoxia and reoxygenation, 
which confirmed insignificant changes in IL-33/sST2 transcripts.  In addition a 
recent study showed that IL-33 is lost by endothelial cells during wound healing 
and angiogenesis 220. While optimizing the culture system it was shown that IL-33 
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expression fluctuates with confluence of cells. To ensure stable base line IL-33 
transcripts at 0hr in the culture, fully confluent cells should be used in the 
future experiments. This would certainly help in consistent results, and add to 
the reliability of data in addressing the impact of hypoxia on IL-33/sST2 
transcripts in vascular endothelial cells.  
The present study also aimed to investigate the impact of oxLDL on IL-33/sST2 
expression. The effects of oxLDL could not be demonstrated because the copper 
sulphate induced modification of LDL did not result in oxidation for us. In 
addition, the time limitation does not allow for establishing a new protocol for 
LDL modification and more experiments in our culture system. 
In summary IL-33 is expressed by vascular endothelial cells of human AA and IMA. 
The protein expression is down regulated in smoking patients AA. In a culture 
system IL-33/sST2 are not affected under hypoxia. Therefore the formal 
explanation for the down regulation of IL-33 in smokers remains unclear. It does 
not however appear to be a direct smoking related phenomenon
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5  The impact of B cell depletion therapy on Atherosclerosis 
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5.1 Introduction  
Rheumatoid arthritis (RA) is a chronic progressive debilitating disease that 
primarily involves the joints. If the treatment is started early in the course of 
disease with DMRDs (methotrexate, sulfasalazine, hydroxychloroquine, 
leflunomide and glucocorticoids)41 this can delay the onset of cartilage and bone 
erosion associated with excruciating pain and joint deformity. Moreover, RA 
patients have a strong association with cardiovascular morbidity and mortality 89, 
90, 99.  
RA patients require lifelong treatment including medications, exercise and even 
surgery in advanced cases. Different treatments are available and the first line is 
primarily DMARDs with or without prednisolone. If upon clinical assessment the 
disease seems to have progressed then either a second DMARD is added or an 
alternate DMARD in combination with anti-TNF (Infliximab, Etanercept or 
Adalimumab) together with methotrexate is started. To prevent further 
deterioration methotrexate can be used in combination with different anti TNF 
therapies. However, patient’s refractory to treatment with anti TNF can respond 
effectively to B cell depletion therapy 205. The only FDA approved B cell 
depleting agent is Rituximab, a chimeric monoclonal antibody to CD20, which is 
specifically expressed on human B cells 45, 228, 229, which has a transmembrane 
protein with 4 domains 230. The antibody started out as a murine antibody and 
was then engineered to contain parts of the human antibody. This resulted in a 
chimeric antibody a combination of constant portion from humans and the 
antigen binding variable portion of a murine origin. The standard Rituximab 
therapy in patients results in more than 95% reduction of detectable circulating 
B-lymphocytes 231. The clinical responses suggest a proinflammatory role of B 
cells in RA pathogenesis. Importantly, RA patients are strongly linked with 
cardiovascular morbidity and mortality and studies suggest that B cells have an 
anti-inflammatory role in atherosclerosis 232. Keeping this in view it becomes 
very important to address the implications of B cell depletion therapy on 
atherosclerosis. Especially when rituximab is used in refractory cases of 
rheumatoid arthritis. One would assume that the majority of the patients would 
be more than 50 years of age at the time this B cell targeted therapy is started 
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and it becomes important to validate the effects of rituximab therapy on 
atherosclerosis. 
To investigate this we decided to use the ApoE-/- mice, an experimental model 
of atherosclerosis. These mice develop atherosclerosis as they age, however, if 
these mice are given a high fat diet then the process of atherosclerosis is 
accelerated 233-235. The human CD20 transgenic mice express the human CD20 
receptor and are therefore susceptible to Rituximab induced B cell depletion 203. 
We crossed these two murine strains to generate the huCD20+/ApoE-/- murine 
line. These mice were fed on a high fat diet and treated with Rituximab to 
deplete B cell. The effect of B cell depletion on atherogenesis was evaluated in 
these mice. 
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5.1.1 Aims of the study  
This study was performed using huCD20+/ApoE-/- mice, allowing us to combine 
the induction of atherosclerosis (by high fat diet) and B cells depletion. The aims 
of this study were  
1. To investigate the impact of B cell depletion therapy on plaque formation in 
atherosclerotic prone mice. 
2. To monitor B cell depletion and recovery during the course of the study. 
3. Examine the outcome of the treatment in relation to different B cell subsets 
in various areas (peripheral blood, spleen and bone marrow). 
4.  Validation of the total serum lipids of mice and correlate these lipid levels 
to different B cell subsets and aortic lesions. 
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5.2 Result 
5.2.1 Model system and plan of the study 
To determine the safety of B cell depletion therapy in RA patients, who are 
prone to atherosclerosis, we developed a model system to mimic the 
cardiovascular clinical situation and thus bred the huCD20+/ApoE-/- mice. The 
rationale for using these mice is that whilst being prone to hyperlipidemia, 
which leads to plaque formation in their blood vessels, they also express the 
human CD20 receptor and therefore render the B cells susceptible to anti-CD20 
antibody mediated depletion.  
5.2.2 Generating huCD20+/ApoE-/- mice   
The huCD20tg were generated using a 168kb human bacterial artificial 
chromosome and maintained as heterozygous 203. To generate the huCD20+/ApoE-
/- mice, human CD20 mice were crossed with ApoE-/-mice. These mice on a 
C57BL6 background, initially from Professor Mark Shlomchik at Yale, came via 
the University of Southampton in Professor Glennie laboratory. Unfortunately, on 
arrival it was observed that these mice had several pathogens. To clean the mice 
so that they were allowed access to our animal facility the mice underwent 
embryo re-derivation prior to initiating the ApoE-/- huCD20tg crossing. In 
addition, due to the poor breeding nature of the ApoE-/- mice it took a 
considerable time to get to a point where we had the required genotype to set 
up productive breeding pairs. During the breeding of these mice the presence of 
the huCD20 and the lack of the ApoE gene was confirmed using tail samples. 
Blood was used to document the expression of the huCD20 molecule on the 
surface of B-lymphocytes. The PCR to detect the huCD20 molecule was 
performed using 4 sets of primers for different regions of the BAC (used to 
derive transgenic CD20 mice) these include huCD20 exon 2, 3UTR, 5 region BAC 
and 3 region BAC. Whereas, the absence of the ApoE gene was confirmed with a 
set of 3 primers. Sequences for all genotyping primers are in appendix 7. 
After two years of breeding we started to get huCD20+/ApoE-/- mice that we 
could use in experiments.  Owing to time limitation, we had to start the study 
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with a limited number of mice (n=4) in the first group. The PCR analysis of tail 
samples demonstrate that in this set of pups 3 out of 4 mice were positive for 
the expression of huCD20 as shown by exon 2 (464bp) in 3 out of 4 mice and this 
was confirmed by positive signal seen for the 5’ BAC region (100bp) (Figure 5.1, 
A). Whereas, the PCR for the ApoE gene results in a band of 245bp for the 
knocked-out gene ApoE-/-, while one mouse with two bands of both 155bp and 
245bp was a heterozygous represented as ApoE+/- (Figure 5.1, B). The genotyping 
confirmed three of the mice as huCD20+/ApoE-/-. Blood samples were also taken 
from these mice and PBMCs were extracted for FACS analysis to confirm protein 
expression of human CD20 on B-lymphocytes. PBMCs were stained for CD19 and 
huCD20; the FACS plot demonstrates huCD20 positive cells (44.9%) out of the 
gated population (Figure 5.1, C). 
 
 
Figure 5.1 Confirmation of hCD20+/ApoE-/- mice 
(A) Genotyping of huCD20/ApoE mice using tail samples show 3 out of 4 mice 
positive for huCD20 receptor as bands are seen for Exon 2 and 5’ BAC. (B) The 
PCR for the ApoE gene show 4 out of 5 pups as ApoE-/- , whereas, the mouse in 
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lane 2 was a ApoE+/- (C) The FACS analysis of PBMCs to determine expression of 
the huCD20 receptor revealed that in a mouse, who was previously genotyped as 
being huCD20+ had expression of the receptor on all CD19+ B cells. C) 
Pseudocolour dot plot were gated on mononuclear cells as shown in the small 
panel. The huCD20 vs. CD19 plot shows 44.9% CD20 positive B cells. 
 
5.2.3 Four huCD20+/ApoE-/- mice on high fat diet  
Mice were fed on high fat diet, which was started around 6 weeks of age. Two 
mice were treated with iv rituximab (100µg) every 4 weeks for a total of 3 
treatments. Control mice (n=2) were treated with 100µg of chromopure human 
IgG. To monitor B cells depletion in these mice, they were bled a week before 
and after each systemic treatment (Figure 5.2). Blood samples were used to 
extract sera and PBMCs. The peripheral blood mononuclear cells were stained 
with fluorescent antibodies for flow cytometric analysis. Mice were weighed 
every time they were injected or bled. This was to ensure that mice gained 
weight during the course of study and if they did not then it can indicate that 
they have overgrown teeth, which impairs their feeding.  
 
Figure 5.2 Model system planed for the study 
To investigate the impact of B cell depletion therapy (rituximab), huCD20+/ApoE-/- 
mice were fed on high fat diet from 6 weeks onwards. Mice were treated with 
(rituximab 100µg) every 4 weeks, with the first treatment started at 6 weeks of age. 
Mice were bled, a week before and after every single treatment shown with red 
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lines. To follow B cell depletion and recovery mice were serially bled to extract 
PBMCs for flow cytometric analysis.  Finally, mice were sacrificed at 19 weeks of 
age (14 weeks on HFD). Heart, aorta, spleen, lymph nodes, bone marrow and 
blood were harvested for various analyses. 
The model was set up to sacrifice mice after 4 treatments around the age of 19 
weeks (14 weeks on HFD). At the end of the study, heart and aortas are to be 
analyzed for lesions.  Spleen, lymph nodes, bone marrow and blood were 
harvested to examine B cells and their subsets. Sera were harvested for 
subsequent lipid analysis. 
5.2.3.1 Monitoring of body weight  
At the age of 6 weeks mice were shifted on to a high fat diet (HFD) to induce 
atherosclerosis. These (huCD20+/ApoE-/-) mice with a genetic susceptibility are 
expected to develop hyperlipidemia and weight gain. Therefore, during the 
course of study weights of these mice (n=4) was recorded at the time of every 
systemic treatment and a week before and after the treatment when the mice 
were bled, which is 3 times a month. All the mice at 6 week of age were 
between 19-23gm, after 1 week on HFD all the mice gained weight a max weight 
gain of 2.5gm was seen in one of the IgG treated mice represented with green 
line. After 4 weeks on HFD one of the rituximab treated mouse died having 
gained 5gm (pink line), the other rituximab treated mouse gained 4gm. 
However, the mice that received IgG showed more increase in their weight they 
started at 23gm and in 4 weeks time reached a maximum of 30gm shown with 
red and green. A week later we saw an unexplained drop in the body weight of 
both the IgG treated mice. However, the only rituximab treated mouse showed a 
rapid increase with a body weight of 28.5gm. In the last 4 weeks mice on 
systemic IgG gained more weight and their final body weight were 30gm and 
33gms. Whereas, the rituximab treated mice ended up 26gms  (Figure 5.3). 
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Figure 5.3 Body weight chart 
Body weight was monitored of the mice in study three times a month till the end of 
the study. Each line represents single mouse; Red and pink are the mice treated 
with rituximab and the mouse represented with (pink) line was found dead (week 
4) of study therefore no more weight recordings. The rest of the mice (n=3) had a 
gradual increase in their weight roughly between 6-10 grams in 9 weeks. 
 
5.2.3.2 Circulating B lymphocytes and rituximab 
Mice were treated intravenously (iv) with either rituximab (100µg, n=2) or IgG 
(100µg, n=2). To examine the impact of treatment on circulating B-lymphocytes, 
mice were bled a week before and a week after the treatment. To determine 
the baseline level of B-lymphocytes in the blood, PBMCs were extracted from the 
blood at week (0) and were stained for CD19, human CD20. FACS analysis showed 
that rituximab treated mice (n=2) had 44.6% ± 0.3 (mean ± SD) huCD20 positive B 
cells while human IgG treated mice (n=2) had 43.4% ± 7.3  (Figure 5.4). 
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Figure 5.4 Circulating huCD20+ cell at first week  
Blood samples were taken at the time of first treatment (week 0) from rituximab 
and control mice, PBMCs were isolated from the blood and stained for FACS 
analysis. Pseudocolour dot plots were gated on lymphocytes as shown in the 
smaller panel in the left corner. CD19 vs. CD20 plots showed that all four mice had 
human CD20 positive cells. The percentages of huCD20 positive cells for 
rituximab treated (A & B) mice were 44.9% and 44.3%, and IgG mice (C & D) had 
48.5% and 38.2% respectively as indicated in each quadrant.  
 
One week after systemic treatment of all the mice (n=4) they were bled and the 
percentage of B cells present in the blood was analysed by FACS. The analysis 
showed significant depletion of B cells in rituximab treated mice. In specific, 
rituximab treated mice had 0.45% ± 0.4 (mean ± SD) B cells, representing a 98% 
reduction (Figure 5.5, A, B). The huCD20 positive cells were not affected by the 
treatment, as the B cells in the control mice a week after the systemic (100µg, 
IgG) were 45.6% ± 1 (mean ± SD) of the gated lymphocytes (Figure 5.5, C, D) 
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Figure 5.5 Circulating B cells (huCD20+) a week after the systemic treatment  
Mice were bled one week after first treatment.  (A & B) are rituximab treated mice 
and (C & D) are the control mice; PBMCs were isolated from the blood and stained 
for 4 colours Flow cytometric analysis. Pseudocolour dot plots were gated on 
lymphocytes as shown in the smaller panel. Then (CD19 vs. CD20) showed 98% 
reduction in CD20+ B cells in the rituximab treated mice as the depletion resulted 
in (0.72% and 0.17%); whereas, the IgG treatment did not affect the CD20 
expressing population. The percentages are shown in each quadrant. 
Thereafter, the mice were bled again a week before the second treatment to 
see if the huCD20 positive cells were replenished in the rituximab treated mice 
(n=2) during the two weeks time. There was a rapid recovery of huCD20 positive 
B cells in rituximab treated mice as a 77% increase was observed evident from B 
cells percentages 34.7% ± 5.2 mean ± SD. In fact B cell percentage increased 
further in the IgG treated mice n=2, 51.75% ± 4.35 (mean ± SD, Figure 5.6).  
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Figure 5.6 B cells (huCD20+) percentages one week before second treatment 
Mice were bled one week before second treatment,  rituximab (A & B), and control 
mice IgG (C & D). PBMCs were isolated from the blood and stained for 4 colours 
FACS analysis. Pseudocolour dot plots were gated on lymphocytes as shown in 
the smaller panel. The (CD19 vs. CD20) showed that there is recovery of CD20 
positive B cells in the two rituximab treated mice 39.9% and 25.9% respectively; 
whereas, the IgG treated mice huCD20+ cells percentage had a small increase 
47.4% and 56.1%. 
Unfortunately, during the course of study one of the rituximab treated mouse 
was found dead a week before second treatment (week 5), which seems one of 
those unexplained deaths. Later, the second rituximab treated mouse developed 
a skin condition probably xanthomas (these are fatty deposits under the skin or 
around nerve endings and can cause irritation) because of this we decided to 
terminate the study around the age (15 weeks) with (9 weeks) of study. 
Therefore, after second treatment mice (n=3) were analyzed for B cells  
(huCD20+) depletion in the peripheral blood. Interestingly, rituximab treated 
mouse showed resistance to treatment with a modest depletion 9% compared to 
the B cells percentage a week before second treatment, whereas, IgG treated 
control mice (n=2) had further 15% increase in their B cells 60.3% ± 0.2 (mean ± 
SD, Figure 5.7).  
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Figure 5.7 B cells (huCD20+) one week after second treatment 
Mice were bled one week after second treatment.  A) Rituximab treated mouse 
and (B & C) are the control mice; PBMCs were isolated from the blood and stained 
for 4 colours FACS analysis. The (CD19 vs. CD20) analysis showed that huCD20+ 
cells showed resistance to second treatment with B cells percentage as 37.9%; 
whereas, the IgG treatment did not reduce the huCD20 expressing population, in 
fact the B cells increased 60.1% and 60.5% respectively. The percentages of cells 
are shown in each quadrant.  
As all the mice were bled a week before and after every treatment, and the 
circulating B cells numbers were assessed with FACS  (CD19 vs. huCD20) staining 
of peripheral blood lymphocytes. The results are expressed as B cells 
percentages of the gated lymphocytes. Rituximab was able to rapidly and 
extensively deplete 98% of B cells after a single dose of rituximab (100µg, iv), 
compared with IgG treated control mice with huCD20+ cells percentage as high 
as 50%. FACS analysis of B cells (huCD20+) percentage a week before second 
treatment confirmed 77% recovery of B cells in rituximab mice (n=2). However, a 
week after the second treatment a modest depletion of 9% was observed in 
peripheral blood in these mice. Whereas, a week after the second treatment 
with IgG, mice had a further 15% increase in there circulating B cells. Moreover, 
one week after third treatment the only rituximab treated mouse had a modest 
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drop of 20% in the circulating B cells and the IgG treated mice had consistent 
levels of circulating B cells (Figure 5.8) 
 
Figure 5.8 Trend of Circulating B cells (huCD20+) during the course of study  
Mice (huCD20/ApoE-/- ) received 100µg of rituximab (black and grey line) and the 
control mice treated with IgG ( yellow and green line) at different time points (day 
0, one week after first treatment, a week before second treatment, a week after 
second treatment and finally a week after third treatment)  . Rituximab treated 
mice (n=2) show a sharp drop in B cell percentage after first treatment. Then a 
week after second and third treatment B cells resisted depletion and showed 
modest changes 37.9% and 30.3% respectively. Whereas, the IgG treated 
controls showed a consistent rise in B cells percentages (represented with green 
and brown lines) 
 
5.2.3.3 Effects of B cell directed therapy on lymphocytes of spleen and 
lymph nodes  
As previously stated the original plan was to harvest different organs from mice 
after 14 weeks on HFD, but because of the skin problem of the rituximab treated 
mouse in study we had to terminate the study at week 9. Having established that 
depletion of circulating B cells is massive (98%) after 1 treatment and later on 
they resisted depletion, even than at least 9% depletion was seen in the 
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replenished B cells in 3 weeks time prior to treatment. Mice were sacrificed and 
heart, aorta, spleen, bone marrow, lymph nodes and blood were all harvested 
from the remaining mice (n=3). Aortas were analyzed for atherosclerotic lesions 
(section 2.5.4.8). Bone marrow and secondary lymphoid organs were assessed for 
B cells depletion. 
At the end of the study, spleen and lymph nodes were harvested from sacrificed 
mice. Single cell suspensions from these tissues were examined for lymphocytes 
content by flow cytometry. The ratios of B to T lymphocytes in the spleen of 
rituximab vs. IgG treated mice were (1.85: 1.6) respectively. Whereas, the 
percentages of lymphocytes (B and T) in the lymph nodes of rituximab and IgG 
treated mice were (0.58: 0.68) respectively. This shows that both spleen and 
lymph nodes had similar ratio of lymphocytes, suggestive of the fact that spleen 
and lymph node huCD20 positive B cells were not affected by rituximab therapy 
(Figure 5.9).  
 
 
Figure 5.9 Depletion therapy and lymphocytes in spleen and lymph nodes  
Single cell suspension of lymphocytes were extracted from spleen (A & C) and 
lymph nodes (B & D) of mice and were examined by 4 colour staining for flow 
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cytometry. Pseudocolour dot plots were gated on lymphocytes as shown in the 
smaller panel on left corner.  B and T lymphocyte percentages in spleen of 
rituximab treated mouse were 47.3% and 25.5% and lymph nodes 28.2% and 
47.8% respectively. Whereas, the B and T lymphocytes in spleen of IgG treated 
mouse were 52.6% and 32.8% and in lymph nodes 31.4% and 46.1% respectively. 
The percentages are indicated in corner of each quadrant.  
5.2.3.4 Effects of rituximab on B cell subsets in spleen  
Transitional type 2 (T2), Marginal zone (MZ) and Follicular (Fo) B cells 
 
Rituximab treatment in (huCD20+/ApoE-/-) mice did not demonstrate B cells 
depletion in spleen and lymph nodes. We further wanted to validate if the 
treatment affected different B cells subsets in secondary lymphoid organs. 
Harvested spleen cells were stained for different B cells subsets. The 
identification of transitional (T2), marginal zone (Mz) and follicular (Fo) B cells 
in the spleen was possible through combination of several markers, which are 
expressed during development. The combination used includes CD19, CD21 and 
CD23; a plot of forward scatter (FSC) vs. CD19 can be used to separate 
(CD21+CD23+) cells. This population was subdivided into Fo (CD21+CD23+lo), T2 
(CD21+CD23+hi) and Mz (CD21+CD23+dull) B cells. There was a difference noted in 
marginal zone B cells between rituximab treated (4.18%) and control mice 
(2.84%). This altered representation of B cells subset percentage could be a 
response of decreased follicular B cells (Figure 5.10). 
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Figure 5.10 Marginal zone (MZ), follicular (Fo) and transitional type 2 (T2) B cells 
The single cell suspension was isolated from rituximab and IgG treated mice. 
These cells were stained for FACS analysis. A plot of forward scatter (FSC) can 
be used to separate out lymphocytes as shown in the top small panel on the left. 
These cells are further gated on to CD19+ cells to separate CD21+CD23+ B cells. 
The CD21+CD23+ fraction can be further subdivided into CD21+CD23+lo Fo cells 
and CD21+CD23+hi T2 and Mz B cells. The percentages of (Fo, T2 and Mz) cells 
are written besides the gated factions. 
Transitional type 1 and 2, marginal zone and follicular B lymphocytes 
 
 Harvested cells from spleen and lymph nodes were stained for T1, T2, Mz and 
Fo B cells. This was possible through combination of several markers, which are 
expressed during development. The combination used includes CD19, CD21 and 
CD24; a plot of forward scatter (FSC) vs. CD19 was used to separate CD21+ and 
CD24+ cells. This population was subdivided into T 1 (CD21+CD24+lo), the T2, Mz 
(CD21+CD24+hi) but this does not allow the discrimination of Mz and T2 cells and 
Fo cells are an intermediate population (CD21+CD24+). The response of the 
rituximab treatment on splenocytes B cells (T1, Mz and Fo) is (31.5%, 8.01%, 
49.6%) vs. IgG treated mice (T1, Mz and Fo) is (16.3%, 5.56%, 63.6%) 
respectively. These demonstrate that rituximab result in an increase in the T1 
31.5% in rituximab treated mice than the IgG, which was a 16.3% B cell (Figure 
5.11). 
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Figure 5.11 B cells subsets in spleen and lymph nodes 
The single cell suspension of spleen and lymph node was isolated from rituximab 
and IgG treated mice. A plot of forward scatter (FSC) was used to separate out 
lymphocytes as shown in the top small panel on the left. A plot of forward scatter 
vs. CD19 was used to separate (CD21+CD24+) B cells. The CD21+CD24+ fraction 
can be further subdivided into T 1 (CD21+CD24+lo), the T2+Mz (CD21+CD24+hi) 
and Fo (CD21+CD24+ intermediate population). The CD21 and CD24 staining 
does not allow discrimination of MZ & T2 cells. The percentage in rituximab 
treated mice in spleen as compared to control mice. The percentages of these 
cells are written besides the gated factions 
B1a cells in spleen and lymph nodes  
 
Previous studies have shown that generation of natural antibodies IgM (T15) can 
be atheroprotective, which imply a role for B1 cells in atherosclerosis. Therefore 
we validated the percentages of B1 cells in spleen and lymph nodes of treated 
mice (n=3). Harvested cells from spleen and lymph nodes were stained for flow 
cytometric analysis of B cell subset (B1a). A plot of forward scatter (FSC) vs. side 
scatter was used to gate lymphocytes. This was then used to gate CD19+IgD+ 
intermediate population. This population was used to separate (CD5+CD43+ Hi) 
population recognised as B1a cells. The response of the rituximab treatment on 
splenocytes B1a cells (4.51%) vs. IgG treated mice (6.64%) show similar 
percentage.  In fact a similar observation was made for the percentage of B1a 
subset in the lymph nodes of rituximab treated mice (14.1%) compared to IgG 
treated mice 11.6% (Figure 5.12). 
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Figure 5.12 B1a cells in spleen and lymph nodes  
The single cell suspension of spleen and lymph nodes were isolated from 
rituximab and IgG treated mice. A plot of forward scatter (FSC) was used to 
separate out lymphocytes as shown in the top small panel on the left. These cells 
are further gated on to (CD19+ IgD+) intermediate population to separate 
(CD43+CD5+)Hi B1a cells.  The percentage of B1a cells in spleen and lymph nodes 
are shown within the gated population.  
 
5.2.3.5 Analysis of Aortic lesions 
Blood was collected from the mice through the vena cava, followed by removal 
of lymph node, spleen and hind legs. After this the mice were perfused and fixed 
through the vena cava so the heart was not touched. Heart and aorta were 
carefully dissected out. To compare the lesions between different mice it is very 
important to cut the heart at the right plane and place. As shown (Figure 5.13, 
A) the heart was separated form the ascending aorta just above the aortic root, 
perpendicular to the longitudinal axis of aorta. After this paraffin embedded 
sections were cut and stained as explained (section 2.5.5). It is important to 
note that aortic valves are important landmarks to identify the aortic level. 
Once we had established the correct slides to be used for lesion analysis, based 
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on the position of the aortic valves, both lesional and luminal areas were 
recorded (Figure 5.13, B). 
 
Figure 5.13 Schematic for dissection of mouse heart and aorta  
The atherosclerotic lesions are mostly seen in the aortic root, where the aortic 
valves end. A) Show the plane at which the cut is made to separate the atria from 
the ventricles and ascending aorta from the root of aorta. This was to ensure a 
horizontal plane perpendicular to the aortic lumen. Whereas, a gradual shift can be 
seen as the aorta is cut B) shows aortic lumen with valves visible in (1) to a point 
where aortic lumen is round and valve are not seen. (3) a lesion is marked to show 
the measured area of the lesion and it is next to the tunica intima of blood vessel. 
All the aortic samples from the 3 mice were cut to generate 7µm thick sections 
and 2 consecutive sections were placed on one slide. Sections were stained with 
H & E and slides numbered 1, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 were visualised 
to confirm the position of the aortic heart valves. Once the aortic valves were 
determined 5 sections were measured for atherosclerotic lesions, one from each 
slide. The representative H and E stained sections from the mice (n=3) 
demonstrate atherosclerotic lesions in the aorta. The lesions seen in the 
rituximab treated mouse are small as compared to the lesions in control mice. 
Cholesterol cleft can be seen as white holes or clefts in the areas of maximum 
elevation of the lesion into the lumen (Figure 5.14). 
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Figure 5.14 Aortic lesions in huCD20+/ApoE-/- mice 
Mice were treated every four weeks with iv rituximab or IgG (control), and were 
sacrificed around 9 weeks on HFD and the aortic lesions were examined by H & E 
staining. The Rituximab treated mouse (A) has small lesions, whereas, both of the 
IgG treated mice (B & C) have much larger lesions that cover more area of the 
lining layer.  
The aortic lesions and the luminal area were measured in µm2 using the imaging 
software (Axiovision version 4). The mean of lesion area for 5 sections 7µm thick 
and each section 7µm apart, in a rituximab treated mice was compared with the 
mean lesion area of IgG treated controls. This showed an almost 2 fold reduction 
in lesion area of rituximab treated mice (Figure 5.15). As the sections used for 
measuring the lesions were from 5 consecutive slides, this means the lesions 
extended longitudinally over 70µm. 
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Figure 5.15 Atherosclerotic lesion areas in rituximab and IgG treated CD20+/ApoE-
/- mice 
Lesion area in aorta of (CD20+/ApoE-/-) mice fed on atherogenic diet (n=3). The 
average lesion size measured in cross section through the aortic origin is indicated 
in µm2. The rituximab (black bar) treated mice have almost half the lesion area as 
compared to IgG treated mice (white bar), these lesions extended longitudinally 
over 70µm.  
We observed a variation in luminal area of the aorta between these mice, so to 
ensure that the results reflect the absolute lesion area compared to vessel size 
we determined the percentage area of the lesion relative to luminal area. We 
calculated the percentage area for all 5 sections per mice by (lesion area / 
luminal area × 100) for each section of the mice (n=3), which revealed the 
percentage of aortic lumen obliterated with lesion, and there was reduction 
seen in the percentage area of aortic lumen obliterated with lesion in the 
rituximab treated compared to IgG treated control mice (n=2). The lesion of 
rituximab treated mouse had small plaques on 1-3 sections. In fact the 2 
remaining section had no lesions at all (blue line, Figure 5.16). On the other 
hand the IgG treated mice (red and yellow) had lesions bigger then rituximab 
treated mice. This demonstrates that not only there is at least 2-fold difference 
in the lesion area between rituximab and IgG treated mice; in fact this 
difference is seen longitudinally for around 35µm from root of aorta towards 
ascending aorta. Moreover, there is a 100% difference seen in the lesions size in 
the last 2 sections. Which imply that the plaque formation has extended upwards 
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from the root of aorta into the ascending aorta for at least 70µm in the IgG 
treated mice, whereas the longitudinal extension of these lesions in the 
rituximab treated mouse is limited to around 35µm as shown by the blue line 
(Figure, 5.16).  
 
Figure 5.16 Percentage area of Aortic lesion in (huCD20+/ApoE-/-) mice  
The aorta from (huCD20/ApoE-/-) mice were analysed for the lesion area 
measured in um2 for all 5 sections per mouse, and the luminal area was also 
measured for all the mice. This graph represents the percentages of the aortic 
lesions relative to the aortic lumen. The mice treated with IgG (red & yellow) show 
a reasonable overlap in the lesion size. However, the mice treated (blue) with 
rituximab (100µg) showed reduction in percentage area of aortic lumen obliterated 
with lesion.  
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5.3 Discussion 
This initial data to address the safety of B cells depletion therapy (Rituximab) is 
interesting for patient management, especially in the late stages of the disease. 
RA patients are vulnerable to cardiovascular morbidity and mortality, we 
hypothesised depletion of B-lymphocytes (atheroprotective cells)232 in the 
experimental model of atherosclerosis might result in aggravation of lesion 
formation in the mice.  However, this preliminary data from a limited number of 
mice (n=3) is surely not enough to draw conclusions but it gives us the clue what 
to expect from a full study with a reasonable number of (huCD20+/ApoE-/-) mice.  
The current data shows a 2-fold reduction in lesion size in response to rituximab 
treatment in comparison with the IgG treated control mice. Variation was 
observed in size of aortic lumen and arterial wall thickness in these genetically 
engineered mice. Therefore not only aortic lesion area was measured but we 
also calculated the percentage area of the aortic lumen obliterated with the 
plaque. Importantly, the measures of aortic lesion area and percentage area of 
the aortic lumen obliterated have both shown that B cell depletion resulted in at 
least 2-fold reduction in atherosclerotic lesions. Importantly, these lesions 
extend vertically from root of aorta towards the ascending aorta. Whereas, the 
overall reduction in the arterial wall thickness of these (huCD20+/ApoE-/-) mice 
needs to be validated in the future studies.  
The B cells depletion every four-week with rituximab (100µg) was monitored 
through out the course of study, and a massive (>90%) reduction was observed in 
the B cell percentage after the first treatment, which was followed by rapid 
recovery of the B-lymphocytes in a three weeks time. Interestingly, the systemic 
treatments (second and third) resulted in modest depletion of 9-20% B cells 
percentage. In a study Rituximab (type I) has been shown to be 5 times less 
potent then tositumomab (type II), the return of B cells was reported 30-35 days 
after the treatment 236. In addition comparison of B cell depletion with a single 
dose of rituximab (250µg) in two different strains of mice was performed, and it 
was demonstrated that C57BL/6 mice are more resistant than BALB/c, in fact 
the analysis of B cells depletion in peripheral lymphoid organ (bone marrow and 
lymph nodes) was resistant to rituximab therapy 236. Although in the present 
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study the rituximab dose (100µg) is less than half the dose used in the study 
mentioned but a massive depletion was confirmed in our mice C57BL/6 
background. However, the spleen and lymph nodes harvested at the end of the 
study showed resistance to rituximab therapy.  
 The B cells subsets Mz and B1 cells are potent responders to TLR activation, 
which has resulted in them being referred as innate B cells 237-239.  Moreover, 
pneumococcal vaccination in Ldlr-/- mouse have been demonstrated to reduce 
the atherosclerotic burden in mice, which was shown to be a result of oxLDL 
specific IgM antibodies produced by spleenic B cells 135.  In the present study we 
observed an increase in the T1 B cells in spleen of rituximab treated mice. Even 
though this subpopulation is small but there is a fold increase in this population, 
which might be because they escape depletion or because of some stimulatory 
response. Moreover, the B1 B cells are mainly found in the peritoneal cavity 240. 
A modest population of B1 B cells was identified in spleen and lymph nodes, 
which was not affected by rituximab treatment. 
Limitation of mice number was not the only factor, in fact due to time 
constraints sera from mice at every bled and at the time of sacrifice could not 
be evaluated to determine the lipid profile. This is very important to confirm if 
this (CD20+/ApoE -/-) mouse model has a normal lipid profile and that the affects 
observed were of B cell directed therapy (rituximab) and not as a result of 
changes in serum lipids. 
 
 
        156                                                                          
 
6 General Discussion 
Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease that 
primarily affects the joints and cause severe deformity and loss of function. The 
aetiology of the disease is not known but epidemiological data has identified 
many genes (HLA-DR, PTPN22, PADI-4) and environmental factor (smoking) that 
could be involved in RA pathogenesis 10. RA diagnosis is based on a criteria put 
forward by the ACR, which include clinical symptoms, radiological features and 
serological marker (RF). A new addition to this diagnostic arsenal is serum titre 
of ACPA (antibodies to citrullinated proteins); a highly specific biomarker for 
diagnosing RA patients even at early stages217. RA patients quality of life is 
severely affected; moreover, RA patients are at increased risk  (1.5 fold to 2 
fold) of developing cardiovascular events 88, 95, 97. It is unclear how the 
underlying disease mechanism of RA, influences the vascular environment in 
atherosclerosis.  
Atherosclerosis is asymmetrical intimal thickening of arterial wall, with an 
inflammatory mechanism involving cells of innate and adaptive immunity 241-243. 
The underlying cause of the disease is not completely understood neither its link 
to RA. However, strong genetic associations with smoking have been identified 
for both the diseases. Klareskog et al has proposed an etiological model for RA 
centred on smoking 10. This was primarily based on presence of ACPA antibodies 
generated in response to smoking and can target CP in the joints. The expression 
of CP an inflammation specific protein is demonstrated in RA synovium 206 and 
RA synovial fluid 27.  
The biopsy cohort of aortic adventitia from patients, with well-established CVD 
and coexisting RA were investigated for the presence of CP. This inflammation 
specific protein was seen in the AA of all the patients but was expressed 
significantly more in CVD patients with comorbid RA. Previous studies have 
shown that the conversion of arginine to citrulline is a PADI dependent 
enzymatic process; which is activated under high calcium concentration; 
physiological calcium level does not support this enzymatic conversion 36. 
However, under stress full conditions like apoptosis, terminal differentiation of 
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cells (stratified skin) and inflammatory responses can cause an increase in the 
calcium concentrations to levels that support citrullination. This was an 
interesting finding and the ACPA levels from sera of RA patients strengthened 
the rationale for citrullinated proteins presence in RA patients. To examine the 
impact of both CP and ACPA in these CVD patient subsets were identified. RA 
patients were subdivided on the basis of maximum CP staining scores in non-RA 
patients, which was (CP=5.5) and therefore it was made the cut off. As a result a 
subset of RA patients (CP>5.5) was identified and their ACPA titre was correlated 
with an inflammatory marker (CRP levels). Importantly, we confirmed that ACPA 
in the subset of patients (CP>5.5) was strongly correlated with raised CRP levels. 
This implies that raised CP and ACPA could be critical in the progress of 
atherosclerosis and hence cardiovascular events seen in ACPA positive patients. 
As the patients with susceptible genetic background when exposed to 
environmental factors like smoking might generate ACPA; In addition 
dyslipidemia in the same patients initiate inflammation in the blood vessels that 
results in CP formation within the blood vessels. Once there is increased titre of 
ACPA in the circulation and expression of CP in the vessel wall they might result 
in immune complex formation. Henceforth, the progress of atherosclerotic 
plaque might be affected by this immune complexes formation in the vascular 
adventitia.  
 
This is the first time presence of CP is demonstrated in the Aortic adventitia.  CP 
expression is significantly more in RA aortic adventitia but a reasonable number 
of non-RA vessels demonstrated CP expression as well. Which confirms the fact 
that citrullination is an inflammation associated phenomenon rather than a 
disease specific 206. This suggests that atherosclerosis might be initiated by risk 
factors (dyslipidemia, hypertension, cigarette smoking or diabetes mellitus), 
which in turn generates citrullinated proteins in aortic adventitia. In fact 
citrullination of adipocytes in aortic adventitia is interesting because adipocytes 
are the major cellular component of the adventitia; with their ability to produce 
cytokines, adipokines and angiogenic molecules one would expect a change in 
their functional ability that might affect the pathogenesis of atherosclerosis; 
which needs to be investigated in the future studies.   
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Our findings were broadened by the analysis of ACPA levels in sera of patients 
with CVD and co existing RA. We confirmed that all non-RA patients were 
negative for ACPA and most of RA patients had high ACPA titre. There is 
increasing evidence to support the fact that cigarette smoking is an individual 
risk factor for both atherosclerosis and rheumatoid arthritis. Moreover, 
accumulating data from the past decade has indicated that citrullination is 
strongly associated with smoking and rheumatoid arthritis (RA)10. However, we 
could not observe any association between CP and smoking in patients of 
rheumatoid arthritis. Perhaps this effect of smoking on citrullination is limited to 
lungs.  
 
In the past B cells were demonstrated in human aortic adventitia and in addition 
the experimental model of atherosclerosis (ApoE-/-) was shown to have B cell 
follicles in the adventitia of abdominal aorta 142, 144. We established B-
lymphocytes presence only in diseased aortic adventitia from CVD patients. None 
of the adventitia of the internal control (IMA) had B-lymphocytes. This confirmed 
the previous observation by researchers regarding B lymphocyte presence in 
human aortic adventitia.210 144 213. In an environment where different cells have 
to be efficient and survive longer, cells require factors especially during chronic 
inflammatory responses. Here we show for the first time that a B cell survival 
niche exist in the aortic adventitia that provide the microenvironment for B cell 
survival and maturation.  B cell activating factor (BAFF or Blys) is a TNF like 
ligand and its close member a proliferation inducing ligand (APRIL) are members 
of tumor necrosis factor (TNF) superfamily. These two factors can mediate B-
lymphocytes behaviour through their interaction with the receptors on B cells. 
Aortic adventitia and IMA express BAFF (adipocytes, monocytes and vascular 
endothelial cells), which was found to be significantly more among smoking 
patients. Furthermore, smoking induced vasoconstriction can result in hypoxia of 
the end arteries like vasa vasorum; which means hypoxia of vascular endothelial 
cells that can result in endothelial dysfunction. To investigate this hypothesis we 
looked at BAFF and APRIL expression under hypoxia in murine vascular 
endothelial cells. Nevertheless, hypoxia or reoxygenation of vascular endothelial 
cells does not affect the transcript level of neither BAFF nor APRIL. This suggests 
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that smoking might be affecting BAFF through another way in aortic adventitia 
of diseased CVD patients. 
B-lymphocytes have been shown to have proinflammatory role in the settings of 
RA, evident from the fact that B cell depletion therapy (rituximab) is an 
approved drug for refractory cases of RA. Whereas, B lymphocytes are 
demonstrated as atheroprotective in atherosclerosis 232.  To investigate the 
impact of B cell depletion therapy on atherosclerosis, huCD20+/ApoE-/- mice 
were generated and a small group of mice n=4 were treated every four weeks 
with rituximab and IgG (100µg). The circulating B-lymphocytes were efficiently 
depleted and before the next treatment they were repopulated. The rituximab 
treated mice showed a 2-fold reduction in lesions area as compared to control 
mice treated with IgG. This preliminary data is suggestive of the fact that the 
reduction in atherosclerotic lesion, as a result of B cell targeted depletion could 
be due to removal of B cell influence, resulting in impaired cell-to-cell 
interaction and suppression of antigen presentation induced T cell stimulation 
244. Studies in murine model of RA and diabetes have shown that B cell depletion 
impairs the antigen specific activation of CD4 (+) cells, despite the fact that 
lymphoid tissue B cells resist this target killing 245. 
There is in vitro data that confirms release of B cell survival factor (Blys) by 
neutrophils 246. In fact Blys protein and APRIL are also found in synovial fluid of 
patients with inflammatory arthritis 247. These survival factors promote 
expansion and survival of B cells and therefore are implicated as protective 
factors for synovial B cells. This is further supported by the evidence that 
patients synovial expression of APRIL, BAFF and SDF-1 was unaltered following 
rituximab therapy 248. Importantly, in this thesis we have established BAFF and 
APRIL in aortic adventitia from patients with advanced atherosclerosis. 
Moreover, we have also validated their expression by mouse vascular endothelial 
cells. If the protective role of survival factors (BAFF & APRIL) is shielding the 
synovial B cells from rituximab, it could be hypothesized that proinflammatory 
environment within the blood vessels might be promoting B cell survival factors.  
These aggregates of B cells might represent sites where B cell selection and 
maturation takes place; presumably high affinity antibodies are raised against 
locally delivered citrullinated protein. The presence of two different subsets of 
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RA patients on account of autoantibodies, the ACPA positive and negative subset 
reduced the possibility of identifying autoantibodies in our samples 217. It is 
interesting to note that when we screened all the samples for autoantibody 
presence five patients were positive for plasma cells and only one of these was a 
RA patient. Our attempt to characterize citrulline reactive antibody secreting 
plasma cells was ineffective, perhaps because of the distribution of plasma cells. 
Whereas, the fact that our samples were quite variable in size. The distribution 
pattern is vital in interpreting this set of data. Besides this it is quite difficult to 
confirm this in only one RA patient positive for plasma cells.  
The RA patients that received systemic treatment with rituximab are shown to 
have 97% decrease in CD19+ but around 80% of the remaining cells were memory 
B cells or plasma cells. An other study showed a small fraction of T lymphocytes 
(3%) and natural killer cells (2%) to express CD20; this was also associated with 
an increase in the immature B cells like CD19+, IgD+, CD38 (high), CD10 (low), 
CD24 (high) cells 249. This would imply that antibody producing plasma cells 
resist depletion and could continue to produce protective antibodies.  
Interestingly, dyslipidemia (high LDL) is an important factor in initiating 
atherosclerosis; due to time limitation we could not validate the lipid profile of 
mice in study. Surely that would have added vital information and more depth to 
the understanding of our model. As for now we do not know whether these 
huCD20+/ApoE-/- mice have a normal lipid profile. 
 Our study does have limitations as we have shown all the differences by 
comparing diseased aortic adventitia and matched IMA (internal control); which 
is not the best option to compare with aortic adventitia. Replacement of aortic 
adventitia with coronary artery with dimensions similar to IMA would have been 
a good internal control.  In addition, matched saphenous vein adventitia is closer 
to aorta in size and calibre, so as a negative control it would have provided a 
better comparison. Moreover, the severity of inflammation in these 
atherosclerotic plaques would have been underestimated as the specimens were 
selectively taken (for some surgical reasons) from areas with less severe disease.  
 
The characteristic of IMA to resist atherosclerosis is established but it is not fully 
understood why it behaves different. However, Ferro et al showed that the 
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lesions are ten times greater in coronary artery then the IMA. This was seen in 
the inner most layer i.e. intima but not in the tunica media 218. The IMA have 
high antioxidant capacity compared to coronary artery SMC; IMA smooth muscle 
cells also express low tenascin and decorin that are involved in the LDL binding 
and SMC migration. Apart from these factors there are extrinsic features like 
axial stretch, sheer stress and small number of side branches that might play a 
role in the IMA resistance to atherosclerosis 219. The underlying mechanism for 
resisting atherosclerosis might not be unfolded yet but there is some unknown 
attribute that makes IMA unique. 
 
It has been shown previously that IL-33/sST2 is important in cardiovascular 
system. The protective effects of IL-33 in the murine model of atherosclerosis 
are shown to exist through Th2 cytokines IL-5 and IL-13. Importantly, the 
blockade of IL-5 results in augmented plaque size despite IL-33 treatment 199. 
Moreover, IL-5 is know to exert its anti atherosclerotic response through natural 
antibodies against oxLDL 139. This might suggest that IL-33 has a link with B-
lymphocytes.  
The salient finding of this study is that expression of IL-33 is down regulated in 
vascular endothelial cells of smokers (AA); the IL-33 levels of non smoking 
patients in the AA were indifferent to IMA suggestive of an indirect association of 
smoking resulting in failure of IL-33 induce protection in AA specifically. Smoking 
is as a danger signal that could be creating an inflammatory environment 
through oxLDL; which is known to cause endothelial dysfunction and damage; 
depending on the duration and severity of the insult. 
 We hypothesized that IL-33 could be released with damage to the vascular 
endothelium; which may stimulate the production of natural antibodies against 
oxLDL through IL-5, these antibodies then perhaps block the uptake of oxLDL by 
macrophages. However, the increase in the reactive oxygen species production 
and the inflammatory environment cause damage to endothelial cells. To 
confirm the impact of hypoxia and reoxygenation on IL-33/sST2 in vascular 
endothelial cells a culture system was established; which revealed that hypoxia 
has no effect on IL-33/sST2 message. A recent study showed that IL-33 is lost by 
endothelial cells during wound healing and angiogenesis 220. While optimizing the 
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culture system it was shown that IL-33 expression is stable when cells are fully 
confluent. 
This thesis has shown that RA associated antigen CP is seen in patient’s aorta 
and is strongly associated with ACPA and CRP, suggestive of their significance in 
atherosclerosis seen in RA patients. Moreover, presence of B cells and their 
survival niche in aortic adventitia imply an important role in the vascular 
environment. In fact B cell depletion in mouse model resulted in reduction of 
atherosclerotic plaques, indicative of depletion of proatherogenic B cell subset, 
perhaps it’ s supportive function towards T cell is impaired that caused the 
reduction in lesion size. However, this needs to be addressed in future studies, 
In fact in a large sample size with rituximab treatments. In addition investigation 
of the lipid profile and antibody titre would be more helpful in understanding 
the underlying mechanism of the impact of B cell depletion in atherosclerosis.
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Appendix 
1. Immunohistochemistry reagents 
a) Peroxidase block:   5 ml 30% Hydrogen peroxide (H2O2) in 295 ml of 
     methanol 
b) Citrate buffer: 2.1 g Citric acid monohydrate dissolved in 1000 
ml of distilled water (pH 6) 
c) Tris buffered saline (TBS)  6.05 g Tris base (50 mM), 8.76 g sodium 
chloride (150 mM) to 800 ml of distilled water. 
Adjust pH to 7.5 with HCl. Adjust to 1 litre with 
distilled water. Add Tween-20 to 0.1% (v/v). 
Stored for up to 3 months at room 
temperature.  
d) 10x Phosphate buffered saline 80 g NaCl, 2 g KCl, 11.5 gNa2HPO47H2O and 2 g 
KH2PO4 to 1 litre distilled water (pH 7.4) 10x 
stock. 
e) Trypsin solution: Trypsin 0.5%, 1% calcium chloride solution and 
pH adjusted to 7.8 with 1N NaOH.  
f) SDS-PAGE Lysis buffer  62.5 mM Tris-HCl (pH 6.8), 2% SDS, 5% 2-
mecaptoethanol, 10% glycerol.    
g) FACS buffer 3% BSA and 0.05% NaN3 in 1x PBS 
    
2. Western blotting reagents  
a) 20x MES SDS running buffer:  The 500 ml contains 97.6 g of MES, 60.6 g Tris 
Base, 10 g SDS and 3 g of EDTA.  
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b) 20x NuPAGE transfer buffer: The 125 ml contains 10.2 g of Bicine, 13.1 g 
Bis-Tris (free base) and 0.75 g EDTA  
c) 4x LDS sample buffer:  10 ml contains 0.66 g of Tris HCl, 0.62 g Tris 
Base, 0.8 g LDS, 0.006 g EDTA, 4 g Glycerol, 
0.75 ml 1% bromophenol and 0.25 ml of Phenol 
red. 
d) Fixative solution: 60% reagent alcohol (95% ethanol, 5% 
methanol) 30% glacial acetic acid. 
   
3. Lipoprotein isolation reagents. 
a) 1.006 density solution  10.07 g/L NaBr, 0.37 g EDTA in distilled water 
pH 7.4 
b) 1.020 density solution  28.31 g/L NaBr, 0.37 g EDTA in distilled water 
pH 7.4 
 
c) 1.063 density solution 84.98 g/L NaBr, 0.37 g EDTA in distilled water 
pH 7.4 
 
d) 1.21 density solution 283.32 g/L NaBr, 0.37 g EDTA in distilled water 
pH 7.4 
e) Copper reagent  20 gm sodium carbonate, 0.4 gm cupric 
sulphate pentahydrate and 0.2 gm sodium 
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4. Lipoprotien (Lipo) Electrophoresis reagents 
a) LIPO gel    0.5% Agarose gel. 
b) B-2 Barbital buffer: 18.2 g (5, 5-Diethylbarbituric Acid), 10mmol/L 
reconstituted; 5, 5-Diethylbarbituric Acid 
sodium salt 50mmol/L. 
c) Paragon lipostain: Sudan Black B stain, 7% (W/W). The working 
Lipo stain was prepared by adding 3 ml of 
Lipostain to 165 ml of reagent alcohol. 
d) Reagent alcohol: 95% ethanol denatured with methanol. 
e) Fixative solution: 180 ml reagent alcohol, 90 ml deionised water, 
30 ml of Glacial acetic acid. 
f) Destain solution: 450 ml of reagent alcohol, 550 ml of deionised 
water. 
 
5. Mouse genotyping buffers 
a) Alkaline lysis buffer: 25 mMol sodium hydroxide (NaOH), 0.2 mMol 
EDTA (pH 12). 
b) Neutralizing buffer:  40 mMol Tris (pH 5). 
 
6. Primers for quantitative PCR 
a) Human Primers: 
Human GAPDH  Forward 5’ ACAGTCAGCCGCATCTTCTT 3’ 
(Annealing Temp: 550C)    Reverse 5’ AAATGAGCCCCAGCCTTCT 3’  
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Human IL-33  Forward 5’ CCATTACTTTTGCTTTGGAGGA 3’ 
(Annealing Temp: 560C)     Reverse 5’ TTACCATCAACACCGTCACC 3’ 
Human sST2   Forward 5’ AGCTGACGTGAAGGAAGAGG 3’ 
(Annealing Temp: 580C)   Reverse 5’ GCCATTCCCATTGTCTTGATG 3’ 
 
b) Mouse Primer: 
Murine GAPDH (inner) Forward 5’ CAGCAAGGACACTGAGCAAG 3’ 
    Reverse 5’ TATTATGGGGGTCTGGGATG 3’ 
Murine GAPDH (outer) Forward 5’ TGTCTCCTGCGACTTCAA 3’ 
(Annealing Temp: 550C)  Reverse 5’ TGCAGCGAACTTTATTGATG 3’ 
Murine β  Actin (inner) Forward 5’ CGTTGACATCCGTAAAGACC 3’ 
    Reverse 5’ CTGGAAGGTGGACAGTGAG 3’ 
Murine β  Actin (outer) Forward 5’ GCTCTTTTCCAGCCTTCCTT 3’ 
(Annealing Temp: 550C) Reverse 5’ GCTCAGTAACAGTCCGCCTA 3’ 
Murine IL-33 (inner) Forward 5’ CCTGGTCTTGCTCTTGGTCT 3’ 
    Reverse 5’ AGTCTCCTGCCTCCCTGAGT 3’ 
Murine IL-33 (outer) Forward 5’ CAGCACCGCAGGCGAAGCCC 3’ 
(Annealing Temp: 590C) Reverse 5’ TATGTACTCAGGGAGGCAGG 3’ 
Murine sST2 (inner) Forward 5’ GACCCCCTTCTCTCTTTTCC 3’ 
        190                                                                          
    Reverse 5’ TGCTCTGAACCCACTACCAA 3’ 
Murine sST2 (outer) Forward 5’ TGGCATGATAAGGCACACCATAAGGCT  
(Annealing Temp: 550C) Reverse 5’ GTTAGTGTCTCTCTCCCTCCCATGC 3’ 
Murine APRIL (inner) Forward 5’ ATGCCAGCCTCATCTCCA 3’ 
    Reverse 5’ GCGACAGCACAAGTCACAG 3’ 
Murine APRIL (outer) Forward 5’ GTAACCCGCTCTTCCCTTCT 3’ 
(Annealing Temp: 620C) Reverse 5’ CAGGACATCAGGACTCTGCTC 3’ 
Murine BAFF (outer) Forward 5’ TGCCTTGGAGGAGAAAGAGA 3’ 
(Annealing Temp: 600C)    Reverse 5’ GGAATTGTTGGGCAGTGTTT 3’ 
Murine SK-1 (outer) Forward 5’ AGGTGGTGAATGGGCTAATG 3’ 
 (Annealing Temp: 600C)   Reverse 5’ CCAGAGGAACAAGGTGTGTG 3’ 
Murine SK-1 (inner)  Forward 5’ CGAGCAGGTGACTAATGAAGA 3’ 
 Reverse 5’ GCAGCCCAGAAGCAGTGT 3’ 
 
7) Murine Primers for genotyping: 
Four sets of primers were used for genotyping of HumanCD20 (hCD20) transgenic 
mice. 
1) hCd20 Exon2 region  Forward 5’ CACAAGGTAAGACTGCCAAAAATC 3’ 
     
Reverse 5’ ATATACAAGCCCCAAAACCAAAAG 3’ 
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2) hCD20 3’UTR region  Forward 5’ GGCCTTTGCATGGAGTGAC 3’ 
     Reverse 5’ AGCCCTGTAGAAAGATAAATGGA 3’ 
3) hCD20 5’ region BAC  Forward 5’ ATTGTTTGAGTGCTCAGCATG 3’ 
     Reverse 5’ GGGAAAAACAATATTGCCTCC 3’ 
 
4) hCD20 3’ region BAC  Forward 5’ GTTGGAGGTTCTGGTTGCAT 3’ 
     Reverse 5’ AATTGGCTTAGGATTGGGCT 3’ 
 Three sets of primers were used for genotyping of Apo E knock out mice. 
1) ApoE IMR0180   Forward 5’ GCCTAGCCGAGGGAGAGCCG 3’ 
2) ApoE IMR0181   Reverse 5’ TGTGACTTGGGAGCTCTGCAGC 3’ 
3) ApoE IMR0182   Reverse 5’ GCCGCCCCGACTGCATCT 3’
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